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CANCER CONTROL, LIVING WITH & BEYOND AND CANCER
OUTCOMES
1. Returning to work after cancer in Romania – the patients'
views on motivations and barriers
Adela Popa1
1Lucian Blaga University of Sibiu, Romania
Background: A substantial proportion of cancer patients in
Europe and Romania are of working age. In Romania, the number
of working-age cancer patients is growing, hence returning to
work (RTW) after treatment is an option that must be considered.
This research aims to explore the cancer survivors’ perspectives on
the motivations and barriers which inﬂuenced their RTW, in a
country where the legislation provides no incentives or support
for RTW.
Method: Data were collected through semi-structured interviews.
Twenty-eight subjects who either returned to work (n= 16) or not (n
= 12) were recruited via oncologists and specialized physicians. The
interviews were thematically analysed using Nvivo 11 http://www.
qsrinternational.com/nvivo/nvivo-products/nvivo-11-for-windows.
Results: The ﬁndings suggest important differences in the two
sub-samples regarding the motivations for RTW and barriers
encountered. The most important motivations mentioned by the
patients who returned to work were: seeing work as a distraction
from the disease, the ﬁnancial and the social motivations. Part of
the patients who did not return to work was intensely motivated
to work, yet they could not return to the same working conditions
or ﬁnd another job due to the diagnosis. Part of the patients which
returned to work mentioned they encountered no barriers but
admitted the RTW was not phased or prepared in any way. The
patients who did not return to work mentioned physical barriers,
unreceptive attitude or discrimination from the employer and fear
of the co-worker’s reaction.
Conclusion: Most of the employees in our sample proved a strong
motivation to return to work but only a few of them were offered
the needed support for returning to work. In the absence of formal
and structured support, RTW was determined by the type of work
and the type and stage of the disease. The study emphasizes the
importance of structured RTW support that will enable employees
to re-enter the workforce.
Disclosure: Funded by Romanian National Authority for
Scientiﬁc Research, CNCS - UEFISCDI
Corresponding author: Adela Popa
2. Randomised controlled trial of holistic needs assessment in
outpatient oncology
Austyn Snowden1, Jenny Young1
1Edinburgh Napier University
Background: Holistic needs assessment (HNA) is a 48-item
checklist designed to help patients articulate their physical, social,
psychological, ﬁnancial and practical concerns during consulta-
tion. The study objective was to establish if and how HNA changes
consultation dynamics. It was hypothesised that HNA will support
greater patient participation, facilitate shared decision-making and
increase self-efﬁcacy.
Method: Randomised controlled trial. Three outpatient oncology
clinics in West of Scotland recruited patients with head and neck
or colorectal cancer who had received treatment (2016-ongoing).
Control group entailed routine consultation. Intervention
group: patients completed HNA before consultation then the
clinician used it to guide consultation. All consultations were
audiorecorded. Patient participation was determined by MEDI-
CODE: dialogue ratio (DR) and preponderance of initiative (PI)
within consultation. Shared decision-making was measured with
CollaboRATE; self-efﬁcacy with Lorig’s measure.
Results: Fifty-ﬁve people were randomised to intervention, 61 to
control. More patient concerns were discussed in the intervention
group (8.9) than control (6,6) (p = 0.00). Emotional concerns were
discussed more frequently (respectively 27,1% and 19,4%, p =
0.01), and clinicians expressed more support (14,4% compared to
10,2%, p=0.08) in intervention group. Discussion was initiated
mainly by clinician in both groups (76,4%), and participation
tended to monologue in both (54.1%). However, patient initiative
was signiﬁcantly higher in experimental group when discussing
symptom control(respectively 40,0% and 24,1%, p=0.03). Dialogue
was higher when discussing symptoms (respectively 75,1% and
63,6%, p=0.01). Self-efﬁcacy was higher in the experimental group
(mean Lorig: 8.3 v 7.6 p=0.093), as was CollaboRATE (25.1 v 23.4,
p=0.121), though neither was statistically signiﬁcant.
Conclusion: These preliminary results showed HNA changed the
dynamics of the clinical consultation away from clinician led
monologue towards shared decision making. These trends may
become statistically signiﬁcant when the study reaches sufﬁcient
power. The presentation will discuss a more nuanced analysis of
the impact of HNA on consultation style.
Clinical Trial Register: NCT02274701, https://www.clinicaltrial.gov
Disclosure: Funded by Macmillan Cancer Support UK
Corresponding author: Jenny Young
3. Socioeconomic status and the risk of breast cancer among
Nigerian women
Samuel O. Azubuike, Richard McNally, Louise Hayes
Institute of Health and Society, Newcastle University
Background: Breast cancer incidence in Nigeria has risen by >
120% since 2000. The mortality rate (25.9 /100 000/year) ranks
highest in Africa. Unfortunately, studies investigating breast
cancer risk factors in Africa are few, and none of these studies
was aimed at investigating the role of socioeconomic status (SES).
In Nigeria, though poverty remains conspicuous in the general
population, recent reports have suggested that the SES of many
women has been improving. This aim of the study was to
investigate if there is an association between socioeconomic
status and risk of breast cancer in Nigeria.
Method: The study was a hospital-based case-control design
involving 379 histologically conﬁrmed breast cancer cases and 403
controls. The participants aged ≥20 years were selected across ﬁve
facilities in northern (Abuja) and southern (Lagos) Nigeria. They
were interviewed in-person between October 2016 and May 2017
using a pretested questionnaire. Cases were selected from
oncology wards, while controls were from ophthalmology wards.
SES was measured based on education, occupation and income.
Data were analysed using multivariable logistic regression. SPSS
version 23 was used for all analyses.
Results: After controlling for the effects of parity, breastfeeding,
age at ﬁrst birth, hormonal contraceptive use, body mass index,
alcohol use, age at menarche, abortion, ethnicity, menopausal
status, urban-rural difference, and family size; women in the upper
categories of family income (OR: 0.4, 95% CI: 0.18, 0.67, ptrend
=0.007) and education (OR: 0.29, 95% CI: 0.12, 0.72, ptrend =
0.035) had reduced risk of breast cancer compared to those in
lowest categories of income and education respectively.
Conclusion: High income and higher educational attainment were
protective against breast cancer in Nigeria. Improving SES of
Nigerian women through increased access to higher education
and income will provide an opportunity for breast cancer
prevention. Future studies could consider using community
controls to authenticate the ﬁndings.
Disclosure: Funded by National Open University of Nigeria
Corresponding author: Samuel O. Azubuike
4. Unsupervised machine learning of integrated health and
social care data from the Macmillan Improving the Cancer
Journey service in Glasgow
Kean Lee Kang1, Margaret Greer2, James Bown1, Janice Preston2,
Judith Mabelis2, Leigh-Anne Hepburn3, Miriam Fisher4, Ruth Fal-
coner1, Sandra McDermott5, Stuart Deed4
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1Abertay University, 2Macmillan Cancer Support, 3Glasgow School of
Art, 4Digital Health and Care Institute, 5Glasgow City Council
Background: Improving the Cancer Journey (ICJ) was launched in
2014 by Glasgow City Council and Macmillan Cancer Support. As
part of routine service, data is collected on ICJ users including
demographic and health information, results from holistic needs
assessments and quality of life scores as measured by EQ-5D
health status. There is also data on the number and type of
referrals made and feedback from users on the overall service. By
applying artiﬁcial intelligence and interactive visualization tech-
nologies to this data, we seek to improve service provision and
optimize resource allocation.
Method: An unsupervised machine-learning algorithm was
deployed to cluster the data. The classical k-means algorithm
was extended with the k-modes technique for categorical data,
and the gap heuristic automatically identiﬁed the number of
clusters. The resulting clusters are used to summarize complex
data sets and produce three-dimensional visualizations of the data
landscape. Furthermore, the traits of new ICJ clients are predicted
by approximately matching their details to the nearest existing
cluster center.
Results: Cross-validation showed the model’s effectiveness over a
wide range of traits. For example, the model can predict marital
status, employment status and housing type with an accuracy
between 2.4 to 4.8 times greater than random selection. One of
the most interesting preliminary ﬁndings is that area deprivation
(measured through Scottish Index of Multiple Deprivation-SIMD) is
a better predictor of an ICJ client’s needs than primary diagnosis
(cancer type).
Conclusion: A key strength of this system is its ability to rapidly
ingest new data on its own and derive new predictions from those
data. This means the model can guide service provision by
forecasting demand based on actual or hypothesized data. The
aim is to provide intelligent person-centered recommendations.
The machine-learning model described here is part of a prototype
software tool currently under development for use by the cancer
support community.
Disclosure: Funded by Macmillan Cancer Support
Corresponding author: Kean Lee Kang
5. Young colorectal cancer patients experience referral delays
in primary care leading to emergency diagnoses
Chanpreet Arhi1, Paul Ziprin1, Alex Bottle1, Elaine Burns1, Paul Aylin1,
Ara Darzi1
1Imperial College London, UK
Background: The incidence of colorectal cancer in young patients
is increasing. In this population based case-control study, we
hypothesise missed opportunities for diagnosis in primary care are
leading to referral delays and emergency diagnoses in young
patients.
Method: We compared the interval before diagnosis, presenting
symptom (red-ﬂag based on NICE guidance 2005 vs non-speciﬁc),
the odds ratio (OR) of an emergency diagnosis and stage at
diagnosis for those under the age of 50 compared with older
patients, sourced from the cancer registry with linkage to the
Clinical Practice Research Datalink database of primary care
records.
Results: 7315 patients were included of which 561 (7.7%) were
under 50, 1287 (17.6%) 50–59, 2458 (33.6%) 60–69 and 3534
(48.3%) 70–79 years old. Young patients were more likely to
present with abdominal pain (21.1%) and were diagnosed with
later stage (48.0%) and via an emergency (29.1%) compared
with all age groups. They experienced a longer interval between
referral to diagnosis by 12.5 days compared with those aged
60–69, reﬂecting the higher proportion of referrals via the non-
urgent pathway (33.3% vs 26.5%). The OR of an emergency
diagnosis did not differ with age if a red-ﬂag symptom was
noted at presentation but increased signiﬁcantly for young
patients if the symptom was non-speciﬁc compared with all age
groups (OR 0.62 95% CI 0.49-0.80 for the 60-69 age group).
Conclusion: Young patients are more likely to present with
symptoms that fall outside the referral guidelines. Referral criteria
should be tailored according to the age group to reduce the risk of
an emergency diagnosis due to missed opportunities in primary
care.
Disclosure: Funded by Imperial College London
Corresponding author: Chanpreet Arhi
6. Delays in primary care are associated with a late stage and
worse prognosis for colorectal cancer patients: A population
based study
Chanpreet Arhi1, Elaine Burns1, Alex Bottle1, George Bouras1, Paul
Aylin1, Paul Ziprin1, Ara Darzi1
1Imperial College London UK
Background: Delays in referral for colorectal cancer patients may
occur if the presenting symptom is falsely attributed to a benign
condition. We hypothesis primary care delays are associated with
a later stage at diagnosis and worse prognosis.
Method: Patients with a non-emergency colon or rectal cancer in
the cancer registry with linkage to the Clinical Practice Research
Datalink were included. All had a colorectal associated symptom
deﬁned as ‘red ﬂag’ (rectal bleeding, abdominal mass, change in
bowel habit, diarrhoea, anaemia) or ‘non-speciﬁc’ (abdominal pain,
weight loss, constipation, other bowel function) and a relevant
referral recorded in the year leading up to diagnosis. The primary
care interval (presentation to referral), hospital interval (referral to
diagnosis) and stage was compared for each symptom individually
and after grouping as above. Cox modelling determined the
hazard ratios (HR) of death for each symptom compared with
rectal bleeding, and whether delays in referral were associated
with a worse prognosis.
Results: 4527(63.5%) colon and 2603 (36.5%) rectal cancer
patients were included. 16.9% and 13.5% presenting with red-
ﬂag symptoms respectively experienced a delay of over three
months before referral, compared with 35.7% and 42.9% of
those with non-speciﬁc symptoms. Delays in primary care did
not increase the hospital interval. Each symptom was associated
with reduced survival compared with rectal bleeding for both
cancers. Patients referred after three months who had presented
with red-ﬂag symptoms (Colon: HR 1.53 (1.29–1.81) Rectal: HR
1.30 (1.06 – 1.60)), demonstrated a signiﬁcantly worse prognosis
compared with referrals within two weeks with similar symp-
toms. This was not seen for patients with non-speciﬁc
symptoms. Delays in referral signiﬁcantly increased the propor-
tion of late stage cancers.
Conclusion: The ﬁrst presentation to the GP provides a referral
opportunity to identify the underlying cancer, which if missed for
patients presenting with red-ﬂag symptoms, is associated with a
later stage in diagnosis and worse survival.
Disclosure: Funded by Imperial College London
Corresponding author: Chanpreet Arhi
7. Embedding patient voice in cancer service improvement: A
qualitative study of patients’ experience of the NHS cancer
diagnostic care pathway
Sarah Sowden1, Anna Haste1, Linda Sharp1, Mark Lambert2, Richard
Thomson1
1Institute of Health and Society, Newcastle University, 2Public Health
England, North East Centre
Background: The 62 day NHS cancer waiting times target for
urgent GP referrals is frequently not achieved. Patient insight is
essential to understanding why this is the case to inform efforts to
reduce waiting times. This study aimed to explore patients’
experiences of the NHS upper gastrointestinal (UGI) cancer
diagnostic pathway, seek patients’ ideas for service improvement
and identify transferrable insights for other areas of cancer care.
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Method: Qualitative semi-structured interviews were undertaken
in 2017 with 20 patients within 6 months of receiving their ﬁrst
treatment for UGI cancer referred through the urgent (2 week) GP
route in the North East and Cumbria. Thematic analysis was
undertaken.
Results: Key themes identiﬁed were organisation of care,
diagnosis, support and expectations of the NHS. Some patients
were offered immediate access to testing, others required
specialist approval ﬁrst. Patients’ were often unclear about the
purpose of visits and journey ahead. Patients contrasted the
‘urgency’ indicated by the requirements placed upon them (and
therefore often upon family and friends) to attend numerous
appointments, at short notice, in close succession, often across
multiple hospital sites, with the seemingly long time taken to
receive results, and the unsettling time spent waiting and ‘not
knowing’ the prognosis. Patients’ were grateful for the NHS and
described how staff were time-pressured but working in their best
interests. They did not want to be seen as ‘complaining’ and were
often reluctant to express concerns or suggest improvements.
Conclusion: Current pathways are complex, varied, can be poorly
communicated to patients and do not always appear to be
patient-centred. Clearer communication is necessary but insufﬁ-
cient without a review of the diagnostic pathway to reduce
unwarranted variation and simplify the patients’ journey. Patients’
gratitude for the NHS and stoic acceptance of the status quo
should not be seen as justiﬁcation for no change.
Disclosure: Funded by NHS England Specialised Commissioning
(North East England hub)
Corresponding author: Sarah Sowden
8. Real-World Treatment Patterns and Clinical Outcomes in
Advanced/Metastatic NSCLC Patients in England
Katharina Verleger1, Nadine Hertel2, Caitlyn Solem1, John R. Penrod2,
Cynthia Macahilig3, Linlin Luo1, S. Michael Crawford4
1Pharmerit International, 2Bristol-Myers Squibb, 3Medical Data
Analytics, 4Airedale NHS Foundation Trust
Background: To describe treatment patterns and clinical out-
comes for squamous (SQ) and non-SQ (NSQ) advanced non-small-
cell lung cancer (aNSCLC) patients in Europe, the LENS (Leading
the Evaluation of NSQ and SQ NSCLC) retrospective medical chart
review was undertaken. This abstract details ﬁndings in England.
Method: Adult patients (≥18 years) with NSCLC stage IIIb/IV
diagnosis between 07/2010-09/2012 were sampled retrospectively
from oncology/respiratory medicine practices in England. Patient
medical chart data were extracted from diagnosis to most recent
visit/death.
Results: 267 patients from 14 hospital-based sites had median age
69.0 years, 53.9% were male, 82.0% stage IV, and 35.6% had ECOG
PS 1 (0: 16.5%; 2: 16.9%). 146 (54.7%) patients had ≥1 systemic
anti-cancer therapy line (SACT), 6 (2.3%) surgery and 106 (39.7%)
radiotherapy. NSQ vs SQ patients were signiﬁcantly more likely to
receive ﬁrst line (1L) (64.2% vs 45.7%) and second line (2L) (22.6%
vs 11.7%) SACT (p<0.05). As 1L treatment, 62.5% of NSQ patients
received a pemetrexed combination (SQ: 0.0%), 19.3% other
platinum-based combinations, and 13.6% geﬁtinib monotherapy.
Controlling for death, median time to discontinuation was 2.2
and 2.3 months (m) for 1L and 2L, median time from end of 1L to
start of 2L was 23.3m. Median overall survival (OS) from date of
aNSCLC diagnosis was 9.8/2.6m for patients with/without 1L SACT.
Median 1-year OS rate OS from start of 1L was 23.4% for both SQ
and NSQ patients. OS was 14.9m (1-year rate: 60.0%) for targeted
1L SACT patients.
Conclusion: The majority of patients in this real-world sample of
aNSCLC patients managed by medical oncologists received 1L
SACT using agents appropriate for their histological type.
However, patient prognosis remained generally poor. The rapidly
decreasing proportion of patients receiving SACT in each
subsequent line and worse OS in patients not receiving 1L
suggest that access to more effective therapies is needed in
England.
Disclosure: Funded by Bristol-Myers Squibb
Corresponding author: S. Michael Crawford
9. Oncology to oncogeriatrics – improving the skill base of
trainees
Cressida Lorimer1, Sally Appleyard1, Tom Levett2
1Brighton and Sussex Medical School, 2Royal Sussex County
Hospital
Background: The ageing population is providing new challenges
for oncologists. Oncology trainees are underequipped to manage
geriatric oncology patients with a recent survey showing 66%
never receive any formal geriatric oncology trainingGeriatric
experience prior to oncology training is mainly limited to inpatient
settings, whereas the majority of oncology workload is outpatient.
The Rapid Access Clinic for Older Persons (RACOP) is a potential
environment in which oncology trainees could experience
geriatric assessment techniques.
This project explores the quantity and quality of geriatric
oncology training available within the RACOP clinic with a view to
implementing a novel training opportunity.
Method: Clinic lists for 3 months of RACOP clinics extracted. Notes
from patients who had previous, current or new cancer diagnoses
made during the clinic were examined. 2 oncology trainees
attended RACOP clinics and provided structured reﬂection on the
potential training value.
Results: 220 patients were identiﬁed in total. 30% had a previous,
existing or new cancer diagnosis made. Of the 30 patients (14%)
that had a new cancer diagnosis made from their appointment
only 2 received active treatment from oncologists due to either
overwhelming comorbidities or patient choice. Approximately 75
other geriatric conditions were managed during this time period.
Trainees are currently attending RACOP clinic and feedback will be
available by the time of the NCRI conference.
Conclusion: Geriatric oncology services are being developed in a
small number of centres, usually run by geriatricians. The growing
numbers of older people living with cancer is likely to outstrip the
supply of geriatricians if this model were to be implemented
nationally. There is a drive to empower non-geriatricians to
perform basic geriatric assessments.
The RACOP clinic provides an excellent resource of an unselected
geriatric population and new geriatric oncology patients. This
experience can up skill clinical oncology trainees to improve
conﬁdence in assessing and managing older oncology patients.
Disclosure: None declared
Corresponding author: Cressida Lorimer
10. The role of dual modality imaging in the detection of
residual nodal disease following radical chemoradiation for
locally advanced head and neck cancer
Vanita Gandhi1, Shelly English2, Anna Thompson2
1Royal Free NHS Trust, 2North Middlesex University Hospital
Background: Adjuvant treatment following deﬁnitive chemor-
adiotherapy (CRT) for node-positive head and neck squamous cell
carcinoma (HNSCC) has evolved from routine neck dissection (ND),
towards risk-stratiﬁcation with positron emission tomography with
computed tomography (PET-CT). Patients with a complete
response (CR) remain on clinical follow-up, and those with residual
disease reported as an incomplete response (IR) have surgery.
However, there remains no consensus for those with an equivocal
response (ER).
The sensitivity of PET-CT is reported at 100% with speciﬁcity
being only 84%. Studies have reported that combining diffusion-
weighted magnetic resonance imaging (DW-MRI) with PET-CT
improves speciﬁcity to 94%. Our centre uses both modalities at
3 months after completing CRT to assess treatment response. We
retrospectively analysed the outcomes of these patients.
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Method: Data was gathered from radiological reports and
specialist multidisciplinary discussions for 43 patients diagnosed
with advanced node positive HNSCC treated with deﬁnitive CRT at
our centre from December 2015 to January 2018.
Results: CR, IR and ER were seen in 84% (n=36); 2% (n=1); and 14%
(n=6) respectively on PET-CT. All DW-MRI scans reported those with
residual lymphadenopathy as reactive or post-radiation change.
The patient with a radiological IR declined a ND and had a
subsequent negative node biopsy. The node remains stable at
one-year clinical follow-up. Of the 6 patients with ER: one
underwent a ND and 0/39 nodes contained viable tumour cells.
The remaining 5 patients are all in remission at a median follow up
of 13.7 months.
Conclusion: These results demonstrate that combination imaging
with PET-CT and DW-MRI may improve the evaluation of
persistent lymphadenopathy following radical CRT. This may
reduce the number of ‘equivocal’ responses identiﬁed and so
avoid the need for salvage surgery, which is associated with
additional morbidity and cost. We recommend performing a
randomised control trial to examine this strategy further.
Disclosure: None declared
Corresponding author: Vanita Gandhi
11. Effects of a 12-week exercise and nutrition programme on
cardiovascular ﬁtness, body composition and psychological
well-being in women at all stages of the breast cancer care
continuum
Joe Othen-Price1, Matthew Thompson1, Yvonne Rumble1, Sam
Olden1, Ivor Cradock1
1Clinical Prevention and Rehabilitation, London, UK
Background: It is well established that breast cancer treatment
can have a deleterious effect on physical function, body
composition and psychological well-being. It has been proposed
that lifestyle factors, such as exercise and nutrition can have an
important role in offsetting these negative changes, however,
exercise programme guidelines remain generic and unvalidated.
We propose that a 4 Pillars® framework provides an effective
model for exercise and nutrition programmes for all breast
cancer patients, from diagnosis through treatment and into
survivorship.
Method: 24 females, aged 50 ± 10.6 years at various stages of the
breast cancer care continuum completed a 12-week 1-2-1
programme at CP+R® based on 4 Pillars; twice-weekly resistance
sessions, twice-weekly cardiovascular training within a prescribed
heart rate zone, daily step-count monitoring and nutritional
guidance. The programme was led by a clinical exercise specialist
and overseen by a clinical nurse. All patients underwent
cardiorespiratory ﬁtness (VO2 peak) testing, body composition
analysis and psychological proﬁling pre and post programme.
Results: There was a signiﬁcant increase in VO2 peak, by 2.9 ± 4.1
ml/kg/min (p<0.05). Body fat percentage reduced by 1.8 ± 3.2 %
(p<0.05) and dry lean mass increased by 0.3 ± 1.2 kg (p=0.25).
Exercise and conﬁdence score increased by 8.9 ± 16.2 % (p<0.05)
and hospital anxiety and depression score reduced by 2.4 ± 6.1
points (p<0.05).
Conclusion: A 1-2-1 exercise and nutrition programme incorpor-
ating a 4 Pillar model signiﬁcantly improved a range of
physiological and psychological factors. The 4 Pillar model could
provide a blueprint for exercise and nutrition programmes for
breast cancer patients at all stages of the cancer care continuum.
Disclosure: None declared
Corresponding author: Joe Othen-Price
12. Headache suspicious of cancer - The Edinburgh early
diagnosis pathway
Karolis Zienius1, David Maxwell2, Lorna Porteous2, Janet Pooley4,
David Summers4, Lesley McKinlay4, David Weller1, Helen Bulbeck6,
Paul Brennan6, Robin Grant7
1University of Edinburgh, 2NHS Lothian, Edinburgh, 3Scottish
Government, 4Western General Hospital, Edinburgh, 6Brainstrust,
7University Department of Neurosurgery, Edinburgh
Background: Patients with “Headache Suspicious of Cancer”
should be referred quickly for evaluation, especially if there is
optic disc swelling or visual ﬁeld loss. Previous work shows
patients with tumour headaches often have asymptomatic
cognitive ﬁndings. Based on this we developed an Edinburgh
Protocol Based Referral (PBR) Pathway.
Method: The Edinburgh PBR for “Headache suspicion of cancer"
incorporates an expedited GP open access CT (OACT) within 24-48
hours, if headache is associated with personality or cognitive
change but in addition requires completion of a semantic verbal
ﬂuency test (SVFT) - a simple fast screening test of cognition
(number of animals thought of in one minute). Also, if GP cannot
see the discs or is uncertain about visual ﬁeld defect, local
optometry services will check the patient within 24-48 hours. The
Edinburgh protocol is integrated into the electronic GP referral
system RefHelp – with supporting information.
Results: In year 1, 20% (169/623) of all, and 74% (169/228) urgent,
OACT scans came through the PBR pathway. Many forms were
incompletely submitted. In forms completed correctly (including
the SVFT) median time to scan was 2 days (1-7); Incomplete PBR
was 9 days (3-13) and routine 13 days (9-16). 16.5% of all PBR
requests were abnormal (3 had tumours: glioma 2, meningioma 1).
Where SVFT was completed there was an association between
abnormal CT scan and poorer SVFT (abnormal - median SVFT 13
(IQR 10-17); normal - median SVFT 19 (IQR 13-22).
The Optometry pathway is being promoted and is being
considered for extension across Scotland in the new Scottish
Cancer Referral Guideline (2018/19).
Conclusion: The Edinburgh PBR for “Headache suspicion of
cancer" has been implemented. Expedited scans are being done.
More work needs to be done around GP compliance with SVFT as
this could be a valuable "risk factor" for secondary headache.
Scottish Optometry support and promote the pathway.
Disclosure: Funded by The Brain Tumour Charity
Corresponding author: Robin Grant
13. Give us the tools... Ensuring consumer involvement adds
value
Richard Stephens1, Mat Baker1
1National Cancer Research Institute, UK
Background: The cancer research community has long encour-
aged consumer involvement in the design, delivery and
dissemination of research, including its oversight, regulation,
funding and priority-setting. Recognition of the beneﬁts that
consumers bring to the research process has prompted the
development of a number of toolkits that assist researchers in
recruiting and using patients, carers and members of the public
in cancer research. Less well developed are approaches to
ensuring that consumer involvement is relevant and effective
and that it adds the value that researchers, funders, patients and
carers are seeking.
Method: The NCRI Consumer Forum provides consumer involve-
ment services to the NCRI and to NCRI partners. It seeks to quality
assure the contributions of its members and to ensure that these
contributions are supported by training and development that
enable members to operate to best effect. These collectively
constitute an expert practice model (EPM) that carries a new
recruit from selection and appointment to a Clinical Studies Group
or other NCRI role, through induction training and developmental
learning, supporting them to make a useful contribution in their
individual role, and to add value to the wider contributions of the
Consumer Forum as whole.
Results: Data from the Value and Impact Measures (VIM) indicate
that this structured approach to the development of NCRI
consumers’ expertise is enhancing the value and the positive
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impact of their contributions. Periodic reviews indicate that
induction training and initial support, sponsored attendance at
the NCRI Conference, tailored instruments to assist contributions,
attendance at Forum meetings, involvement in Dragons Den
events and the availability of the NCRI Consumer Toolkit
are all regarded as helping to shape a coherent professional
approach.
Conclusion: It is a goal of NCRI to improve the quality of research.
Evidence is accumulating that the EPM is underpinning Consumer
Involvement as a key enabler to deliver that goal.
Disclosure: Funded by National Cancer Research Institute, UK
Corresponding author: Richard Stephens
14. A quality toolkit for general practice: improving care after
cancer treatment
Paul Baughan1, Lorna Porteous2, Jean Sargeant1, Lorraine Sloan1,
Andy Murphy1, Judith Mabelis1
1Macmillan Cancer Support, 2NHS Lothian
Background: Primary Care has an important role in supporting
people following a diagnosis of cancer. The ‘Macmillan Cancer
Care in Primary Care: a quality toolkit’ was developed to help GP
practices and GP clusters improve care for people living with
cancer.
Method: By using case studies, reﬂective practice, data collection
and critical analysis, practices identiﬁed opportunities for
improvements in current systems and processes as well as
content of Cancer Care Reviews (CCR). Support and advice was
offered from local Macmillan GPs and health board cancer leads.
Practices completed baseline and follow-up questionnaires, and
a quantitative and qualitative evaluation was also undertaken.
Results: 251 Scottish GP practices (26% of total) from 12 health
boards completed the toolkit. 190 practices (76%) completed both
data collection questionnaires.
At baseline, 45% of practices had a robust system in place to
routinely contact people after a diagnosis of cancer, increasing to
78% of practices following completion of the Toolkit (ﬁgure 1).
The range of topics discussed at a CCR increased following
completion of the Toolkit (ﬁgure 2). More practices reported
discussing the provision of cancer information (increased from
28% to 58%), the beneﬁts of physical activity (increased from 25%
to 46%), and the ﬁnancial impact of a diagnosis (increased from
32% to 61%) at follow-up.
Following completion of the Toolkit, 142 GP practices (76% of
total) reported that they felt better equipped to support people
living with cancer by either a moderate or large extent (ﬁgure 3).
Conclusion: People with cancer often consult Primary Care
professionals following their diagnosis. A signiﬁcant proportion
of Scottish GP Practices (26%) undertook the Macmillan Quality
Toolkit. Following completion there is evidence of improved
systems for contacting people following a diagnosis of cancer, a
broader range of issues discussed at CCR, including further
information regarding cancer, exercise, and the ﬁnancial impact of
diagnosis.
Disclosure: Funded by Macmillan Cancer Support
Corresponding author: Paul Baughan
15. A systematic review update on cost-effectiveness of
colorectal cancer screening: identiﬁcation of an optimal
strategy in Europe
Chih-Yuan Cheng1, Tao Ran1, Michael Schlander1
1Division of Health Economics, German Cancer Research Center
(DKFZ)
Background: Biennial guaiac-based faecal occult blood test
(gFOBT), biennial faecal immunochemical test (FIT) and 10-yearly
colonoscopy are the most commonly adopted colorectal cancer
(CRC) screening strategies in Europe. Evidence regarding the
effectiveness and cost-effectiveness of those strategies have been
substantiated, yet there is no consensus on the most cost-effective
modality. We aimed to identify a cost-effectively optimal CRC
screening strategy among the three by conducting a systematic
review.
Method: We searched PubMed, EMBASE, NHS EED, EconLit, and
three other databases for European cost-effectiveness analyses
evaluating any of the three strategies, published between January
2010 and December 2017. Two researchers independently
conducted the review following the standard systematic review
method. Net monetary beneﬁt approach and incremental cost-
effectiveness ratio (ICER) were used to assess the optimal strategy.
Costs were converted to 2016 USD.
Results: We identiﬁed 17 European studies. Only two studies
compared all three strategies– a French study measured the outcome
with life-year gained (LYG) and a German study with quality-adjusted
life-year (QALY). Both found biennial FIT cost-effectively optimal at
and above the willingness-to-pay (WTP) threshold of $20,000 per LYG/
QALY. If focusing on stool-based strategies, ten studies in total
compared biennial FIT and gFOBT. Compared with gFOBT, FIT was
cost-saving and more effective in two English and one German study,
and had ICERs ranging from $2,406 to $11,310 per LYG or $478 to
$2,591 per QALY in the remaining seven studies.
Conclusion: More evidence comparing all three strategies in Europe
is needed, although two studies pointed at biennial FIT being cost-
effectively optimal among the three at various WTP levels, as opposed
to biennial gFOBT and 10-yearly colonoscopy. Between the two stool-
based strategies, biennial FIT was shown to be highly cost-effective (at
$50,000 WTP threshold), or even cost-saving. Our ﬁndings support the
trend in Europe shifting from gFOBT to FIT in CRC screening
programmes.
Disclosure: None declared
Corresponding author: Chih-Yuan Cheng
16. The development of an exercise focused self-management
app (iExhale) for lung cancer survivors to improve their
symptom control
Catherine Henshall1
1Oxford Brookes University, UK
Background: Lung cancer affects over 33,000 people per year in
the UK and many of these have signiﬁcant smoking related co-
morbidities, which can negatively impact on their activities of daily
living and subsequent quality of life. Common symptoms
experienced include breathlessness, fatigue and depression.
Exercise practices have been shown to improve symptom control
in lung cancer patients and exercise based self-management
mobile applications have the potential to provide tailor made,
individualised care to lung cancer survivors and decrease pressure
on NHS services.
The aim of this study was to design and develop an exercise-
focused self-management mobile application for lung cancer
survivors to improve their symptoms of breathlessness, fatigue
and depression.
Method: The study design consisted of three stages. Stage 1 was a
systematic review to examine the impact of exercise interventions in
improving breathlessness, fatigue and depression in lung cancer
survivors. Stage 2 consisted of qualitative focus groups with lung
cancer patients, carers and health professionals to explore their
views on the usefulness of exercise in improving symptom control.
Findings from Stages 1 and 2 informed Stage 3 which consisted of
mobile application development and a usability study.
Results: Stages 1 and 2 found evidence that exercise does improve
symptom control for lung cancer survivors and that exercises need to
be carefully tailored to meet the preferences and needs of individual
lung cancer survivors. These ﬁndings were used to develop the
content and format of the mobile application, which was further
modiﬁed following a usability study with lung cancer survivors.
Conclusion: A working, theoretically underpinned, patient centred
exercise mobile application (iExhale) has now been developed to
help improve the symptom control of lung cancer survivors. Plans
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are to test the feasibility and acceptability of the application in the
community setting, before conducting a full scale randomised
controlled trial.
Disclosure: Funded by Oxford Brookes University
Corresponding author: Catherine Henshall
17. Living with and beyond cancer with comorbid illness: a
qualitative systematic review
Debbie Cavers1, Liset Habets2, Sarah Cunningham-Burley1, Eila
Watson3, Elspeth Banks4, Christine Campbell1
1University of Edinburgh, 2University of Leiden, 3Oxford Brookes
University, 4Independant
Background: There is a need to explore the experience of the
growing number of people living with and beyond cancer with
additional long term chronic conditions, with implications for
cancer survivorship management and support. This review aims to
identify the qualitative evidence on the experience of cancer and
comorbid illness from the perspective of patients, carers and
health care professionals to identify psycho-social support needs,
experience of health care, and to highlight areas where more
research is needed.
Method: PRISMA guidance was used to review the evidence.
Relevant research databases were searched using an exhaustive list
of search terms. Two reviewers independently screened titles and
abstracts and discussed variations. Included articles were subject to
quality appraisal before data extraction of article characteristics and
ﬁndings. Thematic synthesis of extracted ﬁndings was undertaken
following Thomas and Harden’s prescribed method.
Results: 30 articles were included in the review covering a range
of cancer types and comorbid conditions; with varying time since
cancer diagnosis and apparent severity of disease for both cancer
and other conditions. Studies are set in developed countries and
include the views of patients and professionals but not carers. Few
studies focused exclusively on the experience of living with
comorbid conditions alongside cancer. Key themes identiﬁed
included: the interaction between cancer and comorbid condi-
tions; the added symptom burden; illness identities and ageing;
self-management; prioritising conditions, and treatment decision-
making.
Conclusion: In addition to a better understanding of the complex
experience of such illness to illuminate developing models of
patient-centred care, the review will combine with patient
engagement work to inform an interview study with the deﬁned
patient group.
Acknowledgement: A version of this abstract has been
published previously, see https://onlinelibrary.wiley.com/doi/
10.1002/pon.4639 for original and CC-BY license.
Disclosure: Funded by CSO
Corresponding author: Debbie Cavers
18. Changes in physical activity and quality of life in men with
prostate cancer participating in a physical activity behaviour
change pathway
Louis Fox1, Nicola Peat2, Isla Veal2, Mieke Van Hemelrijck1
1Translational Oncology and Urology Research, King's College
London, 2Guy's and St Thomas' NHS Foundation Trust
Background: Exercise has been demonstrated to be beneﬁcial to
men with prostate cancer (PCa). However, maintaining these
exercise behaviours remains a challenge. This study examined a
12-month person-centred physical activity behaviour change
pathway, delivered through a London-based NHS cancer centre,
and determined changes in self-reported physical activity (PA) and
self-reported quality of life (QoL) over the course of 12 months.
Method: 221 men diagnosed with PCa were given the option of
exercising independently/in the community; or undergoing 8-12
weeks of supervised exercise, followed by independent/commu-
nity exercise. All men were given an initial 1-hour consultation,
subsequently followed up via telephone at 4, 7, and 12 months. All
men were offered motivational interviewing, aimed at encoura-
ging exercise behaviour, at all time points.
Results: 68% (n=150) of men remained engaged with the
pathway at 12 months. This retention rate was similar across
treatment groups. Overall, there were increases in self-reported PA
compared with baseline, which were signiﬁcant at 4 and 7, but not
12 months. The trend for increases in PA amongst men on curative
treatment showed signiﬁcance at 4 months compared with
baseline, but not at 7 or 12 months. Men undergoing systemic
treatment reported increases in PA compared with baseline which
were signiﬁcant at all follow up time points. There was a trend
toward increases in reported QoL over time, with signiﬁcant
increases at 4 and 12 months compared with baseline. Men
undergoing curative treatment showed the most pronounced
changes in QoL.
Conclusion: Men with PCa who receive a 1-hour PA behaviour
change consultation, followed by optional supervised exercise classes
for 8-12 weeks, and behaviour change follow-up telephone consults
tend to report increases in PA levels and QoL over 12 months,
compared with baseline. Improvements in PA and QoL were most
apparent for men on systemic and curative treatment, respectively.
Disclosure: Funded by Guy's and St Thomas' NHS Foundation
Trust; Mr Christopher Cottrell (independent donor)
Corresponding author: Louis Fox
19. Impact of psychological counselling service at Penny
Brohn UK
Jo Durrant, Helen French, Marian Naidoo, Sarah Churchward,
Michelle Grifﬁths, Helen Seers
Penny Brohn UK
Background: For people with cancer, research has shown
counselling may be beneﬁcial for wellbeing, anxiety, depression
and helping with the sexual side-effects of cancer. Penny Brohn
UK (PBUK) is a cancer charity that supports people to live well with
cancer. It offers face-to-face or telephone counselling for anyone
aged over 18 with a cancer diagnosis and their close supporters.
Method: PBUK’s counselling service was evaluated using the
validated person-centred outcome measure MYCaW (Measure
Yourself Concerns and Wellbeing), measuring the impact of cancer
support services on the severity of people’s cancer related
concerns and wellbeing. Concerns were rated at the start of
counselling and re-rated at the end of the last session. Qualitative
data was captured on the MYCaW tool regarding other things
going on in people’s life affecting health and what was important
about the service they received. Data was analysed using the
accompanying qualitative coding framework.
Data was analysed for all clients who had attended counselling
appointments in January- December 2017 and provided full pre-
post-counselling MYCaW data.
Results: 40 clients provided pre-post MYCaW data and attended
an average of 6 sessions (range 1 to 18). Psychological and
emotional concerns were top rated for concern 1 and 2 (81% and
78% respectively). Prior to counselling, concerns were rated fairly
severely (5.1/6 for concern 1 and 2; 6 being the worst). After
counselling concerns showed a statistically signiﬁcant improve-
ment (2.2/6 and 2/6 for concern 1 and 2 respectively, p<.000 for
both). 90% of clients showed a clinically signiﬁcant improvement
in their concerns. Qualitative data indicated that counselling at
PBUK gave clients the opportunity to talk, provided time for
themselves and made them feel supported and understood.
Conclusion: Counselling at PBUK led to a statistically signiﬁcant
improvement in cancer-related concerns and wellbeing. A larger
sample is needed to explore this further.
Disclosure: Funded by Penny Brohn UK
Corresponding author: Helen Seers
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20. An exploratory study on the use of game-based learning
using Microsoft Kinect to teach oncology phase I clinical trial
designs
Alan Bilsland1, Caroline Kelly2, Jennifer Roccisana3, James Paul2,
Rob Jones2, Joanne Edwards3, Antonia Roseweir4, Torsten Stein3,
Katherine West5
1Institute of Cancer Science, Wolfson Wohl Cancer Research Centre,
University of Glasgow, 2Cancer Research UK Clinical Trials Unit,
Institute of Cancer Science, University of Glasgow, 3Institute of Cancer
Science, University of Glasgow, 4School of Medicine, Dentistry and
Nursing, University of Glasgow, 5School of Life Sciences, University of
Glasgow
Background: Phase I trials are the ﬁrst stage in drug development.
Major objectives include determining toxicities of new agents and
maximum tolerated dose (MTD) for later clinical stages. The 3+3
design is most common, although support is growing for newer
“model-based” designs. One criticism of these is their complexity.
To investigate gamiﬁcation in teaching these designs to MSc/
BMedSci Cancer Science students, a computer game using
Microsoft Kinect motion sensing was used to supplement existing
lectures.
Method: The game objective is to ﬁnd MTD of “drug X”. Groups
of 3-5 receive a draft trial protocol, pre-clinical toxicology report,
and instructions for allometric scaling to human dose. Players
ﬁrst decide dose ranges to investigate. Using the game, patient
cohorts are recruited, administered drug X, and toxicities
checked. Players decide if dose limiting toxicity (DLT) is
observed and whether to dose-escalate/de-escalate, expand
the cohort, or stop. Each group plays a different trial design.
Feedback was taken using a questionnaire investigating
technology interaction, group working, learning outcomes and
engagement.
Results: The game was tested with 3 student cohorts using
different control methods (student-led, tutor-led, or mixed). 7/10,
7/8, and 12/21 students consented to analysis of their responses.
Across cohorts, learner engagement items scored particularly
highly. Nearly all also reported improved understanding of the
concepts of DLT and MTD. Many also reported improved
understanding of different phase I designs. Mann-Whitney analysis
of responses under the different control conditions revealed few
signiﬁcant differences. Our favoured approach is mixed-mode
control.
Conclusion: In the clinical trials education literature, studies of
active learning approaches appear to be sparse. We have not yet
formally evaluated student-reported learning improvements in a
test/re-test setting. However, positive feedback across items of our
questionnaire suggests that students value the activity. We
envisage potential future extensions to the game addressing
aspects of phase I design beyond recruitment and dosing.
Reference: Microsoft Kinect, https://marketplace.xbox.com/en-
GB/Product/Kinect-for-Xbox-360/66acd000-77fe-1000-9115-
d8025858084b
Disclosure: Funded by Glasgow Experimental Cancer Medicine
Centre (funded by Cancer Research UK and the Chief Scientist
Ofﬁce, Scotland); University of Glasgow
Corresponding author: Alan Bilsland
21. Successes and challenges in the implementation of the
HOPE self-management programme for people living with
and beyond cancer
Gemma Pearce1, Sally Pezaro1, Joanne Parsons1, Andy Turner1,
Paramjit Gill2, Tracey Norris3
1Coventry University, 2University of warwick, 3Associate Learning and
development Manager and regional lead for H.O.P.E Macmillan
Cancer support
Background: The HOPE Programme© is a self-management
course developed with people living with and beyond cancer
and licensed by Macmillan Cancer Support to be delivered across
the UK. Despite this, delivery is inconsistent across regions. The
aim of this research was to examine barriers and successes of
implementation to improve future delivery.
Method: 10 focus groups and 27 interviews were completed across
6 UK regions using an Interpretive Description approach. Participants
(n=73) were recruited by Macmillan gatekeepers for being involved
in the promotion and delivery of the HOPE Programme (Macmillan
staff, commissioners, healthcare professionals, attendees and facil-
itators). Analysis was completed using Framework Analysis.
Results: Barriers to implementation included getting the course
up-and-running regularly, incorporating the programme into the
care pathway, buy in from professionals, time, money, venue,
supporting people returning to work, recruiting men, younger
people and BME groups.
Successes of implementing the course occurred when Macmil-
lan staff, healthcare professionals, volunteers and management
were involved in the plans from the beginning, actively referring
and encouraging course retention. Cancer Information Centres
were useful hubs to recruit onto the course. Patients liked the
friendly neutral space and professionals found it useful to signpost
patients. The most successful time to refer patients to the course
was after being discharged from treatment when patients often
felt isolated like “falling off of a cliff”. Professionals liked having the
HOPE Programme to refer patients to meet their unmet
psychosocial needs.
Conclusion: These ﬁndings help understand barriers further and
provide examples of how some sites have successfully overcome
them. Some felt that more of a nationwide recruitment strategy
and advertisement scheme would be beneﬁcial, encouraging
regions to incorporate the programme into the patient’s care
pathway. Sharing these lessons of implementation will hopefully
improve implementation consistency across the nation, increase
the impact of the course and inform the implementation science
ﬁeld.
Disclosure: Funded by Coventry University
Corresponding author: Gemma Pearce
22. Introduction of treatment summaries and holistic needs
assessments for teenagers and young adults after cancer
treatment in Scotland: a national feasibility study
Angela Edgar1, Nicola Davison1, Simita Kumar1, Bernadine Wilkie1,
Jeff White2
1NHS Lothian, 2NHS Greater Glasgow and Clyde
Background: The Scottish Government recommends that all
teenagers and young adults (TYA) treated for cancer, receive a
Treatment Summary (TS) and Holistic Needs Assessment (HNA) to
aid communication, education, self-management and identify
areas of concern. The objectives of this study were: i) To determine
the feasibility of implementing TS and HNA for Scottish TYA after
cancer treatment; and ii) to share the TS with health professionals
to improve communication and engagement.
Method: Scottish TYA (16-24 years) completing cancer treatment,
between April 2016 -April 2017, were identiﬁed at the weekly
National TYA Multidisciplinary Team (TYA MDT) meeting. Treat-
ment Summaries and HNA were completed and distributed to
patients and health professionals.
Results: Of 83 eligible patients, 51 were recruited (response rate
61%); 26 (51%) males, median (range) age 22 (16 – 25) years.
Among non-recruits: 2 relocated, 1 relapsed, lead consultant
deemed the process ‘not relevant’ (n=6), or did not respond
(n=23). Cancer diagnoses: germ cell tumours (39%), lymphomas
(27%) and bone tumours (14%) over represented; carcinoma (8%),
melanoma (2%) and CNS tumours (2%) under-represented.
Conclusion: Treatment Summaries and Holistic Needs Assess-
ments were completed for almost two thirds of TYA identiﬁed
after cancer treatment. Recruitment failure was due largely to
consultant disengagement. Based on incidence data, current
pathways do not allow identiﬁcation of almost half of patients at
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the end of treatment. Completion of TS/HNA is labour intense and
adequate time and training must be provided. By sharing
Treatment Summaries, we have improved communication and
engagement with Primary Care and provided clear pathways for
referral of patients to hospital when problems arise.
Disclosure: Funded by Macmillan Cancer Care
Corresponding author: Angela Edgar
23. Holistic needs assessments for teenagers and young adults
after cancer treatment in Scotland identiﬁed a signiﬁcant
burden of unmet needs
Angela Edgar1, Nicola Davison1, Simita Kumar1, Bernadine Wilkie1,
Jeff White2
1NHS Lothian, 2NHS Greater Glasgow and Clyde
Background: Psychosocial issues are common amongst Teen-
agers and young adults (TYA) after cancer treatment and TYA
report feeling unsupported. The objective of this study was to
determine the burden of needs amongst TYA after cancer
treatment and evaluate whether these needs are being met.
Method: Scottish TYA (16-24 years) completing cancer treatment,
between April 2016-April 2017, were identiﬁed. Treatment
Summaries (TS) and Holistic Needs Assessment (HNA) were
completed and distributed (TS only) to patients and health
professionals. Qualitative analysis identiﬁed concerns.
Results: Fifty-one of 83 eligible TYA were recruited (response rate
61%); 26 (51%) males, median (range) age 22 (16 – 25) years with
over-representation of germ cell tumours (39%), lymphomas
(27%), bone tumours (14%). TS data was available for 51 (100%)
and raw HNA data for 26 patients (50%). 45 TYA (88%) reported
concerns: 35 (69%) reported 1-5 concerns; 2 (4%) reported 6-10
concerns; 5 (10%) reporting 11-15 concerns; 1 (2%) reported 1
concern and 2 (4%) reported >20 concerns: general appearance,
physical ﬁtness and emotional issues, were the most numerous.
One third of TYA were referred for psychological support; two-
thirds beneﬁtted from third sector support programmes.
Conclusion: Almost 90% of TYA reported at least one concern
after cancer treatment, with more than two-thirds of patients
reporting ﬁve to 10 concerns, and 10% reporting up to 15
concerns. While support services, largely provided by third sector,
are in place for many patients, further evaluation of the Health
Needs Assessments, exploring relationships to diagnoses, and
identiﬁcation of gaps in services, are required to inform future
developments.
Disclosure: Funded by Macmillan Cancer Care
Corresponding author: Angela Edgar
24. Identifying and counting people living with treatable but
not curable cancer in the England cancer registry
Rachel White1, Joanna Pethick2, Archie Macnair3, Gregory Fallica1,
Jennifer Than4, Jane Maher1
1Macmillan Cancer Support, 2National Cancer Registration and
Analysis Service, Public Health England, 3Macmillan Cancer Support
& The Royal College of Radiologists, 4Macmillan Cancer Support &
National Cancer Registration and Analysis Service, Public Health
England
Background: There is a growing cohort of people who, although
they cannot be cured of their cancer, are on treatments that can
reduce cancer burden, alleviate symptoms and prolong life. This is
a heterogeneous group with different prognoses and treatments,
which could be described as living with treatable but not curable
cancer (TNCC).
This project aims to build a search criterion to identify the TNCC
population using the England cancer registry.
Method: A set of possible search criteria were developed for
evaluation by 20 oncologists, haematologists and specialist nurses.
Through their expertise and analysis, we will reﬁne this into a
single, comprehensive search criterion.
Results: Our ﬁrst criterion was based on distant metastatic cancer
at diagnosis. There were 76,000 people in England in 2015
diagnosed either at stage IV cancer, with a secondary malignancy
or with certain haematological cancers. Our next criterion focused
on metastatic disease developed post-diagnosis. It included
135,000 people identiﬁed in inpatient HES and 10,000 from the
Cancer Waiting Times dataset.
Our next set of criteria focused on treatment. This selected
46,000 people who, in 2015, received one of 236 chemotherapy
regimens thought to target TNCC; or had a second chemotherapy
treatment over a year from their ﬁrst treatment. It found 7,000
people who had a second round of radiotherapy after a six-month
gap. Another criterion pinpointed 99,000 people who received
palliative chemotherapy or radiotherapy.
In the ﬁnal searches we identiﬁed 57,000 people diagnosed
with an intermediate survival cancer and 78,000 with a shorter-
term survival cancer. McConnell et al. (2017) hypothesised that
intermediate survival cancers are often long-term conditions. New
treatments will make the shorter-term survival group an important
part of TNCC.
Conclusion: The criteria will not cover all circumstances but,
ultimately, this project will allow better recognition of people with
TNCC and help appropriate services to be provided for them.
Disclosure: Funded by Macmillan Cancer Care
Corresponding author: Rachel White
25. A randomised controlled trial to assess the impact of
regular early specialist symptom control treatment on quality
of life in malignant mesothelioma – ‘RESPECT-Meso’
Fraser Brims1, Samal Gunatilake2, Iain Lawrie3, Laura Marshall2,
Carole Fogg4, Cathy Qi5, Nick Maskell6, Karen Forbes6, Najib
Rahman5, Steve Morris7, Stephen Gerry5, Anoop on behalf of the
RESPECT-Meso investigators Chauhan2
1Sir Charles Gairdner Hospital, 2Portsmouth Hospitals NHS Trust, 3North
Manchester General Hospital, 4University of Portsmouth, 5University of
Oxford, 6University of Bristol, 7University College London
Background: Malignant pleural mesothelioma (MPM) is a cancer
with a high symptom burden and a median survival of less than one
year. Evidence from other cancer types suggests there may be some
beneﬁt in health related quality of life (HRQoL) with the integration
of early specialist palliative care (SPC) with existing oncological
services, but the level of certainty of evidence is low.
Method: Participants with newly diagnosed MPM were rando-
mised to early SPC integrated with standard care, or standard care
alone, in a 1:1 ratio. Main carers were recruited additionally.
Quality of life (QoL) and mood were assessed at baseline and
every 4 weeks for up to 24 weeks with the EORTC QLQ–C30
questionnaire for QoL and General Health Questionnaire (GHQ-12)
for anxiety/depression. The primary outcome was the change in
EORTC C30 Global Health Status (GHS) QoL 12 weeks after
randomisation.
Results: Between April 2014 and October 2016 we randomised 174
participants. The two groups were well matched after randomisa-
tion. There was no signiﬁcant between group difference in QoL
score at 12 weeks (mean difference adjusted for baseline between
groups 1.8 (95% CI: -4.9 to 8.5; p = 0.59)). QoL did not differ at
24 weeks (mean difference adjusted for baseline -2.0 (95% CI: -8.6 to
4.6; p = 0.54)). There was no difference in depression/anxiety scores
at 12 or 24 weeks. In carers there was no between group difference
quality of life and mood at 12 or 24 weeks, although there was a
consistent preference for care, favouring the intervention arm.
Conclusion: There is no role for routine referral to SPC soon after
diagnosis of MPM for patients who are cared for in specialist
centres with good access to SPC when required.
References: QLQ-C30 - Aaronson NK, Ahmedzai S, Bergman B,
Bullinger M, Cull A, Duez NJ, et al. The European-Organization-For-
Research-And-Treatment-Of-Cancer QLQ-C30 – A quality-of-life
instrument for use in international clinical trials in oncology. J Natl
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https://books.google.co.uk/books/about/
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id=LpSuGQAACAAJ&redir_esc=y
Clinical Trial Registry: ISRCTN18955704; http://www.isrctn.com
Disclosure: Funded by British Lung Foundation and Australian
Communities Grant
Corresponding author: Cathy Qi
26. Prevalence, characteristics and outcomes of bone
metastases in patients with neuroendocrine neoplasms (NENs)
Hussain Raja1, Kok Haw Jonathan Lim2, Paolo D'Arienzo2, Jorge
Barrisuso3, Mairéad McNamara3, Richard Hubner2, Was Mansoor2,
Juan Valle3, Angela Lamarca2
1The Christie NHS Foundation Trust, 2Department of Medical Oncology,
The Christie NHS Foundation Trust, Manchester, United Kingdom,
3Department of Medical Oncology, The Christie NHS Foundation Trust,
Manchester, United Kingdom. Division of Cancer Sciences, University of
Manchester, Manchester, United Kingdom
Background: Bone metastases (BMs) from NENs are rare. Updated
guidelines for adequate management of BMs in NENs are lacking,
with current practice based on recommendations for other
malignancies.
Method: This is a retrospective study of patients with NENs (any
grade); patients with grade 3 NENs were eligible if non-lung
primary. BMs were classiﬁed as symptomatic in the presence of
pain, hypercalcaemia and/or skeletal-related events (SRE; patho-
logical fracture or metastatic spinal cord compression). Median
survival was estimated using Kaplan-Meier analysis (SPSS V.23.0,
https://www.ibm.com/analytics/spss-statistics-software).
Results: Of 1459 patients screened, 85 (7.0%) were identiﬁed to
have NEN-related BMs. Median age was 58 years (IQR 47.5 – 67.5).
Most patients were male (56.5%), and had non-functional (43.5%),
grade 1/2 (81.2%), gastro-entero-pancreatic (49.4%) NENs. Only
28.2% of patients presented with BMs at ﬁrst diagnosis of
metastatic disease. The median time from diagnosis of metastatic
disease to identiﬁcation of BMs was 4 months (95%CI 0.0 – 8.2).
The most frequent pattern of BMs was widespread (61.2%)
(oligometastatic 32.9%, unknown 5.9%). Most patients were
asymptomatic (58.8%) at initial diagnosis of BMs, although a
majority (77.6%) later develop BM-related symptoms (pain/
hypercalcaemia 63.5%, SRE 20.0%). In this cohort, BMs were
managed mainly with analgesia (43.5%). Radiotherapy and
bisphosphonates were used in 34.1% (36.5% when analysis
limited to patients with BM-related pain) and 21.2% (26.9% when
analysis limited to patients with widespread BMs), respectively.
Surgery was rarely performed (2.4%). Median overall survival from
identiﬁcation of BMs was 31.0 months (95% CI 19.6 – 24), and from
the time of development of BM-related symptoms was
18.9 months (95%CI 8.7 – 29.1).
Conclusion: BMs, albeit rare in NENs, frequently become
symptomatic. Radiotherapy and bisphosphonates are used less
frequently in NENs. Increased awareness and earlier interventions
may improve patients’ quality of life following diagnosis/
symptoms of BMs.
Disclosure: Funded by The Christie NHS Foundation Trust
Corresponding author: Hussain Raja
27. Patient-reported outcomes in men with advanced and
localised disease: Results from the UK-wide Life After Prostate
Cancer Diagnosis study
Amy Downing1, Penny Wright1, Sarah Wilding1, David Donnelly2,
Luke Hounsome3, Eila Watson4, Richard Wagland5, Hugh Butcher1,
Paul Kind1, Peter Selby1, James Catto6, William Cross7, Dyfed Huws8,
David Brewster9, Anna Gavin2, Adam Glaser1
1University of Leeds, 2Queens University Belfast, 3Public Health
England, 4Oxford Brookes University, 5University of Southampton,
6University of Shefﬁeld, 7Leeds Teaching Hospitals NHS Trust, 8Public
Health Wales, 9University of Edinburgh
Background: Prostate cancer (PCa) outcome studies frequently
focus on localised cancer and little is known regarding advanced
disease. The Life After Prostate Cancer Diagnosis (LAPCD) study is
a large-scale population-wide evaluation of patient-reported
outcomes in men with PCa, including all stages of disease and
all treatments. Here we report the functional outcomes and
health-related quality of life (HRQL) of men with advanced and
localised disease.
Method: Men diagnosed 18–42 months previously were identiﬁed
through cancer registration data in each United Kingdom (UK)
nation. Postal surveys were used to collect data on functional
outcomes (EPIC-26 plus interventions for sexual dysfunction) and
generic HRQL (EQ-5D-5L and self-assessed health [SAH; rated 0-
100]), alongside sociodemographic and treatment information.
Results: 35,823 (60.8%) men responded; median age 71 years.
Stage at diagnosis was known for 85.8% of respondents; 63.8%
stage I/II, 23.5% stage III, 12.8% stage IV. Overall HRQL reports
were good. Poor sexual function was common (78.9%), regardless
of disease stage and few men received help for this (medication:
41.4%; devices: 22.6%; specialist services: 14.8%; 56.5% offered no
intervention). Androgen deprivation therapy (ADT) use was
associated with poorer HRQL, hot ﬂushes and lack of energy. A
quarter of men with stage IV disease reported no problems on any
EQ-5D dimension (compared to 42.1% stage I/II, 36.4% stage III).
SAH was 6 points lower in men with stage IV disease (71.6)
compared to men with localised cancer (77.8) but this difference
was greater in younger men.
Conclusion: 18-42 months after diagnosis of PCa, a high
proportion of men report sexual dysfunction and less than half
were offered intervention. Loss of HRQL through ADT is common
and is more pronounced in younger men. The good overall HRQL
allows clinicians to present positive goals for quality of survival
after PCa, including for many diagnosed with advanced disease.
Disclosure: Funded by the Movember Foundation, in partner-
ship with Prostate Cancer UK (grant number BO26/MO)
Corresponding author: Adam Glaser
28. Home renal monitoring for cancer patients: technical
assessment and patient acceptability
Leanne Ogden, Donal Landers, Jenny Royle, Laura Stephenson, Laura
Hutchinson
Digital Experimental Cancer Medicine Team
Background: Recruitment to cancer clinical trials is challenging and
usually limited to patients with preserved kidney function. Restrictions
that allow those with an eGFR >50ml/min is arbitrary and not a risk-
based approach driven by current clinical science. Due to increased
survival rates for both conditions, there is now a signiﬁcant population
who have both cancer and chronic kidney disease. The aim of this
research was to assess whether new technological advances in point
of care (POC) creatinine meters and digital science could be used to
give these people access to oncology clinical trials through
personalised risk-based monitoring. We created an approach that
explored the potential and acceptability of using a POC device, data
capture via a smartphone, and risk-categorisation through an Acute
Kidney Injury (AKI) algorithm, to enable decision-making and the ﬁrst
step in addressing this unmet clinical need.
Method: Three POC devices were evaluated for usability, size and
complexity. A smart phone app was developed, which captures
device data and sends securely to a Cloud environment.
Creatinine testing, calibration and patient acceptability in the
hospital was conducted over a 2 week period with 17 interactions
(patient/carer/nurse) and including two patient focus groups.
Results: The Nova Biomedical Creatinine StatSensor® was the
preferred device chosen to enable home creatinine readings with
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good user feedback and stable performance characteristics. The
smartphone app user interface design was acceptable with
patients based on patient acceptability testing- producing near-
real time creatinine readings which could be reviewed by the
medical team.
Conclusion: This proof of concept demonstrated that creatinine
can be measured by a POC device, the data captured by an app
and reported in near-real time. Further work is now being
conducted to develop a clinical rules engine based on the NHS/
NICE published algorithm for AKI; and apply this in clinical trials to
alert investigators to impending AKI.
Disclosure: Funded by AstraZeneca
Corresponding author: Leanne Ogden
29. Patient reported experiences (PREs) from the
PERSEPHONE early breast cancer (EBC) trial
Janet Dunn1, Maggie Wilcox2, Claire Balmer1, Sophie Gasson1, Louise
Hiller1, Anne-Laure Vallier3, Claire Hulme4, Kerry Raynes1, Donna
Howe1, Helen Higgins1, David Miles5, Andrew Wardley6, David
Cameron7, Helena Earl3
1University of Warwick, 2Independant Cancer Patients’ Voice (ICPV),
London, UK, 3Cambridge University Hospitals, 4University of Leeds,
5Mount Vernon Cancer Centre, 6The Christie Clinical Research Facility,
7University of Edinburgh
Background: PERSEPHONE is a Phase 3 randomised non-
inferiority trial comparing 6 months of trastuzumab to the
standard 12 months in patients with HER2 positive EBC. An
important component of the trial was collecting information
about patient experiences. Collecting ‘quasi-qualitative’ data via
open-ended questions is becoming increasingly common and
championed as a way to add depth to assessments and
complement quantitative survey data.
Method: Alongside the toxicities reported on the trial case report
forms (CRF) and patient booklets being collected, including quality
of life (QoL) and Health Care Resource Usage, patients were
invited to record comments about the study and their treatment.
Experiences were recorded prior to commencement of trastuzu-
mab, then 3-monthly for a year, then every 6 months up to year 2.
Within a mixed methods framework, both the trial researcher and
patient representatives explored the information collected using a
thematic content analysis.
Results: Between Oct’07 and Jul’15, 4088 patients were rando-
mised. In total, 5542 experiences were recorded from 2456
patients across the 6 time-points. Patients offered information on
all aspects of the study, including their views on the treatment,
their care, the QoL questionnaire and the research itself. Most
often mentioned was the impact the treatment had on
participants personally - physically, psychologically or socially.
Most frequently cited were aches and pains and fatigue; for many,
these did appear to be particularly distressing and intractable. In
parallel, the CRFs reported 20% of patients reporting a grade 3/4
toxicity during treatment (23% 12 month, 18% 6 month, p=0.004),
with signiﬁcantly higher rates of cough, pain, fatigue, chills and
palpitations reported by 12 month patients (p<0.05).
Conclusion: Patients’ experiences during and beyond trastuzu-
mab highlighted the long-term cumulative effects of their
treatment and conﬁrm that patients do suffer from burdensome
toxicity with dramatic impact on their QoL.
Disclosure: Funded by NIHR Health Technology Assessment
(HTA)
Corresponding author: Janet Dunn
30. Evaluation of Penny Brohn UK’s national programme of
‘Living Well With and Beyond Cancer’ services
Helen Seers1, Michelle Grifﬁths1, Sarah Churchward1, Rebecca
Samuel2, Marian Naidoo1, Helen French1, Rachel Jolliffe1, Jo Durrant1
1Penny Brohn UK, 2University of Bath
Background: Penny Brohn UK (PBUK) is a leading UK charity
specialising in helping people live well with the impact of cancer.
National Lottery’s Big Lottery funding between 2015-18 has
supported PBUK Living Well with and Beyond Cancer (LWWBC)
services in ﬁve areas of the UK. Services include Living Well
courses (LWC), Follow-Up (FU) support.
Method: Pre and 6-weeks post-LWWBC questionnaires used were:
Patient Activation Measure (PAM) for health self-management,
Measure Yourself Concerns and Wellbeing (MYCaW) for concerns
and wellbeing perception, and Patient Reported Experience
Measure for personal reﬂection on support gained.
Results: 145 courses (123 LWC and 22 FU), located in North
England (8), South Coast (32), Midlands (29), South East (43) and
South West (33) are running over 3 years. 901 people with cancer
enrolled in the ﬁrst 2 years with between 12-23% (111-206)
evaluation postal response rate for pre-post paired data. Year 3 is
still underway. Years 1 and 2 data as follows: 43% (48/111) had a
meaningful improvement in their post Patient Activation Measure
scores indicating they were more likely to go on to self-manage
their health. 87% (163/188) of people stated they had been better
able to self-manage their own health after LWWBC services.70%
(144/206) had a clinically signiﬁcant improvement in their MYCaW
main cancer related concerns, and 43% (89/205) had a clinically
signiﬁcant improvement in MYCaW wellbeing.There were
reported improvements in: diet (87% 174/199), exercise (74%
143/193) relationship issues (63% 120/189) and use of stress
management techniques (90% 179/199). Of the 199 respondents,
65% reported subsequently attending a meditation or group and
60% joined an exercise class after the LWWBC. Patterns of
improvement in MYCaW cancer-related concerns and wellbeing
were reported across all regions, demonstrating a successful
expansion of PBUK support services across England.
Conclusion: PBUK’s LWWBC evaluation responses indicate a
positive and potentially beneﬁcial experience.
Disclosure: Funded by Penny Brohn UK
Corresponding author: Helen Seers
31. Evaluation of a Chemotherapy Closer to Home model for
breast cancer patients
May Teoh1, Nicola Daws Twilley2, Emma Bond3, Judith Dua2, Regina
Santos4, Sara Wills Percy1, Victoria Mumford1, Susan Dargan2
1Royal Surrey County Hospital NHS Foundation Trust, 2Ashford and
St Peter's Hospital NHS Foundation Trust, 3Ashford and St
Peter'sHospital NHS Foundation Trust, 4Ashord and St Peter's Hospital
NHS Foundation Trust
Background: The Chemotherapy Closer to Home model is aimed
at improving patient experience by facilitating more convenient
access to treatment for patients closer to their homes. A joint
initiative by Ashford and St Peter’s Hospital (ASPH) and Royal
Surrey County Hospital (RSCH) successfully launched a chemother-
apy outreach service at Ashford Hospital so patients could receive
treatment locally. The service at Infusion Suite Ashford (ISA)
commenced with breast cancer patients and an evaluation of the
service was conducted.
Method: Patients who attended ISA for breast cancer treatment in
2016 were included. Data on patient demographics, treatment
details and time-distance savings were analysed. A patient
feedback survey was conducted to evaluate patient satisfaction
and experience.
Results: 108 breast cancer patients received treatment at ISA in
2016 (total 883 attendances). Median age was 60 years (range 26
– 89 years). Median number of attendances per patient was 7
(range 1-20). 53.7% had stage IV disease and were receiving
palliative treatment. 61% of attendances were for systemic anti-
cancer therapy, 29.1% for supportive treatment (e.g. Zoledronic
acid) and 9.3% for both. Average round-trip distance for patients
treated at ISA was 9.8 miles per attendance, compared to 40.8
miles if treated at RSCH. Average round-trip time for patients
treated at ISA was 27.4 minutes, compared to 56.7 minutes if
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treated at RSCH. Of survey respondents (n = 17), 100% rated their
overall care as excellent or very good. Satisfaction scores were
high for support and information given during chemotherapy
(e.g. advice on managing side effects).
Conclusion: The chemotherapy outreach service at ASPH has
successfully provided a high quality, convenient option for
patients to receive treatment closer to home. This is especially
valuable as a signiﬁcant proportion of patients have advanced
disease and often require multiple attendances for palliative
treatment. The service is now expanding to include other tumour
sites.
Disclosure: None declared
Corresponding author: May Teoh
32. Future of clinical trials after Brexit
Zoe Martin1, Nerea Cuadra2, Peter Glenday2, Guy Yeomans2
1Cancer Research UK, 2School of International Futures
Background: Brexit has introduced uncertainty over the future of
clinical trials and the UK's ability to collaborate with the EU. There
is a need for a more developed evidence base on how to ensure a
successful future for clinical trials. Cancer Research UK (CRUK)
commissions policy research to inform our thinking and to
develop a wider evidence base for positive change.
Method: The School of International Futures are delivering the
study using a futures approach based on horizon scanning, trend
analysis and scenario planning to explore the future of clinical
trials. The project had 4 phases: (1) Identiﬁcation of what is
shaping the future of clinical trials; Rapid evidence assessment of
literature; 23 interviews with researchers, patients, clinicians,
industry, government and regulators in the UK, EU and
internationally. (2) Online survey assessment to gather sector
views on the most important and uncertain drivers of change and
to gather additional perspectives. (3) Scenario development – ﬁve
potential scenarios were developed for the future of clinical trials.
(4) A participative workshop with the 38 participants explored the
scenarios to identify implications and develop recommendations.
Results: The study identiﬁes implications of the different potential
Brexit scenarios on the future of clinical trials, grouped into ﬁve
themes. For each theme, there are recommendations aimed to
ensure a successful future of clinical trials and a positive outcome
for patients. Results will be ﬁnalised by July 2018.
Conclusion: Findings and recommendations will be used to
inform policy makers during negotiations of the UK’s exit from the
EU and to ensure the best outcome in any Brexit scenario. There is
interest in the study from policy makers who were informed and
involved during the study, including attending our workshop.
Disclosure: Funded by Cancer Research UK
Corresponding author: Zoe Martin
33. Cisplatin-induced kidney injury is transient and associated
with short-term elevation of urine interleukin-18 in patients
with testicular cancer
Alan Cameron1, Kelly McMahon2, Paul Welsh1, Ashita Waterston3,
Michael Zappitelli4, Jeff White3, Patrick Mark1, Rhian Touyz1, Ninian
Lang1
1University of Glasgow, 2McGill University, 3Beatson West of Scotland
Cancer Centre, 4University of Toronto
Background: Cisplatin causes acute kidney injury (AKI) but
changes in urinary AKI biomarkers are not well deﬁned clinically.
We investigated short- and intermediate-term AKI using novel
biomarkers over 9 months in patients with testicular cancer
treated with cisplatin.
Method: Prospective observational study of men with testicular
cancer in 3 groups following orchiectomy: 1) surveillance; 2)
adjuvant cisplatin-based chemotherapy (1-2 cycles); 3) metastatic
cisplatin-based chemotherapy (3-4 cycles). Blood and urine was
collected at 6 visits: baseline, 24h, 6 weeks, 3, 6 and 9 months for
renal injury markers.
Results: 27 men (median age 34y [IQR 31-40y]) were recruited:
surveillance (N = 10); adjuvant cisplatin (N = 7); metastatic
cisplatin (N = 10). Urinary renal injury biomarkers (interleukin-18
[IL-18], neutrophil gelatinase-associated lipocalin [NGAL], vascular
endothelial growth factor [VEGF], kidney injury molecule-1 [KIM-1],
albumin/creatinine ratio [ACR]) and serum cystatin C (CysC) were
elevated at 24h and 6 weeks (KIM-1) post-cisplatin in adjuvant and
metastatic groups (all: P<0.05 vs. baseline). These normalized by
6 weeks (IL-18; NGAL; VEGF; ACR; CysC) and 3 months (KIM-1).
eGFR was within normal range throughout.
Conclusion: Novel biomarkers indicate cisplatin nephrotoxicity is
reversible over 3 months. Elevation of IL-18 supports a major
inﬂammatory renal insult. This provides evidence to support
investigation of anti-inﬂammatory drugs for cisplatin nephrotoxi-
city prevention.
Disclosure: Funded by British Heart Foundation
Corresponding author: Alan Cameron
34. Information giving in breast cancer: A service review of
the Mid-Yorks NHS Trust
Georgina Appleyard1, Hannah Jones1, Jay Naik2
1University of Leeds, 2Mid Yorks NHS
Background: This study aimed to understand patient information
needs and explore information giving in the Mid-Yorks Breast
Cancer Service.
Method: A service evaluation was conducted via a questionnaire
distributed to patients at outpatient-clinics across Mid-Yorks
Hospitals and was completed by 53 patients.
Results: Patient experience was largely positive; 91% of partici-
pants reported fully understanding the explanation of their breast
cancer diagnosis and 89% felt involved in treatment decisions. The
majority of patients (62%) preferred verbal information, closely
followed by written information (26%), email (4%) and video (2%).
Verbal and written information combined was viewed as most
effective, providing greatest patient satisfaction and opportunities
to clarify with questions, aiding later recall. Yet, the older
participants preferred written information above all else. The
majority of patients (83%) wanted to be told as much as possible
about their cancer; however, some only wished to know important
details about their diagnosis. Patients valued their doctor and
nurses equally as information-givers, due to their respective
skillsets. Communication style was important, with patients
requiring sympathetic, straightforward and honest healthcare
professionals who are able to provide care tailored to the
individual patient. Clinical Nurse Specialists were found to be
vital for high patient satisfaction and a care plan useful in
individualising care.
Conclusion: The results highlight the need for clear and honest
information provision by healthcare professionals that is focused
to suit the needs and preferences of the patient. Personalised care
plans for each patient, along with provision of contact details for a
Clinical Nurse Specialist, can help facilitate this. Future research
could involve implementing an information checklist as part of
breast cancer patient care to ensure all patients’ information
needs are provided for. In summary, all healthcare professionals
must ensure that effective tailored communication is at the heart
of the care they provide to improve patient satisfaction.
Disclosure: Funded by University of Leeds
Corresponding author: Hannah Jones
35. “…you can feel..a little isolated if you haven’t got the
contact”; qualitative analysis of an innovative service to
support prostate cancer survivors with radiotherapy late
effects (the EAGLE study)
Stephanie Sivell1, Elin Baddeley1, John Staffurth2, Sophia Taylor3,
Annmarie Nelson1
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Background: Prostate cancer survivors may experience bowel
gastrointestinal side effects of radical radiotherapy for prostate
cancer. These symptoms can lead to severe difﬁculties including
limiting work, travel or socialising. To improve the care for patients
with bowel problems, the EAGLE study implemented an
innovative gastroenterological service in three NHS centres (two
led by a specialist nurse). The purpose of the qualitative analysis
was to assess the acceptability of the new service and monitor the
experiences of patients and professionals.
Method: Semi-structured interviews were held with healthcare
professionals and patients at baseline, 6 months and 12 months.
Interviews were audio-recorded and transcribed verbatim; data
were analysed using framework analysis.
Results: Thirty-ﬁve healthcare professionals (Baseline n = 17;
6 months n = 13; 12 months n = 2) and 16 patients (including
their companions: Baseline n=9; 6 months n = 5; 12 months n =
2) were interviewed. Four key themes emerged from the
qualitative analyses: 1) Making a difference: patients reported
the information they were given to manage their symptoms to be
useful and effective, making a positive difference and providing
support they did not have previously; 2) capacity: both patients
and professionals were supportive of the service, hoping that this
service could continue after the research study; 3) Expertise:
patients and professionals were supportive of the nurse-led model
- the professionals found this freed-up consultation time; 4)
Barriers and facilitators: patients were happy to both join the
service and the research study to evaluate the service, although
some patients did not differentiate a difference between the two.
Conclusion: The new service was well received by both patients
and professionals. Patients felt the new service has provided them
with support, helping them to relieve and improve long-standing
side effects of bowel radiotherapy. We will triangulate additional
health economics and statistical data to determine the overall
value of the service and explore its expansion beyond research.
Disclosure: Funded by Prostate Cancer UK
Corresponding author: Stephanie Sivell
36. Trends in mortality from malignant melanoma: an
observational study of the World Health Organisation
mortality database from 1985 to 2015
Dorothy Yang1, Justin Salciccioli2, Dominic Marshall3, Joseph
Shalhoub4
1Royal Free London NHS Foundation Trust, 2Department of Medicine,
Mount Auburn Hospital, 3Oxford University Clinical Academic
Graduate School, John Radcliffe Hospital, 4Academic Section of
Vascular Surgery, Department of Surgery and Cancer, Imperial
College London
Background: Malignant melanoma (MM) has the highest
mortality among skin cancers. MM incidence is reported to have
increased over the past decades, particularly in regions with
predominantly fair-skinned populations. We report 30-year global
MM mortality trends using the World Health Organisation (WHO)
mortality database.
Method: An observational analysis of the WHO mortality
database between 1985 and 2015 was performed. ICD-9 and
10 codes for MM were used to extract age-standardised death
rates (ASDRs) for all countries classiﬁed as having high usability
death registration data by the WHO. Trends were described
using Joinpoint regression.
Results: 33 countries were included in this analysis. For both
sexes, 3-year average ASDRs for 2013-2015 were highest in
Australia and Slovenia and lowest in Japan: rates of death were
5.72/100 000, 3.86/100 000, and 0.24/100 000 respectively in
males, and 2.53/100 000, 2.58/100 000, and 0.18/100 000
respectively in females. In all countries, MM mortality remained
greater in males than females across the observation period. All
countries demonstrated increased mortality rates in males over
the observation period except Czech Republic, which demon-
strated a single decreasing trend in mortality on Joinpoint analysis
(estimated annual percentage change -0.7%). More countries
exhibited decreasing or stable MM mortality in females, with Israel
and Czech Republic demonstrating the greatest percentage
decreases in mortality rates over the observation period
(−23.4% and −15.5% respectively).
Conclusion: There is a persisting global sex disparity in MM
mortality over the past 30 years. In some regions, this is due
either to greater increases in mortality rates in males compared
to females, or to decreasing or stabilising mortality trends in
females not paralleled in males. Future work will explore
potential explanatory factors for the observed trends and sex
disparity in MM mortality.
Disclosure: None declared
Corresponding author: Dorothy Yang
37. Phase II randomised control trial of a nutrition and
physical activity intervention after radical prostatectomy for
prostate cancer
Lucy Hackshaw-McGeagh1, Chris Penfold1, Ellie Shingler2, Athene
Lane2, Richard Martin1
1University of Bristol, 2University of bristol
Background: Dietary factors and physical activity may alter
prostate cancer progression. We explored the feasibility of lifestyle
interventions following radical prostatectomy for localised pros-
tate cancer.
Method: We recruited patients into a pre-surgical observational
cohort; following their radical prostatectomy, we offered the men
randomisation into a 2x3 factorial randomised controlled trial
(RCT). This involved randomisation into both a modiﬁed nutrition
group (either increased vegetable and fruit and reduced dairy
milk; or lycopene supplementation; or control) and a physical
activity group (brisk walking or control). Outcomes were collected
at trial baseline, three and six months, with daily adherence
reported throughout. Primary outcomes were measures of
feasibility: randomisation rates and intervention adherence at six
months follow-up.
Results: 108 men entered the pre-surgical cohort and 81 the post-
surgical RCT (randomisation rate: 93.1%). Of 25 men in the
nutrition intervention, 10 (40.0%; 95% CI: 23.4%-59.3%) adhered to
the fruit and vegetable recommendations and 18 (72.0% 95% CI
52.4%-85.7%) to reduced dairy intake. Adherence to lycopene
(n = 28), was 78.6% (95% CI: 60.5%-89.8%), whilst 21/39 adhered
to the walking intervention (53.8%; 95% CI: 38.6%-68.4%). Most
men were followed up at six months (75/81; 92.6%).
Conclusion: Interventions were deemed feasible, with high
randomisation rates and good adherence.
Clinical Trial Registry: ISRCTN:99048944; http://www.isrctn.com
Disclosure: Funded by NIHR
Corresponding author: Athene Lane
38. Living with and beyond cancer: Self-managing
chemotherapy side-effects and eating behaviours
Gianina-Ioana Postavaru1, Hilary McDermott2, Fehmidah Munir2,
Tanweer Ahmed3
1Bishop Grosseteste University, 2Loughborough University, 3United
Lincolnshire Hospitals NHS Trust
Background: With improved cancer survival, more people are
experiencing short- and long-term chemotherapy side-effects,
such as reduced taste and smell. These effects may be temporary
or permanent and are associated with altered quality of life due to
reduced food enjoyment, weight loss, changed patterns of food
intake and social activities linked to eating and drinking,
emotional distress and interference with daily life. Taste and smell
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problems are difﬁcult to diagnose and treat in clinical oncology
settings, often because of a lack of routine assessment practices.
The aim of this study was to gain insight from people living with
and beyond cancer about their experiences of chemotherapy side-
effects and strategies used to manage their eating behaviours and
diet.
Method: Data was collected through in-depth face to face semi-
structured interviews with people living with and beyond cancer
in the East Midlands of England. Data were analysed using
interpretative phenomenological analysis (IPA).
Results: Data analysis led to a narrative organized in two parts.
The ﬁrst part (retrospective understanding of chemotherapy side-
effects experiences) reports on the experience of temporary and
permanent reduced taste and smell, and their impact on eating
behaviours and quality of life, as well as feelings of desolation
contrasted to exceptional received support. The second part
explains strategies used by participants to manage their health,
barriers to and facilitators of access to information and profes-
sional advice.
Conclusion: This retrospective investigation of survivors’ experi-
enced chemotherapy side-effects gave access to aspects of their
experience that often remain undiscussed with healthcare
professionals. Further research is needed to develop a taxonomy
of taste and smell alterations and food hedonics, which may give
clinicians better diagnostic clues to the precise nature of these
challenges and inform the design of interventions to ameliorate
speciﬁc treatment-related side-effects.
Disclosure: Funded by Bishop Grosseteste University
Corresponding author: Gianina-Ioana Postavaru
39. Relapse rate and relapse patterns in patients undergoing
curative resection for Pancreatic Ductal Adenocarcinoma
(PDAC): Identifying high risk patients
Akul Purohit1, Abdullah Malik2, Rahul Deshpande2, Mairead
McNamara3, Thomas Satyadas2, Melissa Frizziero4, Saurabh Jam-
dar2, Rille Pihlak5, Aali Sheen2, Ajith Siriwardena2, Richard Hubner4,
Derek O'Reilly2, Juan W Valle3, Nicola De Ligouri Carino2, Angela
Lamarca4
1The Christie NHS Foundation Trust, 2Hepatobiliary & Pancreatic
Surgical Team, Department of Surgery, Manchester Royal Inﬁrmary,
Manchester, UK, 3Medical Oncology Department, The Christie NHS
Foundation Trust, Manchester, UK & Division of Cancer Sciences,
University of Manchester, Manchester, UK, 4Medical Oncology
Department, The Christie NHS Foundation Trust, Manchester, UK,
5Medical Oncology Department, The Christie NHS Foundation Trust,
Manchester, UK & Division of Cancer Sciences, University of
Manchester, Manchester, UK
Background: PDAC has a 5-year relapse rate >80% following
curative resection. Identifying patients at higher risk of relapse and
factors related with speciﬁc patterns of disease spread may inform
selection of candidates for closer follow-up.
Method: The outcome of patients with PDAC (Jan’05-Sep’17) who
underwent curative resection, and with available follow-up and
relapse status data, was analysed retrospectively. The aim was to
identify factors associated with higher relapse risk and speciﬁc
relapse patterns. Kaplan Meier, Log-rank, Chi squared and T-tests
were used for analysis.
Results: Of 228 patients, 182 were eligible. Patient characteristics:
55.5% male, median age 65.7 years (95%CI 64.2-67.2), T3 (81.9%),
lymph node (N)1 (71.4%), involved resection margin (R)1 (61.5%).
Adjuvant chemotherapy was given to 113 patients (62.1%) [5-
ﬂuorouracil (5-FU)(38.9%), Gemcitabine (G) (31.9%), G+5-FU
(29.2%)-based]. Median overall survival (OS) was 21.6 months
(95%CI 17.9–28.9). After a median follow-up of 17.9 months, 143
patients relapsed [relapse rate 78.6%, median time-to-relapse
8.9 months (95%CI 7.7–10.1)]. Median OS was shorter (log-rank p-
value <0.001) in the “relapse” group (17.5 months (95%CI 15.9-
20.9) vs. “non-relapse” (not reached).
Patients with “relapse” had higher rate of N1 disease (76.2% vs
53.8%; p-value 0.0161). No other factors related with increased
relapse rate were identiﬁed. Local relapse (59.4%): resection bed
(54.6%) +/- regional N (16.8%). Distant relapse (69.9%): median
number of organs affected was 1; liver 41.3%, lung 20.9%,
peritoneum 11.9%, distant N 4.9%, bone 2.8%, others 2.1%. Three
relapse patterns were identiﬁed: regional only (30.1%), distant
only (40.6%) and combined (regional + distant) (29.3%). Adjuvant
chemotherapy reduced the risk of combined relapse (p = 0.04).
Conclusion: Relapse rate following curative resection for PDAC
remains high, with predominance for distant recurrence. Patients
with N1 disease have the highest risk of relapse and may beneﬁt
from closer follow-up.
Disclosure: None declared
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40. Living with and beyond colorectal cancer: ColoREctal Well-
being (CREW) study at ﬁve years
Claire Foster1, Sally Wheelwright1, Lynn Calman1, Samantha
Sodergren1, Joanne Haviland2, Amanda Cummings1, Jane Winter4,
Amy Din1, Deborah Fenlon4, Janis Baird1, Jessica Corner5, Alison
Richardson3, Peter W Smith1, Study Advisory Committee Members1
1University of Southampton, 2Institute of Cancer Research, 3Uni-
versity of Southampton, University Hospital Southampton NHS
Foundation Trust, 4Swansea University, 5University of Nottingham
Background: The ColoREctal Well-being (CREW) study is the ﬁrst
study to prospectively recruit a representative sample of colorectal
cancer (CRC) patients, carry out the ﬁrst assessment pre-treatment
and then follow up longitudinally over ﬁve years in order to
explore the impact of treatment on health and wellbeing.
Method: CRC patients from UK cancer centres received ques-
tionnaires at baseline (pre-surgery), 3, 9, 15, 24, 36, 48 and
60 months. Quality of life (QOL), self-efﬁcacy (conﬁdence to
manage illness-related problems), mental health, social support,
affect, socio-demographics, clinical and treatment characteristics
were assessed. Data were analysed using multivariate statistical
techniques.
Results: A representative cohort of 872 non metastatic CRC
patients were recruited from 29 UK cancer centres. Most
participants recovered well after curative treatment but around
30% had poor psychosocial outcomes and this persisted up to the
5 year follow-up1. Baseline psychosocial factors (particularly self-
efﬁcacy and depression) were more important than disease stage
and location of tumour in determining who is most likely to have
problems over the ﬁrst 5 years1. Self-efﬁcacy remained stable over
time whereas social support declined for a signiﬁcant number of
participants. Both low self-efﬁcacy and perceived decline in social
support were associated with poorer outcomes 1-3. Comorbidities
that limit an individual’s typical daily activities were associated
with poorer health and wellbeing outcomes.
Conclusion: This unique study provides robust evidence that
psychosocial factors, such as self-efﬁcacy, are important predictors
for the longer term outcomes of CRC patients. We call for early
assessment and intervention, including assessment of depression
and conﬁdence to manage illness related problems and limiting
co-morbidities, from diagnosis onwards. Early assessment would
identify those most likely to need support in their recovery. Early
intervention has the potential to reduce need and improve
outcomes throughout treatment and beyond.
Disclosure: Funded by Macmillan
Corresponding author: Lynn Calma
41. CTCAE-based comprehensive toxicity assessment
following radical radiotherapy for head & neck squamous cell
carcinoma (HNSCC)
David Noble1, Amy Bates2, Jessica Scaife3, Jo Gemmill2, Richard
Benson2, Gill Barnett2, Sarah Jefferies2, Neil Burnet4, Raj Jena1
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Sciences
Background: Radiotherapy is an effective but toxic treatment for
head and neck squamous cell carcinoma (HNSCC). Many
published studies report data on a narrow range of side effects
and time-points, and a more comprehensive understanding of
post-radiotherapy sequelae is required.
Method: All HNSCC patients recruited to the consolidation cohort
of the CRUK-VoxTox study were included. Patients were treated
with IG-IMRT on TomoTherapy, and standard radical protocols.
Clinician-assessed toxicity was prospectively recorded at baseline,
months 3, 6, 12, then annually to year 5, using CTCAEv4.03.
Results: 188 patients were included with median follow-up
20 months. Primary sites: oropharynx 122, larynx 18, oral cavity
16, maxilla 9, CUP 7, nasopharynx 6, hypopharynx 5, skin 5. 39
underwent neck dissection before deﬁnitive radiotherapy, 149 did
not. Concomitant SACT: 106 received cisplatin, 15 cetuximab, 67
none. Rates of Grade 2+ toxicity are reported in the following
table.
Conclusion: The range of toxicities and time-points presented
demonstrate that most peak 3 months after radiotherapy, and
gradually improve thereafter. Dysphagia and salivary gland
toxicity are commonest. Dry mouth appears to improve with
time, whilst dysphagia is more persistent. Further research,
treatment development, and clinical trials are all necessary to
reduce the incidence of these toxicities, and improve the quality
of life of patients living beyond cancer.
Disclosure: Funded by Cancer Research UK
Corresponding author: David Noble
Table 1 [Abstract 41].
Gr2+ Toxicity (%) Baseline 3m 6m 12m 24m 36m 48m
Drymouth 2.7 78.8 64.7 58.5 45 34.6 31.6
Salivary ductInﬂammation 3.1 58 48.7 36.7 28.5 25 26.3
Dysphagia 5.9 36.8 26.9 17 18.7 19.2 21.1
Nausea 0.5 2.3 2.5 0 0 0 0
Anorexia 6.4 25.3 17 12.3 9.9 5.8 5.3
Trismus 3.8 14.9 9.2 6.8 5.5 9.6 0
Hoarseness 7.5 37.9 25.6 23.8 20.9 13.4 10.5
HearingImpaired 12.2 17.2 14 13.6 15.4 19.2 15.8
Tinnitus 1.6 4.6 3.7 4.8 4.4 3.8 0
Cataract 2.1 0 1.2 0.7 2.2 1.9 5.3
42. Process mining to explore variation in chemotherapy
pathways for breast cancer patients
Angelina Kurniati1, Geoff Hall2, David Hogg3, Owen Johnson3
1University of Leeds; Telkom University, 2University of Leeds; Leeds
Teaching Hospital, 3University of Leeds
Background: There is concern that standard chemotherapy
pathways of six cycles scheduled every two or four weeks reﬂect
administrative and operational needs rather than patients’
personal and biological needs. Process mining of routine data
can help identify and explore common pathway variants.
Method: We extracted anonymised records from routine data at
Leeds Cancer Centre for breast cancer patients with a ﬁrst
diagnosis between 2004 and 2013 with an adjuvant chemother-
apy pathway (n = 738). This produced an event log data ﬁle
(containing events, dates and times) which was analysed using the
ProM and DISCO process mining tools. We used the Inductive
Miner plug-in and constructed statistical and visual models of the
clinical pathways. The data covered a ten-year period and we
created multiple splits of the event log to examined statistically
signiﬁcant variations over time.
Results: Most patients varied from the expected pathway (712
variants for 738 patients). We produced a pathway model which
included these variants and checked conformance. Overall ﬁtness
of data to model was high (97.1%) but we noted signiﬁcant
changes to the ﬁt in 2006 (a 5.1% change) and 2011 (8.9% change)
which require further investigation. In total 51% (n = 376)
of patients did complete all six cycles, less than half (21% of total,
n = 158) completed the cycles without an adverse event
while many (30%, n = 218) experienced at least one adverse
event including missed appointments, neutropenic sepsis and
emergency admissions. Of the 49% (n=362) who did not
complete six cycles, 28% (n=207) experienced adverse events
with the remainder (21%, n=155) not completing for other
reasons.
Conclusion: Process mining of routine data showed extensive
variation from standard chemotherapy pathways including
incomplete treatment and adverse events. Future work is needed
to explore potential causal links and understand changes in the
pathway over time.
Ethics number: IRAS206843, https://www.hra.nhs.uk/planning-
and-improving-research/application-summaries/research-
summaries/ .
Disclosure: Funded by ClearPath Connected Health Cities
Project, the Indonesia Endowment Program for Education (LPDP)
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43. The Northern Oncology Trainees Collaborative for
Healthcare Research (NOTCH): A new trainee-led collaborative
initiative for the evaluation of non-surgical cancer outcomes
Christopher Jones, Caroline Dobeson, Matthew Howell, Anna Olsson-
Brown, Eileen Parkes, Abdulazeez Salawu
Northern Oncology Trainees Collaborative for Healthcare Research
Background: Insufﬁcient time, competing priorities and the
limitations of drawing inferences from underpowered, single-
centre populations are commonly cited barriers to the effective
study of real-world cancer outcomes. Doctors not in a dedicated
academic post may also lack sufﬁcient training to undertake
research, despite recognition from medical bodies of the
importance of research education. In a number of surgical
disciplines, trainee-led research collaboratives spanning multiple
institutions are now well established as a means to meeting these
challenges. To our knowledge, there have been no previous
attempts at establishing similar approaches in non-surgical
oncology (NSO). The Northern Oncology Trainees Collaborative
for Healthcare Research (NOTCH) has recently been established to
promote trainee-led NSO outcomes research. We provide here an
overview of this group’s aims, scope and early activities.
Method: Two clinical and two medical oncology trainees were
invited to lead the initiative from each of six large cancer centres
within the north of England and Northern Ireland. Trainees from
each centre are supported by a wider advisory group consisting of
senior clinicians and academics. A call for project proposals was
launched between March-May 2018, with proposals submitted by
trainees in partnership with senior clinicians.
Results: Twelve proposals were received, ten of which focussed
on a speciﬁc malignancy and two of which focussed on outcomes
across a number of cancers. All but one of the proposals involved
retrospective data analysis. Proposed outcomes included analys-
ing compliance with existing guidelines, the development of
prognostic indices and analyses of toxicity, recurrence and survival
patterns. One or more of the proposals will be selected to be
undertaken by trainees from across the six centres.
Conclusion: NOTCH provides a novel trainee-led approach for
collaborative multi-centre real-world NSO outcomes research for
which there is evidence of engagement from trainees and senior
clinicians alike.
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44. Cancer and pregnancy: A national and tertiary unit
experience
Arti Kara1, Angela Yulia2, Pete Wallroth3, Jacque Gerrard3, David
Williams4
1University College London Hospitals NHS Foundation Trust & UCL,
2University College London Hospitals NHS Foundation Trust,
3Mummy’s Star, 4University College London Hospitals NHS Founda-
tion Trust and UCL
Background: Cancer during pregnancy affects approximately
1:1000 pregnancies, but is becoming more common. More women
are becoming pregnant having survived childhood cancer. The
lack of UK data on cancer and pregnancy outcomes has meant
management is often idiosyncratic and not evidence-based. We
aim to establish a UK Registry for pregnant women affected by
cancer to improve cancer and pregnancy outcomes for affected
women and children.
Method: We report data collected by ‘Mummy’s Star’, a UK charity
dedicated to the support of women and their families affected by
cancer during pregnancy and up to one-year post-partum. We also
collected data on pregnancies affected by cancer at University
College London Hospital (UCLH).
Results: Mummy’s Star reported a total 419 women of whom 257
(61%) were diagnosed with cancer during pregnancy and 162
(39%) were diagnosed postnatally. Breast cancer was the
commonest malignancy affecting 180 (43%) women. Thirty two
(8%) women had died and approximately one third of women had
metastatic cancer.
In a preliminary data collection at UCLH we identiﬁed 30
women; 23 were cancer survivors and 7 were diagnosed with
cancer during pregnancy. The majority, 17 (57%) were aged
between 32 and 40 years old. Hodgkin lymphoma was the
commonest malignancy in 7 (23%) patients. Chemotherapy was
delayed until childbirth for 3 (10%) patients. Three (10%) patients
suffered from anxiety and depression during pregnancy. All
women were alive 42 days post-delivery.
Conclusion: Cancer during pregnancy is a heterogeneous and
relatively rare condition. No single centre can gain enough
experience to provide evidence-based care for optimal pregnancy
outcome. A national Registry in association with Mummy’s Star
will build on an established data-set to accelerate our under-
standing of best practise for these vulnerable women and their
families.
Acknowledgement: A version of this abstract has been
published previously, see https://obgyn.onlinelibrary.wiley.com/
doi/abs/10.1111/1471-0528.15191 for original and CC-BY license.
Disclosure: Funded by Mummy's Star which is self funded by
charitable funds
Corresponding author: Arti Kara
45. Updated polygenic risk score in breast cancer patients is
not associated with increased radiotherapy toxicity
Gillian C Barnett1, Leila Dorling2, Laura Fachal2, Morag Brothwell1,
Charlotte E Coles1, John R Yarnold3, Neil G Burnet4, Paul DP
Pharoah2, Catharine ML West4, Alison M Dunning2
1Cambridge University Hospitals NHS Foundation Trust, 2Centre for
Cancer Genetic Epidemiology, University of Cambridge, 3Institute of
Cancer Research & Royal Marsden NHS Foundation Trust, 4University
of Manchester
Background: It has been hypothesized that increased genetic
predisposition to breast cancer may increase risk of toxicity
following breast irradiation. Polygenic risks scores (PRS) can be
generated from genotypes at breast cancer susceptibility loci by
summing risk-allele dosages. A polygenic risk score including 90
genotypes previously showed no association with increased risk of
early or late radiotherapy toxicity at 5 years. Recent developments
in the Breast Cancer Association Consortium (BCAC) have
increased the number of conﬁrmed breast cancer risk variants to
a set of 352 at all the risk loci identiﬁed to date.
Method: Common variant genotypes were determined in 1134
breast cancer patients from the RAPPER (Radiogenomics:
Assessment of Polymorphisms for Predicting the Effects of
Radiotherapy) study using the Illumina CytoSNP12 genome-
wide array. A further 15,582,449 genotypes were imputed using
the 1000 Genomes Project reference panel. Univariable and
multivariable regression analyses were performed to assess
association between both polygenic risk score and the 352
individual variants with radiotherapy toxicity at 2 years including
telangiectasia, breast oedema, photographic shrinkage, indura-
tion, pigmentation, breast pain, breast sensitivity and overall
toxicity.
Results: After correction for multiple testing, no association was
found between polygenic risk score and development of late
radiotherapy toxicity. On multivariable analysis of individual
variants, rs138944387 was signiﬁcantly associated with breast
pain (beta = 1.12; 95% CI 0.62-1.61; p = 1.09 x 10−5) and
rs17513613 was associated with risk of breast oedema (beta=-
0.21; 95% CI -0.31 to -0.12; p = 2.01 x 10−5).
Conclusion: Cancer patients with a high polygenic predisposition
to breast cancer calculated using an updated polygenic risk score
do not have increased risk of radiotherapy toxicity up to two years
following radiotherapy. The association between 2 individual
variants and late toxicity require validation in independent
cohorts.
Disclosure: Cancer Research UK
Corresponding author: Gillian C Barnett
46. Feasibility of a community pharmacy lifestyle intervention
to increase physical activity and improve cardiovascular
health of men after prostate cancer treatment
Sara Faithfull1, Agnieszka Lemanska1, Karen Poole1, Bruce Grifﬁn1,
Ralph Manders1, John Marshall2, John Saxton3
1University of Surrey, 2Prostate Cancer UK, 3Northumbria University
Background: Evidence that physical activity improves prostate
cancer treatment outcomes is now recognised. This research
explores the feasibility and acceptability of a community
pharmacy lifestyle intervention for improving physical activity
and health related outcomes. Pharmacy-led health assessment
provide opportunities for lifestyle prescription in cancer survivors,
we used a computerised algorithm to support personalisation for
physical activity and diet. This was repeated at three months and
supported by two phone calls and instructional materials in nine
community pharmacies.
Method: Particpants included men with non-metastatic prostate
cancer, completed cancer treatment and at least one of the three
risk factors: underweight, overweight or obese; active androgen
deprivation therapy; hypertension. Physical and functional ﬁtness
were measured with Siconolﬁ step test and physical activity was
assessed objectively using accelerometry. Upper body strength
(grip strength), lower body strength (sit-to-stand test) and
cardiovascular health (QRISK2 algorithm including weight, body
mass index, blood pressure and cholesterol) were also assessed.
Feasibility and acceptability were evaluated.
Results: 403 men were eligible, 172 (43%) responded and 116
(29%) were subsequently recruited. We report 15% attrition as
99 (85%) men completed the pharmacy intervention. The
intervention was feasible and acceptable for men. At three
months compared to baseline scores, men’s moderate to
vigorous physical activity (MVPA) increased by an average of
34 minutes (95% CI: 6 to 62, P = 0.018). The level of MVPA was not
sustained at six months (average increase was 14 minutes, 95% CI:
-27 to 54, P = 0.509). QRISK2 score was reduced at 3 months
(P = 0.001).
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Conclusion: This study demonstrates that a community
pharmacy-led intervention is feasible and acceptable to non-
metastatic prostate cancer patients. The increase in physical
activity and improved health, support the development of this
delivery approach after cancer treatment. An adequately powered
randomised controlled trial is needed to assess the relative cost-
efﬁcacy of this intervention.
Disclosure: Funded by Movember Foundation and Prostate
Cancer UK
Corresponding author: Sara Faithfull
47. Ethnicity and the tumour characteristics of breast cancer
in a large nationally representative sample of women in
England
Toral Gathani1, Isobel Barnes1, John Broggio2, Gillian Reeves1
1University of Oxford, 2Public Health England
Background: Some studies have suggested that ethnic minority
women have more aggressive breast cancer compared to White
women. However, the evidence is limited and inconsistent, and
has generally not accounted for sociodemographic differences.
Complete data on tumour characteristics by ethnicity are available
from Public Health England for over 68000 breast cancers
registered between 2006 and 2013 and are reported here.
Method: The data analysed includes patient characteristics (age,
deprivation and ethnicity) and tumour characteristics (size, grade,
nodal status and receptor proﬁle). Each tumour characteristic was
dichotomised and treated as the outcome variable in a logistic
regression model yielding odds ratio (OR) for each characteristic
by ethnicity adjusted for age, region, deprivation, and all other
tumour characteristics.
Results: There were 66,192 breast cancers in White women, 1233
in South Asian women and 641 in Black women. The mean age at
diagnosis was ﬁve years younger in South Asians and Blacks
compared to Whites (55 versus 60 years). In unadjusted analyses,
both South Asian and Black women were more likely than White
women to have higher risks of more biologically aggressive
tumour factors including higher grade, larger size, ER negativity
and node positive tumours. However, after adjustment for age in
particular, and other factors, these differences between the ethnic
groups were reduced substantially. For example, compared to
White women, the unadjusted and adjusted OR for grade 3
tumours was 1.49 (95%CI 1.33-1.67) and 1.20 (95%CI 1.05-1.37) for
South Asian women, and 1.94 (95%CI 1.66-2.27) and 1.44 (95%CI
1.20-1.72) for Black women. Similarly, compared to White women,
the unadjusted and adjusted OR for node positive cancer was 1.32
(95%CI 1.18-1.48) and 1.16 (95%CI 1.03-1.31) for South Asian
women and 1.60 (95%CI 1.37-1.87) to 1.20 (95%CI 1.02-1.41) for
Black women.
Conclusion: Much of the apparent differences in tumour
characteristics by ethnicity are due to differences in age at
presentation.
Acknowledgement: A version of this abstract has been
published previously, see http://www.iarc-conference2016.com/
build-preview.php?emailUser=toral.gathani%40ceu.ox.ac.
uk&idUser=1317638&paramProjet=56329&type=projet for origi-
nal and CC-BY license.
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48. BAP1 loss induces BRCA1 dependent and independent
defective spindle organization, checkpoint dysfunction and
genomic instability
Anita Singh1
1University of Leicester, UK
Background: BRCA1 associated protein 1 (BAP1) is a tumour
suppressor that is commonly inactivated in the majority of
mesotheliomas. We have previously reported that loss of BRCA1
expression in mesothelioma is a common event, and is associated
with resistance to spindle checkpoint activator vinorelbine, a drug
with relevance to treatment of mesothelioma. However, 1. The
mechanism of BRCA1 loss is unknown, and 2) the potential
functional interaction between BRCA1 and BAP1 linked to spindle
checkpoint is unknown. The aim of this study was to assess the
functional relationship between BAP1 and BRCA1 and examine
their role in genome stability in mesothelioma cells.
Method: We conducted functional genetic analysis of BAP1 and
BRCA1 in two MPM cell lines, MSTO and H2452, the latter carrying
an inactivating A95D mutation in the UCH domain of BAP1. BAP1
knockdown was achieved by siRNA transfection, while BRCA1
knockdown was achieved by doxycycline induction of an
integrated shRNA.
Results: Loss of BAP1 expression led to reduced expression of
BRCA1. Treatment with the proteasome inhibitor, MG132, restored
BRCA1 expression in the absence of BAP1 indicating that
BAP1contributes to post-translational stabilization of BRCA1
protein. Consistent with previous data, knockdown of BAP1
induced SAC deﬁciency and vinorelbine resistance concurrent
with reduced expression of BRCA1. Loss of BAP1 and BRCA1 also
led to an increased frequency of ampliﬁed centrosomes.
Unexpectedly though, additional defects were observed in mitotic
spindle architecture in response to BAP1 loss that were not seen
upon loss of BRCA1.
Conclusion: Our data demonstrate that BAP1 controls BRCA1
expression through regulating its protein stability. They also
demonstrate both BRCA1-dependent and independent roles for
BAP1 in mitotic progression. These ﬁndings suggest that BAP1 loss
may disrupt spindle checkpoint function and predict resistance to
agents such as vinorelbine, a hypothesis that we will test in our
randomised trial VIM.
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49. Glycolysis supports EGFR-mutant Lung Adenocarcinoma
Cell Survival by blocking Autophagy-mediated EGFR
Degradation
Wonjun Ji1, Jin Kyung Rho1, Jaekyoung Son1, Jae Cheol Lee1, Chang-
Min Choi1
1Asan Medical Center
Background: Oncogenic epidermal growth factor receptor (EGFR)
is essential for the development and growth of non-small cell lung
cancer (NSCLC), but the precise roles of EGFR in lung cancer
metabolism remain unclear.
Method: We studied the effect of EGFR on metabolism via
targeted liquid chromatography-tandem mass spectrometry (LC-
MS/MS) metabolomic analysis, glucose consumption and lactate
production assay, and extracellular acidiﬁcation and oxygen
consumption assay in NSCLCs. Mechanisms regulating EGFR
stability were investigated using RNA interference/pharmacologi-
cal inhibitors followed by immunoblotting, cell death assay, and
functional assays. Therapeutic potential of JNK activator was
determined by monitoring cell growth and death and in mouse
xenograft models. Immunohistochemistry was used to analyze
JNK phosphorylayion and EGFR expression in NSCLC tissues
(n = 244). All statistical tests were two-sided.
Results: EGFR knockdown in EGFR-mutant NSCLC signiﬁcantly
decreased the levels of glycolytic pathway intermediates (p < 0.05)
via transcriptional regulation of glycolytic genes. EGFR-mutant
NSCLCs exhibited signiﬁcantly elevated glucose uptake and
lactate production compared with EGFR-WT NSCLCs. Glucose
deprivation markedly triggered EGFR-mutant NSCLC cell death
through robust reduction of EGFR levels, but had no signiﬁcant
effects on EGFR-WT NSCLCs. EGFR-mediated enhanced glycolysis
was a major source of carbon for TCA cycle in EGFR-mutant
NSCLC, which is essential for maintaining EGFR levels. Glucose
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deprivation-mediated mitochondrial ATP depletion enhanced
reactive oxygen species accumulation and subsequent JNK-
mediated autophagy activation, which in turn induced EGFR
degradation. The expression of phosphorylated JNK was signiﬁ-
cantly decreased in patients with EGFR-mutant NSCLCs (7.94%)
compared with WT EGFR (23.28%) (p = 0.001). A reverse
correlation between phosphorylated JNK and EGFR expression
was observed in all tissues regardless of EGFR mutation
(p = 0.0394).
Conclusion: These data suggest that enhanced glycolysis by EGFR
mutation is required for maintaining EGFR levels through
inhibition of JNK-induced autophagy, providing a promising
rational for exploring JNK activators for patient bearing EGFR-
mutation NSCLC.
Disclosure: None declared
Corresponding author: Wonjun Ji
50. Understanding the role of gamma-delta (γδ) T cells in
pancreatic cancer
Mark Lawrence1, Saadia Karim1, Jennifer P. Morton1, Seth B. Coffelt1
1Cancer Research UK Beatson Institute
Background: Pancreatic ductal adenocarcinoma (PDAC) is a
lethal malignancy with a 5-year survival rate of around 5%,
where 80% of patients present with metastases on diagnosis.
Metastasis is driven by inﬂammation, which potentiates the
invasive and migratory behaviour of pancreatic cancer cells.
Our lab is interested in a rare subset of immune cells known as
gamma delta (gd) T cells that have pro-metastatic properties in
breast cancer mouse models. Pro-metastatic gdT cells are
deﬁned by their ability to produce IL-17 and by the lack of
expression of the costimulatory molecule CD27. IL-17-
producing (CD27—) gdT cells promote breast cancer metas-
tasis by expanding and polarising the neutrophils to an
immunosuppressive phenotype, which inhibits anti-tumour
CD8+ T cells. Additionally, recent reports have shown that
gdT cells are crucial for pancreatic cancer progression in
transplantable mouse models, and they constitute a large
proportion of tumour-inﬁltrating lymphocytes within human
PDAC. However, the mechanisms by which IL-17-producing
(CD27—) gdT cells function are largely unknown.
Method: To investigate the mechanisms of gdT cell function, we
use the KrasG12D;Trp53R172H;Pdx1-Cre (KPC) mouse model, which
develops PDAC and liver metastasis at around 150 days of age.
Results: We have found that gdT cells are absent from normal
pancreas, but relatively abundant in tumours from KPC mice.
gdT cells are also reduced in livers from KPC mice when compared
with livers from wild-type control mice.
Conclusion: Current efforts are underway to determine whether
PDAC progression and metastasis are affected in gdT cell-deﬁcient
mice and to examine the potential crosstalk between gdT cells
and neutrophils. These studies may uncover speciﬁc immunother-
apeutic strategies to counteract metastatic pancreatic cancer.
Disclosure: Funded by Pancreatic Cancer UK Future Leaders
Academy
Corresponding author: Mark Lawrence
51. Wnt/beta-catenin synergises with FOXG1 to drive exit
from quiescence in neural stem cells, including glioblastoma
stem cells
Faye Robertson, Harry Bulstrode, Maria-Angeles Marques Torrejon,
Eoghan O'Duibhir, Steve Pollard
University of Edinburgh
Background: Glioblastoma is a malignant brain tumour which is
universally fatal. Stem cells within the tumour exist in a quiescent
state, evade destruction and reactivate, causing relapse. These
stem cells are known to overexpress the transcription factor
FOXG1.
Method: We used an in vitro model of quiescence in mouse
neural stem cells, incorporating a conditional human FOXG1
overexpression cassette, to identify, through high content
pharmacological screening, a synergistic relationship between
high FOXG1 expression and inhibition of glycogen synthase kinase
3 (GSK3) in driving cells into an active, proliferative state. We
quantiﬁed this effect using EdU incorporation and colony forming
assays. Wnt inhibitors were used to abrogate the effect and a
genetic approach, using a constitutively active beta-catenin
cassette, was used to elucidate the nature of the synergy.
Patient-derived human glioblastoma stem cells (GSCs), with or
without CRISPR-Cas9 excision of FOXG1, were used to conﬁrm the
relevance of the effect.
Results: EdU incorporation, following a 2 hour pulse, was
increased from 4% in growth factors alone, 5.9% with FOXG1
overexpression, 5.5% with GSK3 inhibition, to 31.3% with FOXG1
overexpression and GSK3 inhibition combined. Colony forming
assays conﬁrm high efﬁciency cell cycle re-entry in cells with
FOXG1 overexpression treated with a GSK3 inhibitor.
We subsequently show that this effect is present in patient-
derived human GSCs and is abolished by excision of FOXG1.
The effect of GSK3 inhibition can be phenocopied both by a
ligand of the canonical Wnt signalling pathway and by inducible
constitutively active beta-catenin, suggesting that the synergy is
effected through beta-catenin, the key downstream effector of
canonical Wnt signalling.
Furthermore, the combined effect of FOXG1 overexpression and
GSK3 inhibition on exit from quiescence can be abrogated by Wnt
inhibitors.
Conclusion: Targeting the synergistic relationship between
FOXG1 and beta-catenin may provide an exciting therapeutic
opportunity in preventing relapse and improving the prognosis of
glioblastoma.
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52. Investigating Aspirin and Ticagrelor for the prevention of
tumour cell-induced platelet aggregation
Meera Chauhan, David Adlam, Anne Thomas, Alison Goodall, Joy
Wright
University of Leicester
Background: Tumour cell induced platelet aggregation (TCIPA)
may affect the metastatic potential of cancer. Mechanisms include
protection of circulating tumour cells from immune destruction,
interaction of platelet receptors with tumour ligands to facilitate
adhesion, and enrichment of the tumour microenvironment,
promoting extravasation and proliferation. Reducing these inter-
actions using anti-platelet agents could alter metastatic progres-
sion. This study investigated the effects of Ticagrelor and Aspirin
as monotherapy and dual therapy on TCIPA in metastatic breast
cancer patients compared to healthy controls.
Method: Participants recruited to this randomised, crossover
study received Aspirin or Ticagrelor for 2 weeks, followed by a 2-
week washout and crossover to the other monotherapy, before
completing 2 weeks of dual therapy. Platelet rich plasma was
prepared from blood samples taken at baseline and the end of
each treatment. Flow cytometry measured platelet activation
markers (P-selectin expression, ﬁbrinogen and Annexin-V binding)
at rest and after agonist stimulation of the platelets in vitro.
Results: 20 healthy and 10 breast cancer participants completed
the study. Fibrinogen binding was higher on resting platelets from
breast cancer patients compared to healthy participants (49.5
±7.8% vs 31.4±4.2%; p = 0.03). Ticagrelor reduced ﬁbrinogen
binding to platelets in healthy subjects to 17.9±3.6%(p = 0.008)
and 26.7±5.2%(p = 0.048) in patients. Dual therapy reduced
ﬁbrinogen binding in breast cancer platelets to 31.3±6.8%(p =
0.008). Ticagrelor and dual therapy inhibited the response to
platelet ADP stimulation in both populations, with reduced
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ﬁbrinogen binding in comparison to untreated, stimulated
platelets. (Healthy: Untreated 83.5±2.31% vs Ticagrelor
46.6±4.1%; p<0.0001, dual 48.4±4.5%; p<0.0001. Breast Cancer:
Untreated 88.1±2.3% vs Ticagrelor 43.4±4.9%; p<0.0001, dual 58.1
±7.9%; p = 0.0096)
Conclusion: Platelets from breast cancer patients are activated
compared to healthy subjects when comparing levels of ﬁbrino-
gen binding. Ticagrelor as monotherapy and dual therapy
signiﬁcantly reduces platelet activation in vivo and inhibits the
platelet response to ADP. The pilot study indicates Ticagrelor may
reduce TCIPA in breast cancer patients.
Disclosure: Funded by Astra Zeneca, ECMC, Hope Against
Cancer
Corresponding author: Meera Chauhan
53. Regulation of IL-17-producing γδ T cells in breast cancer
metastasis
Sarah C. Edwards1, Anna Kilbey2, Robert Wiesheu2, Erin R. Morris3,
Liam Hayman2, Damiano Rami2, Seth B. Coffelt2
1Beatson Institute for Cancer Research, 2Beatson Institute for Cancer
Research. Institute of Cancer Sciences, University of Glasgow, 3Baker
University, Baldwin City, KS, USA
Background: In breast cancer, patients who develop stage IV
metastatic disease have a median survival rate of 15%. Under-
standing the cellular mechanisms underpinning the progression
of metastatic disease may present novel therapeutic interventions.
In cancer, subsets of γδ T cells have been shown to present as
anti-tumorigenic and pro-tumorigenic. In the K14-Cre;Cdh1F/F;
Trp53F/F (KEP) model of breast cancer, IL-17-producing γδ T cells
promote lung metastasis by expanding neutrophils to suppress
anti-tumorigenic CD8+ T cells. Selectively targeting IL-17-secreting
γδ T cells in breast cancer metastasis may have therapeutic
potential.
Method: To investigate which molecules govern the activation of
pro-tumorigenic γδ T cells, we measured the expression of various
activating receptors on CD27+ and CD27— γδ T cells from tumour
naïve or tumour-bearing mice, as CD27 stratiﬁes IFNγ-producing
(CD27+) from IL-17-producing (CD27—) γδ T cells.
Results: Surprisingly, we found that expression of NKG2D, a
receptor involved in recognition of stressed or malignantly
transformed cells is higher on CD27— γδ T cells compared with
CD27+ cells. This increased expression of NKG2D on CD27— γδ
T cells was speciﬁc, as other cytotoxic receptors were elevated on
CD27+ γδ T cells. Furthermore, in the K14-Cre;Brca1F/F;Trp53F/F
(KB1P) model of breast cancer, we found that NKG2D ligands are
upregulated in the myeloid compartment at metastatic sites, such
as the lung of tumour-bearing mice.
Conclusion: We are currently investigating the interplay between
these NKG2D ligand-expressing myeloid cells and IL-17-producing
γδ T cells to determine whether the NKG2D axis plays a role in
breast cancer metastasis.
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54. Speciﬁc features of DNA methylome in Glioblastoma
Multiforme
Maria Eleftheriou1
1University of Nottingham
Background: DNA methylation (5-methylcytosine, 5mC) is the
major epigenetic modiﬁcation involved in transcriptional regula-
tion during the early stages of development in eukaryotes. The
patterns of 5mC are frequently altered in cancer. TET proteins can
enzymatically oxidize 5mC producing 5-hydroxymethylcytosine
(5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC).
Although the exact biological roles of these oxidized forms of
5mC in cancer pathogenesis are still unknown, there are
indications that they might contribute to malignant transforma-
tion. According to several reports, 5hmC levels are reduced in
human tumours; however, the distribution of 5fC and 5caC in
cancers is poorly studied. Although our previous studies showed
that 5caC is surprisingly enriched in a proportion of breast cancers
and pediatric brain tumors, the distribution and the biological role
of this mark in glioblastoma multiforme (GBM) has not been
systematically assessed.
Method: Here, using mass spectrometry and immunoﬂuores-
cence, we examine the global levels of 5hmC and 5caC in four
human GBM cell lines (LN18, LN228, U251 and U87MG).
Results: We show that while the GBM cell lines exhibit low levels
of 5hmC, they are, rather unexpectedly, characterized by relatively
high immunochemistry and mass-spec detectable 5caC levels
paralleled by the absence of 5fC. Remarkably, 5caC content in
GBM does not correlate with 5hmC levels but corresponds to
elevated levels of TET2 transcript in these cancers where its
transient siRNA mediated knockdown leads to a dramatic
decrease in 5caC levels.
Conclusion: Our data reveals the unique epigenetic signature of
GBM contributing to potential development of novel approaches
for diagnosis and therapy of these tumours.
Disclosure: Funded by University of Nottingham
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55. Investigating the Interplay between Wilms' Tumour 1
Protein and DNA Demethylation in Brain Tumours
Ashley Ramsawhook1
1University of Nottingham
Background: 5-methylcytosine (5mC) is an epigenetic modiﬁca-
tion usually associated with transcriptional repression. The
Ten–Eleven Translocase proteins (Tet1/2/3) can oxidise 5mC
(oximC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosie
(5fC) and 5-carboxylcytosine (5caC) in vertebrate DNA. These
oxidised forms of 5-methylcytosine exhibit distinct genomic
distributions in different biological systems. Whilst embryonic
stem cells exhibit elevated levels of oxi-mC modiﬁcations, adult
somatic tissue genomes display depletion for 5fC and 5caC
modiﬁcations. Curiously, neoplasms of the central nervous system,
particularly ependymoma, medulloblastoma and glioblastoma
possess signiﬁcant enrichment of these oxidised forms, however
the precise functional roles of these modiﬁcations are not fully
understood. Transcription factor and tumour suppressor/onco-
genic protein Wilm’s Tumour 1 (WT1) possesses preferential
binding afﬁnity for 5mC and 5caC over unmodiﬁed cytosines,
5hmC and 5fC in vitro and exhibits elevated expression in multiple
cancers. Expression of WT1 in embryonic neural epithelial
progenitors during lineage commitment but absence in terminally
differentiated neurons and astrocytes may be indicative of
aberrant developmental signalling resulting in malignant neo-
plasm formation.
Method: By employing mass spectrometry-validated immunohis-
tochemistry and confocal microscopic quantiﬁcation, we demon-
strate that high levels of both 5caC and WT1 are characteristics of
brain tumour cell lines. Moreover, 5caC is present on promoters of
core brain tumour signalling pathway genes. Furthermore, we
endeavour to perform CRISPR cas9 facilitated WT1 targeted
knockout and subsequently implement next generation sequen-
cing technologies to globally map 5caC genomic distribution and
inﬂuence on brain tumour transcriptomes.
Results: Ultimately this will facilitate the elucidation of a
mechanistic relationship between WT1 and 5caC which may
aetiologically induce or functionally perpetuate clinical aspects of
brain tumour pathogenicity.
Conclusion: Our ﬁndings may gain novel insights on the
biological roles of oxidised forms of 5mC and, potentially,
highlight deleterious developmental origins of lethal brain
tumours.
Disclosure: Funded by The Biotechnology and Biological
Sciences Research Council
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56. Molecular mechanisms underlying phenotypic plasticity in
malignant glioma
Costanza Lo Cascio1, Ernesto Luna, Rohit Khurana1, Roberto Fiorelli,
Shwetal Mehta1
1Barrow Neurological Institute
Background: Glioblastoma (GBM) is characterized by rapidly
proliferating and invasive cells that inﬁltrate normal brain regions.
Following exposure to aggressive treatment regimens, GBMs
frequently shift their biological features upon recurrence, acquir-
ing a more resistant phenotype. However, the dynamics and
molecular mechanisms that facilitate GBM recurrence are still
poorly understood. Considering the unchanged dismal prognosis
for GBM patients, there is a need to understand, at a systems level,
how plastic processes (molecular switches) in glioma stem-like
cells (GSCs) may drive tumor maintenance and cancer cell
adaptability in GBM. The objective our study was to determine
how GSCs temporally adjust their expression proﬁle and pheno-
type in response to ionizing radiation in vitro and in vivo using
patient-derived xenograft (PDX) models of GBM.
Method: We established PDX GBM models by intracranially
implanting two patient-derived GSC lines belonging to different
GBM molecular subgroups into immunocompromised mice. The
tumor-bearing mice were treated with single doses of ionizing
radiation to assess acute responses to treatment. Mice from each
cohort were be sacriﬁced at multiple distinct time points following
treatment. Using immunohistochemical methods, we assessed
changes in the expression of GBM subclass markers, stemness and
differentiation markers, and DNA damage/repair proteins across
the entire tumor population over time. To understand how GSCs
respond to radiation at a molecular level, we employed mass
cytometry (CyTOF) and RNA-seq to determine how important
cellular signaling pathways and transcriptional programs neces-
sary for GSC self-renewal, invasion and growth are altered at
various time points post-treatment.
Results: We demonstrate that GSCs, both in vitro and in vivo,
undergo an immediate response following exposure to radiation
that results in a global modulation of the expression of key
stemness and proliferation genes under adverse conditions.
Conclusion: Our results suggest that this acute response allows
GSCs to enter a transient semi-differentiated state that favors GSC
adaptability and resistance to therapy
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57. Identiﬁcation of C1orf106 as a TGF-β target gene which
promotes clonogenicity and anchorage-independent growth
Lauren Strathearn1, Susan Mason2, Lindsay Spender1, Karen Blyth2,
Gareth Inman1
1University of Dundee, 2Beatson Institute for Cancer Research
Background: The dual and opposing roles of Transforming
Growth Factor-β signalling (TGF-β) in tumorigenesis are well
recognized. However the exact mechanisms behind this switch in
biology from tumour suppressive to tumour promoting are
complex and lesser understood. Microarray analysis identiﬁed
the uncharacterised open reading frame C1orf106 as a novel TGF-
β target gene required for TGF-β induced anchorage-independent
growth of vulval squamous cell carcinoma cells. Here we further
investigate TGF-β regulation of C1orf106 and its potential role in
tumorigenesis.
Method: C1orf106 gene and protein expression was assayed by
qRT-PCR and western blotting following exogenous stimulation or
inhibition of TGF-β signalling. The role of the canonical TGF-β
pathway in regulating C1orf106 transcriptional induction was
explored by siRNA-mediated gene silencing. C1orf106 mRNA
expression levels and inﬂuence on clinical outcomes were
assessed in the Oncomine™ and KM Plotter platforms. The
phenotypic effects of stable overexpression or shRNA mediated
knockdown of C1orf106 expression was investigated in breast
cancer cell lines. Anchorage-independent growth and colony-
forming assays, and a limiting dilution xenograft were carried out
to assess tumourigenicity in vitro and in vivo, respectively.
Results: C1orf106 mRNA and protein induction in response to
TGF-β stimulation was observed in a plethora of cell types and
determined to be SMAD3-dependent. Analysis of publically
available datasets indicated that elevated C1orf106 mRNA
expression is associated with poor clinical outcomes in breast
cancer. C1orf106 expression correlated with metastatic progres-
sion in the 4T1 murine mammary carcinoma model. High C1orf106
was associated with enhanced anchorage-independent growth
ability, colony forming capacity and clonogenicity in vitro in this
model system and trended towards increased tumour initiation
frequency in vivo.
Conclusion: We have identiﬁed C1orf106 as a novel and robust
TGF-β target gene correlating with poor prognosis in breast
cancer and shown it to enhance tumourigenicity in a series of
breast cancer cell lines.
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58. Deﬁning microRNA mediated regulation of CD157
involved in colon cancer progression
Mahnaz Darvish Damavandi1, George Vlachogiannis2, Gift Nyamun-
danda2, Andrea Lampis2, Harold Parkes3, Somaieh Hedayat2, Jens
Hahne2, Matteo Fassan4, Anguraj Sadanandam2, Owen Sansom5,
Nicola Valeri2
1Division of Molecular Pathology, The Institute of Cancer Research,
London, 2The Institute of Cancer Research, 3Division of Radiotherapy
and Imaging, The Institute of Cancer Research, London, 4Department
of Medicine DIMED, University of Padova, Padova, 5Cancer Research
UK Beatson Institute, Glasgow
Background: Progressive accumulation of mutations in oncogenic
and tumour suppressor pathways (e.g., KRAS and p53) and also
microRNA (miR) deregulation are associated with colorectal cancer
(CRC) development. Very little has been done to dissect speciﬁc
CRC pathways involved in miR regulation in response to stress and
metabolic changes. Therefore, we investigated the interaction
between miR-mediated regulation of bone marrow stromal cell
antigen 1 (BST1) or CD157, a metabolic enzyme involved in the
conversion of nicotinamide adenine dinuclease (NAD) to paracrine
factor cyclic ADP ribose (cADPR), following the acquisition of KRAS
mutation in metastatic CRC.
Method: A combination of array analysis data, in-silico prediction
tools and nuclear magnetic resonance (NMR) system were used to
analyse gene (mRNA) and miR expression, as well as metabolic
changes associated with different rounds of knock in/out
mutations in Apc, Kras, and p53 CRC mouse models and their
tumour-derived organoids (TDOs). Subsequently, we genetically
modiﬁed human CRC cell lines and patients KRAS mutant (mut)
TDOs from CRC metastases to modulate the candidate gene and
miR. Organoids formation, growth rate and viability were
measured with Live-Cell imaging systems.
Results: We identiﬁed mRNA/miR networks involved in cancer
metabolic pathways and assessed the most signiﬁcant candidates.
Further target validation and analysis of human tissues micro-
arrays showed an association between KRAS mutations, miR-203
down-regulation and over-expression of BST1, which was identi-
ﬁed as a direct target of miR-203 regulation in our studies.
Repressing BST1 and over-expressing miR-203 had a signiﬁcant
effect on the proliferation and migration abilities of organoids in
3D culture in normal and calorie-deprived conditions.
Conclusion: This project aimed to ﬁnd a promising candidate as a
therapeutic target in KRAS mut CRC. Although we showed KRAS
mut CRC cells lost a growth advantage with miR-203 and BST1
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deregulation ex vivo, work is on going to conﬁrm the
consequence of their interaction in vivo.
Acknowledgement: A version of this abstract has been
published previously, see PO346 https://esmoopen.bmj.com/
content/3/Suppl_2/A364.1 For original and CC-BY license.
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59. Phenotypic subtyping of matched primary colonic
tumours and liver metastases
Kathryn Pennel1, Arfon Powell2, Donald McMillan1, Paul Horgan1,
Antonia Roseweir1, Joanne Edwards1
1University of Glasgow, 2Cardif University
Background: Colorectal cancer (CRC) is a heterogeneous group of
malignancies that arise in the same organ. The 5-year survival rate
for CRC is 60% and this is signiﬁcantly reduced in stage four
metastatic disease. A common site of metastasis is the liver. In
2017, phenotypic subtypes for CRC were developed in an effort to
move towards precision medicine. The phenotypic subtypes
(immune, canonical, latent and stromal) are derived from three
features; inﬂammation, stromal invasion and proliferation. This
study aimed to investigate the relationship between primary
tumour and liver metastases phenotypic subtypes and association
with clinicopathological outcomes.
Method: Matched patient-derived colonic primary tumours and
liver metastases were stained for Ki67 proliferation index and an
H&E analysed for Klintrup-Makinen grade and tumour-stroma-
percentage to determine phenotypic subtype. The relationship
between the primary tumour subtype (PS-primary) and liver
metastases (PS-met) was investigated using bivariate correlations
and paired sample T-tests. The relationship between PS-primary/
PS-met and clinicopathological features was analysed using Chi-
squared tests.
Results: Phenotypic subtype was observed to correlate between
the primary tumour and metastasis (n = 42, p = 0.001). In the
primary tumours, immune subtype associated with age (p =
0.047) and nuclear HIF1a (p = 0.043); canonical subtype
associated with cytoplasmic MMP9 expression (p = 0.015);
latent subtype associated with marginal involvement (p =
0.013); and stromal subtype associated with modiﬁed Glasgow
Prognostic Score (p = 0.044) and cytoplasmic HIF1a expression
(p = 0.012). In the metastases, immune subtype associated with
age (p = 0.01) and albumin levels (p = 0.043); latent subtype
associated with cytoplasmic MMP9 expression (p = 0.031); and
stromal subtype associated with cytoplasmic CRP expression (p
= 0.032). However, the canonical subtype showed no signiﬁcant
association.
Conclusion: The results suggest that PS-primary is predictive of
PS-met, and that each phenotypic subtype associates with
different speciﬁc clinicopathological features differing between
primary or metastatic lesions. This may provide a step towards the
development of precision medicine for CRC.
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60. A novel cis-acting lncRNA controls HMGA1 expression and
is deregulated in non-small cell lung cancer
Greg Stewart, Adam Sage, Katey Enﬁeld, Erin Marshall, Victor
Martinez, Wan Lam
BC Cancer Research Centre
Background: High mobility group A1 (HMGA1) is aberrantly
expressed in several aggressive cancer types, including non-
small cell lung cancer (NSCLC), where high HMGA1 expression
has been associated with poor survival and chemotherapy
resistance. While HMGA1 is known to be deregulated in lung
cancer, the mechanisms that mediate its expression remain
unknown. Since their discovery, long non-coding RNAs
(lncRNAs) have been increasingly implicated in cancer-
associated phenotypes. Recently, some lncRNAs have been
shown to regulate the expression of neighbouring protein-
coding genes, including oncogenes and tumour suppressor
genes. These lncRNAs, known as cis-acting, may represent
undiscovered therapeutic action points in cancer driving
pathways. Here we investigate the deregulation of a putative
cis-acting lncRNA in NSCLC, and its relationship with the
oncogene HMGA1.
Method: LncRNA expression was generated from RNA-sequencing
data from 36 microdissected tumour and matched non-malignant
tissues. Normalized sequence read counts were used to identify
transcripts with signiﬁcantly deregulated expression (Wilcoxon
Signed-Rank Test, BH-p<0.05). Validation was performed in
sequencing data obtained from The Cancer Genome Atlas (TCGA).
SiRNA-mediated knockdown of lncRNA candidates was performed
in a non-malignant epithelial lung cell line (BEAS-2B). Quantitative
real-time PCR was used to observe the effects of lncRNA
knockdown on the expression of neighbouring protein-coding
genes.
Results: Our analyses identiﬁed RP11.513I15.6, an
undescribed lncRNA neighbouring HMGA1, to be signiﬁcantly
downregulated in 2 cohorts of LUAD samples. HMGA1 expression
was found to be anticorrelated with RP11.513I15.6, as
tumours with downregulated RP11.513I15.6 displayed signiﬁcant
overexpression of HMGA1. In vitro experiments demonstrated
siRNA-mediated inhibition of RP11.513I15.6 in immortalized lung
epithelial cells resulted in a signiﬁcant increase in HMGA1
expression.
Conclusion: Our results suggest that RP11.513I15.6 is a novel cis-
acting lncRNA that negatively regulates HMGA1, and may
contribute mechanistically to the maintenance of lung cancer
phenotypes. Further characterization of this oncogenic regulatory
mechanism may uncover a novel therapeutic intervention point
for tumours driven by HMGA1.
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61. Regulatory heterogeneity in glioblastoma multiforme
informs novel drug target discovery
Yunpeng Liu1, Ning Shi2, Shan He2, Michael Hemann1, Aviv Regev1
1Massachusetts Institute of Technology, 2University of Birmingham
Background: Glioblastoma multiforme (GBM) is one of the most
malignant forms of cancer. Bulk and single-cell transcriptome
proﬁling have revealed high levels of both inter- and intratumour
heterogeneity in GBM. The disease has been stratiﬁed into four
molecular subtypes according to gene expression - Classical,
Neural, Proneural and Mesenchymal, each of which exhibiting
distinct mutational signatures and therapeutic responses. How-
ever, the underlying regulatory circuitry that gave rise to such
heterogeneity and its implications for rational design of therapy
are unclear.
Method: We have developed a nonlinear regression model to
understand key regulatory networks across the four GBM subtypes.
We ﬁrst constructed a backbone network of transcription factor
(TF) - target gene pairs inferred from chromatin landscape data
and TF binding motifs, and applied nonlinear regression using
expression proﬁles of each subtype to derive subtype-speciﬁc
regulatory parameters for each TF-gene pair. Next, we mined for
co-regulatory TF pairs using correlation analysis. Mechanisms
responsible for subtype-speciﬁc behaviour of TFs were then
inferred from expression, regulatory and co-regulatory signatures.
Finally, we simulated the effects of perturbing druggable signature
TFs and their partners by propagating changes in expression to the
corresponding target genes and then to the protein signaling layer
using a random walk-based algorithm.
Results: We show that subtype-speciﬁc repurposing of TFs
explains a signiﬁcant proportion of subtype-speciﬁc transcription
landscapes. At least two mechanisms for TF repurposing are
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implied - differential expression of the TF itself and differential
partnering with co-regulatory TFs. Using effectors of the apoptosis
pathway as readout in our in silico perturbation analysis, we show
that targeting a subset of druggable signature TFs and/or their
partners may be speciﬁcally beneﬁcial for treating the correspond-
ing subtypes of GBM.
Conclusion: Data-driven modeling of transcription regulation in
GBM is capable of gaining new biological insight into the
molecular underpinnings of its heterogeneity and aids rational
design of subtype-speciﬁc targeted therapy.
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62. An Effective Pipeline for Whole Genome Sequencing for
Research in a Tertiary Cancer Centre
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Katie Snape1, Ruth Pettengel1, Nirupa Murugaesu2
1St George's University Hospital NHS Trust, 2Genomics England
Background: The 100,000 Genomes Project is performing whole
genome sequencing (WGS) on paired tumour and germline DNA
from patients with cancer. It aims to provide genomic data to
inform patient management, contribute to a database for future
research, and establish new diagnostic pathways in histopathol-
ogy and genetics. We describe the experience of St Georges
University Hospital, part of South London Genomic Medicine
Centre.
Method: Patients are identiﬁed as eligible by screening of
biopsy and theatre lists and multidisciplinary team meetings
(MDTs). After liaising with the clinical team and histopathology,
a fresh tumour sample is obtained. Patients are approached
prospectively or retrospectively, for consent and blood or
saliva for germline testing. If adequate DNA is extracted, it is
sent to Illumina for sequencing and Genomics England (GEL)
for annotation. Resulting genomic reports provide detailed
information on somatic and germline single nucleotide
variants, copy number and mutational signatures. These are
discussed at a Genomic MDT consisting of Consultant
Oncologist, Consultant Clinical Geneticist and Consultant
Clinical Scientist. A summary report of actionable or potentially
actionable ﬁndings is produced and sent to the referring
clinician.
Results: From 1st June 2016 to 11th May 2018, we collected
873 samples, 324 biopsies and 549 resections. 1060 patients were
consented, and 556 patients had DNA extracted. To date, 492
cases have been submitted to GEL, of which 121 have been
discussed at MDT and had results returned.
57 patients (47%) had clinically actionable or potentially
actionable mutations. The most frequently occurring were
mutations in KRAS and PIK3CA, each found in 16.5% of patients.
Two patients had germline ﬁndings, one in BRCA2 and one in
MSH2.
Conclusion: We demonstrate an effective pipeline for tumour
WGS and review of results. Our data suggests that WGS has the
potential to affect patient management and increase recruitment
to trials.
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63. eIF4A2 is a regulator of hypoxic translation and colorectal
tumour cell survival
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Background: Colorectal cancer kills more than half a million
people a year worldwide. Hypoxia (low oxygen) is associated with
increased chemotherapy and radiotherapy resistance. 1 in 3
colorectal tumours contain regions of low oxygen. Under hypoxic
conditions components of the protein synthesis machinery
undergo an adaptive change as do the translational efﬁciencies
of a subset of pro-survival mRNAs. eIF4A2, an RNA helicase is
differentially expressed in a variety of cancers. We hypothesised
that eIF4A2 played a role in normoxic and hypoxic colon tumour
cell survival through its regulation of proteins required for hypoxic
survival.
Method: Using a panel of colorectal cancer cell lines we assessed
hypoxic regulation of eIF4A2 and its role in survival and cell
viability in 2D and 3D spheroid cultures and in on-going in vivo
experiments using inducible shRNA eIF4A2 knockdowns. RNA-seq
was used to identify eIF4A2 regulated transcripts.
Results: eIF4A2 was signiﬁcantly upregulated by hypoxia at the
protein and RNA level under control of HIF1α. Knockdown of
eIF4A2 signiﬁcantly reduced cell survival and proliferation in 2D
and 3D spheroid cultures, and we identiﬁed increased apoptosis
and necrosis in the hypoxic core of the spheroids. RIP-seq
identiﬁed a number of key hypoxia pro-survival proteins are
eIF4A2 dependently translated.
Conclusion: eIF4A2 is required for hypoxic tumour cell survival in
colorectal cancer. This highlights the value of the development of
small molecule inhibitors that speciﬁcally target eIF4A2 to target
the therapy resistant hypoxic tumour microenvironment.
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64. Long non-coding RNA LINC00973 is a putative biomarker
of colon cancer relapse
Nikolai Lisitsyn, Olga Zinovieva, Evgenia Grineva, Maria Prokofjeva,
Dmitry Karpov, Andrei Zheltukhin, George Krasnov, Anastasiya
Snezhkina, Anna Kudryavtseva, Peter Chumakov, Tamara Mashkova,
Vladimir Prassolov
Engelhardt Institute of Molecular Biology
Background: Early prediction of tumor relapse depends on
identiﬁcation of novel prognostic cancer biomarkers, which are
suitable for monitoring of the response of various cancer types to
the action of chemotherapeutic drugs.
Method: RNA-sequencing (RNA-Seq), RT-qPCR, and bioinformatics,
combined with the study utilizing murine tumour xenograft
model.
Results: We have found most signiﬁcant (up to 100-fold) and
consistent changes in the abundance of LINC00973 upon
treatment of HT-29 and HCT-116 colon cancer cells with 5-
ﬂuorouracil, oxaliplatin, and irinotecan at different doses and
durations, both in vitro and in vivo. Though the function of
LINC00973 has not yet been determined, the RAID v2.0 database
suggests that this RNA may form a complex with lncRNA CRNDE
that is a part of the Polycomb repressive complex 2. This complex
epigenetically silences DUSP/CDKN1A expression, promoting
proliferation and suppressing apoptosis of colon cancer cells.
Using CRISPR/Cas9 system we knocked out the LINC00973
encoding gene in HT-29 cells and found signiﬁcant decrease in
their proliferation and activation of apoptosis, as compared to
intact controls. Besides, LINC00973 KO cells were much less
resistant to chemotherapeutic drugs, which imply that over-
expression of this RNA is a key event in the acquisition of
chemoresistance by colon cancer cells. In accordance with these
data, bioinformatics search revealed that expression of LINC00973
is drastically reduced in most types of carcinomas, but even small
increase in LINC00973 abundance in most aggressive subtypes of
colon cancer results in sharp increase in the probability of tumour
relapse (hazard rate=1.34). Prognostic value of LINC00973 was
also demonstrated for kidney and head and neck cancers.
Conclusion: LINC00973 is a perspective biomarker for prognosis
of several cancer types. Further clinical studies are necessary in
order to determine, if measurement of the LINC00973 abundance
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throughout the course of neoadjuvant therapy might be useful for
the reliable prediction of colon cancer relapse.
Disclosure: The Russian Science Foundation
Corresponding author: Nikolai Lisitsyn
65. Nuclear morphometry features distinguish cell types and
outcome groupings in lung cancer
Katey Enﬁeld1, Spencer Martin1, Erin Marshall1, Zhaolin Xu2, Martial
Guillaud1, Calum MacAulay1, Wan Lam1
1British Columbia Cancer Research Centre, 2Dalhousie University
Background: The shape and organization of tumour cell nuclei
has been shown to be associated with aggressiveness in several
cancers, including prostate and cervical cancer. Fortunately, this
data can be obtained using a single quantitative nuclear stain on
FFPE tissues. We sought to determine whether nuclear features
could be utilized to distinguish cell types within the lung tumour
microenvironment and to classify outcome groupings.
Method: A tissue microarray of non-small cell lung cancer samples
was stained with the quantitative nuclear dye, Feulgen/thionin.
The stained slides were scanned using a hyperspectral imaging
platform, images were spectrally unmixed, and cell nuclei were
identiﬁed using a segmentation algorithm. Nuclei were then
analyzed to identify 245 nuclear morphometry features. Nuclear
features were assessed in order to dichotomize good outcome
(alive at 5 years) and bad outcome (survival of 3 years or less)
patients, as well as several cell types within the tumour
microenvironment. Finally, we assessed the spatial organization
of these different classes of nuclei in good and poor outcome
cases.
Results: Nuclear features derived from thionin stain classiﬁed
epithelial, stromal, and immune cells. Of the 245 nuclear features
assessed, 87 differed signiﬁcantly between good and poor
outcome groups. While many distinguishing features were
identiﬁed in tumour cell nuclei, we were also able to identify
distinguishing features of non-tumour cell nuclei. Using pairs of
features, good and poor outcome cases were stratiﬁed with up to
69% accuracy. However, the addition of spatial information to our
classiﬁer resulted in the improvement of sample stratiﬁcation to
86% accuracy.
Conclusion: Using a single nuclear stain on FFPE lung cancer
histology specimens, we were not only able to sub-classify cell
types, but also to distinguish between good and poor outcome
cases. The spatial organization of these cell types greatly improved
our classiﬁer, indicating the potential of this approach for
prognostic purposes.
Disclosure: Funded by NSA, CIHR
Corresponding author: Katey Enﬁeld
66. Identiﬁcation and targeting of metabolic vulnerabilities in
leukaemic stem cells using integrated omic approach
Vignir Helgason1, Zuzana Brabcova1, Kevin Rattigan1, Lisa Hopcroft1,
Eyal Gottlieb2, Alexei Vazquez3
1University of Glasgow, 2Technion Integrated Cancer Center, 3Cancer
Research UK, Beatson Institute
Background: Leukaemia progression and relapse are fuelled by
leukaemic stem cells (LSCs) that are resistant to current
treatments. Therefore, identiﬁcation of targetable pathways that
selectively maintain LSC survival is critical. Metabolic reprogram-
ming is a core feature of cancer cells making them susceptible to
manipulation in a selective manner. We aimed in this study is to
identify and target metabolic dependencies in LSCs, using
primitive primary cells isolated from individuals with chronic
myeloid leukaemia (CML) and healthy donors.
Method: We have recently developed improved protocols for
metabolic ﬂux assays in patient-derived LSCs, where heavy
isotope-labelled carbons (13C), are used to detect different
isotopes of intracellular metabolites over time, using a state-of-
the-art liquid chromatography-mass spectrometry system (Kuntz
et al. Nat Med, 2017). To fully understand the metabolic properties
of LSCs, we have extended our work and combined functional
studies with integrative-omics and data-driven computational
approach to assess the metabolic changes from transcriptomic
and metabolomics datasets.
Results: We show that LSCs display an increase in fatty acid
oxidation (FAO) and ﬂux of glucose carbons through the
tricarboxylic acid (TCA) cycle, along with an elevated mitochon-
drial respiration, when compared with normal hematopoietic stem
cells (HSCs). Integrative omic approach conﬁrmed upregulation of
FAO and the TCA cycle in LSCs. Additionally, increased activity of
pyruvate carboxylase, together with increase in 13C enrichment in
TCA cycle metabolites, indicate a signiﬁcance of pyruvate
anaplerosis and reductive carboxylation, when comparing LSCs
to HSCs. This suggests that LSCs may be selectively sensitive to
inhibition of mitochondrial oxidative phosphorylation (OXPHOS).
Of clinical signiﬁcance, we show that inhibition of mitochondrial
translation reduces this aberrant oxidative metabolism and
induces death in LSCs in vitro and in a robust pre-clinical
patient-derived xenograft model.
Conclusion: We conclude that LSCs are dependent on anaplerosis
and mitochondrial OXPHOS for their survival and inhibition of
mitochondrial metabolism selectively targets drug-resistant CML
LSCs.
Disclosure: Funded by Cancer Research UK; KKLF; Leuka; The
Howat Foundation
Corresponding author: Vignir Helgason
67. Identifying breast-to-brain metastasis-associated gene
mutations by whole exome sequencing
Mark Morris1, Ivonne Olivares1, Timothy Dawson2, Kate Ashton2,
Charles Davis2, Michael Jenkinson3, Andrew Brodbelt3, Angel
Armesilla1, Tracy Warr1
1University of Wolverhampton, 2Royal Preston Hospital, 3The Walton
centre
Background: Over recent years breast cancer survival rates have
improved. However, even after many years of apparent disease-
free health, cancer can recur. Many of these tumours occur
speciﬁcally in the brain and metastatic brain tumours have very
poor prognoses. Identifying genomic alterations that occur in
breast primary tumours that eventually metastesise to the brain
will provide new opportunities for treatment and prognosis.
Method: Whole-exome sequencing (WES) was carried out in 18
brain metastasis samples that originated from breast tumours.
Each sample was sequenced to a depth >100X. Bioinformatic
analysis was carried out to identify common recurrent
mutations. We are in the process of validating the candidate
mutations by Sanger sequencing and screening a larger
cohort of Breast to Brain Metastasis (BBMs) and non-metastatic
primary breast tumours to conﬁrm metastasis-associated
alterations.
Results: Each of the 18 BBMs analysed by WES contain >7000 non-
synonymous variants. All variants were screened for their
consequence on the protein product (via Polyphen and the
Exome Aggregation Consortium(ExAc)). Those variants with high
scores relating to pathogenicity were retained. Following this
ﬁltering, potential germline polymorphisms were excluded by
removing those variants with a minor allele frequency (MAF) of
>0.1%. This screening has generated a long list of 300 variants
found across all 18 tumours analysed. A ﬁnal screen identiﬁed
genes that contained pathogenic variant in more than 2/18
tumours and had been described in any other cancer type (via the
catalogue of somatic mutations (COSMIC)).
Via this stringent screen, we have identiﬁed 22 candidate
metastasis-associated genes. we are currently screening non-
metastatic primary breast tumours and BBM tumours to determine
how frequently these occur. The genes identiﬁed have varied
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cellular roles, including cell surface proteins, migration and gene
regulation.
Conclusion: We expect that this analysis will identify genes that
are frequently mutated in BBMs, but infrequently in non-
metastatic breast tumours.
Disclosure: Funded by University of Wolverhampton
Corresponding author: Mark Morris
68. The role of translational elongation loss in colorectal
cancer
Nikola Vlahov1, John Knight1, Owen Sansom1
1The Beatson Institute for Cancer Research
Background: The elongation phase of mRNA translation is the
most energy and amino acid consuming part of protein synthesis.
This process is controlled by the Eukaryotic elongation factor 2
kinase (eEF2K), an atypical calmodulin-dependent protein kinase
that slows down translation elongation by phosphorylating eEF2.
eEF2K functions as a negative regulator of protein synthesis and
cell growth. Cancer cells may possess mechanisms to inhibit
eEF2K. We have previously shown that in colorectal cancer
Rapamycin-induced reduction of elongation suppresses intestinal
regeneration and tumourigenesis following APC loss. This process
was shown to be controlled by eEF2K.
Method: We generated in vivo mouse models with acute deletion
of either a single or both copies of Apc with either conditional
expression of eEF2K kinase dead allele (D273A) or conditional
deletion of eEF2K in the mouse intestine. We followed the rates of
intestinal proliferation and tumourigenesis and the response to
various drug therapies.
Results: In both of these models we observed loss of the
inhibitory phosphorylation of eEF2. Intestinal crypt organoids from
these mice showed increased ribosome run-off rate associated
with inhibition of elongation control due to the loss of eEF2K
function. We have also demonstrated that loss of eEF2K function
or total eEF2K levels, following Apc loss, led to signiﬁcant increase
in survival compared to mice with Apc deletion alone. Deletion of
eEF2K in addition to Apc and Kras, one of the most frequently
altered genes following Apc, did not have an effect on survival.
Conclusion: We found that eEF2K deletion increases survival in
mice that have lost Apc and we have explored the possibility to
combine eEF2K inhibition with conventional drug treatments for
colorectal cancer.
Disclosure: Funded by Wellcome Trust
Corresponding author: Nikola Vlahov
69. Single cell copy number variation analysis (CNV) of
circulating tumour cells (CTCs) in neuroendocrine tumour
(NET) patients
Alexa Childs1, Clare Vesely1, Francesca Rizzo1, Leah Ensell1, Helen
Lowe1, Christina Thirlwell1, Christos Toumpanakis2, Martyn Caplin2,
John Hartley1, Tim Meyer1
1University College London Cancer Institute, 2Royal Free Hospital,
London
Background: The identiﬁcation and characterisation of CTCs as
part of a minimally invasive “liquid biopsy” provides an
opportunity to explore NET biology, identify therapeutic targets
and investigate tumour heterogeneity. Here we report the ﬁrst
genomic analysis of NET CTCs at the single cell level.
Method: Peripheral blood samples from metastatic neuroendo-
crine patients were enriched for CTCs using the EpCAM-dependent
CellSearch and EpCAM-independent, size-based Parsortix plat-
forms. Enriched samples were ﬂuorescently labelled with DAPI, CK,
+/- EpCAM and CD45 antibodies to enable identiﬁcation and
recovery of single CTCs and white blood cells (WBC) using
DEPArray technology. Whole genome ampliﬁcation was performed
on individual cells, followed by quality-control PCR to assess
ampliﬁed DNA quality. Low pass whole genome sequencing was
undertaken and the CNV proﬁle of CTCs analysed to identify
chromosomal gains and losses. WBC were used as controls.
Results: CNV proﬁle analysis revealed copy number alterations
among CTCs and ﬂat proﬁles for WBC. CTCs derived from a midgut
patient showed distinct CNV proﬁles in keeping with genomic
heterogeneity, despite conserved gains on chromosome 7 and 16,
corresponding to gains in CDK6, MET and BRAF. Hierarchical
clustering of CTCs derived from a renal NET patient demonstrated
a conserved CNV proﬁle characterised by losses in Chr 3, 10, 11 &
13. All cells demonstrated loss of the VHL gene and a single cell
also had unique gains in Chr 2 & 7 not seen in other cells, giving
insight into clonal evolution in this patient. Potentially druggable
targets including CDK6 and CDK4 were consistently present in CTC
populations from single patients.
Conclusion: CNV analysis is feasible in CTCs derived from patients
with NET and demonstrates both conserved and heterogeneous
alterations. This type of analysis may allow personalised therapy
and real time monitoring of tumour evolution.
Acknowledgement: A similar version of this abstract has been
published previously, see https://www.karger.com/Article/
Abstract/487699 for original and CC-BY license.
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70. Antibiotic use and efﬁcacy of small molecule inhibitors in
patients with advanced cancer
Grace Tan1, Nadina Tinsley2, Cong Zhou1, Shaun Villa2, Paul
Lorigan2, Fiona Blackhall2, Matthew Krebs2, Louise Carter2, Fiona
Thistlethwaite2, Andrew Hughes1, Natalie Cook2
1University of Manchester, 2Christie NHS Foundation Trust
Background: Antibiotic use (ABX) has been shown to reduce the
efﬁcacy of immune checkpoint inhibitors (CKIs) in the treatment of
cancer by eradication of the gut microbiome. The gut microbiome
is known to be involved in the regulation of anti-tumour
responses. Here, we determine if the a similar relationship exists
between ABX use and small molecule inhibitors (SMIs) in patients
with advanced cancer.
Method: Retrospective data analysis was performed on meta-
static cancer patients treated with SMIs at the Christie NHS
Foundation Trust between January 2015 and March 2017.
Patients with melanoma, renal cell carcinoma (RCC) and non-
small cell lung cancer (NSCLC) patients were included. Patient
demographics, prior treatments, extent of disease, SMI agent
and use of antibiotics (route, duration, multiple ABX/successive
courses) were collected. Progression free survival (PFS) and
overall survival (OS) were compared between ABX+ (patients
treated with ABX either 2 weeks before SMI initiation, or 6 weeks
after) and ABX- groups (patients with no ABX within the
speciﬁed timeframe). Statistical analyses were carried out with
univariate and multivariate models.
Results: Of 261 patients, 69 (26%) received ABX of which the
commonest were beta-lactams and quinolones. Multivariate
analyses of ABX+ and ABX- groups found that no correlation
exists between ABX use and PFS but ABX use was linked to shorter
OS (median 490 days (ABX-) vs 309 days (ABX+)).
Conclusion: This is the ﬁrst analysis investigating the impact of
ABX on SMI therapeutic outcomes. The data demonstrated
evidence of a link between ABX and shortened OS therefore
further studies are warranted to fully evaluate the potential
causative role of the gut microbiome in reduced treatment
outcomes of SMIs as other forms of anti-cancer therapies.
Disclosure: None declared
Corresponding author: Grace Tan
71. MCL-1 regulates breast cancer stem cells
Kirsteen Campbell1, Karen Blyth2, Stephen Tait1
1Glasgow University/Beatson Institute for Cancer Research, 2Beatson
Institute for Cancer Research
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Background: MCL-1 is a pro-survival member of the BCL-2 protein
family that has been shown to be up-regulated in a range of
cancers. We have shown that high levels of MCL-1 predict poor
prognosis in breast cancer. This is particularly relevant in triple
negative breast cancer where treatment resistance and disease
recurrence remain a major challenge. A new class of drugs
speciﬁcally targeting MCL-1 have been developed and are
currently in clinical trials for haematopoietic malignancies. We
are investigating the therapeutic potential of targeting MCL-1 in
breast cancer and the role of MCL-1 in breast cancer stem cells.
Method: We have used a combination of approaches to system-
atically evaluate the role of MCL-1 in breast cancer. This includes
the use of small molecule MCL-1 inhibitors and knock-down/
knock-out of MCL-1 in vitro and in vivo xenograft/genetically
engineered mouse models to investigate the therapeutic potential
of targeting MCL-1 in breast cancer.
Results: We ﬁnd that in addition to the poor prognosis indicated
by high levels of MCL-1, breast cancer cells are highly dependent
on MCL-1. Therapeutic targeting or genetic deletion of MCL-1 is
sufﬁcient to delay tumour development and regress established
tumours in vivo. We ﬁnd that MCL-1 is important in breast cancer
stem cells and targeting MCL-1 could be particularly important in
the context of treatment resistance and recurrence.
Conclusion: New targeted therapeutic approaches are required in
both triple negative breast cancer and treatment resistant/
recurrent disease. Our evidence suggests that targeting MCL-1
may offer a new therapeutic axis in breast cancer.
Disclosure: None declared
Corresponding author: Kirsteen Campbell
72. Amino acid transporter SLC7A5 is required for growth of
Kras-mutant colorectal cancer in vivo
Arafath Najumudeen, Fatih Ceteci, Owen Sansom
Beatson Institute for Cancer Research
Background: Colorectal Cancer (CRC) is the third most common
cancer worldwide and Ras/MAPK pathway deregulation is strongly
associated with the development of CRC, often through activating
KRAS mutations (40%) and inactivation of APC (80%). Recent
studies from our laboratory and others showed that expression of
oncogenic Kras dramatically increases intestinal tumorigenesis
initiated by the inactivation of APC in mice. However, the role of
Kras mutation in metabolic rewiring of intestinal tumours is not
yet fully understood.
Method: We use extensive combinations of genetically engi-
neered mouse (GEM) models of intestinal cancer, targeted liquid
chromatography/Mass spectrometry (LC/MS) metabolomics and
transcriptomic analysis on intestinal organoids.
Results: Here we demonstrate in GEM models of intestinal cancer
that Wnt activation (by Apc loss) and Kras mutation co-ordinately
rewire intestinal metabolism in vivo and in vitro by increasing
both glucose and glutamine consumption to support anabolic
processes that fuel cell proliferation. From this analysis, we
identiﬁed Solute carrier member 7a5 (Slc7a5) to be signiﬁcantly
upregulated in both mouse and human CRC to meet the increased
nutrient demand of the cancer cells. This work aims to determine
the mechanism by which Slc7a5 contributes to CRC. Using genetic
deletion of Slc7a5 in murine models of CRC we show that Slc7a5 is
functionally required for Kras driven (not wildtype) epithelial cell
proliferation and tumorigenesis. Mechanistically, Slc7a5 is needed
for Kras mediated nutrient sensing and subsequent
mTOR1 signaling downstream. Importantly, Slc7a5 deletion
sensitises Kras tumours to rapamycin (further suppressing
mTORC1 signalling) causing tumour cells to undergo growth
arrest.
Conclusion: In conclusion, our results reveal a Kras mediated
metabolic rewiring mechanism that couples amino acid transport
by Slc7a5 and mTOR1 activation with control of intestinal
tumorigenesis and further suggest that altering Slc7a5 activity
may provide a therapeutic opportunity for colorectal cancer.
Disclosure: Funded by Beatson Institute for Cancer Research
Corresponding author: Arafath Najumudeen
73. The role of ELTD1/ADGRL4 in tumour angiogenesis
Koon Hwee Ang
University of Oxford
Background: ELTD1/ADGRL4, is an orphan adhesion GPCR. ELTD1
is expressed in endothelial and vascular smooth muscle cells but
its expression in the tumour vasculature is signiﬁcantly increased.
Our aims were to analyse ELTD1’s function in endothelial cells and
breast cancer to explore its potential as an anti-cancer therapeutic
target.
Method: Primary human breast cancers (n = 245) and matched
primary & nodal secondary breast cancers (n = 79) were stained
for ELTD1. Staining intensity was scored and compared with
survival. ELTD1 was expressed in breast cancer cell lines to assess
the effect on tumour growth in xenograft experiments and
knockout mice were generated with 1) tamoxifen-inducible
knockout of Eltd1 in all tissues 2) constitutive Eltd1 knockout in
vessels or 3) inducible Eltd1 knockout in vessels. Extracellular
vesicles (EV’s) were harvested from ELTD1 expressing cells and
their effects assessed in vitro and in vivo.
Results: Human breast cancer staining revealed a higher intensity
vascular ELTD1 staining within the tumour stroma compared to
normal stroma and ~15% of the tumours had ELTD1 expression
within tumour cells. Higher ELTD1 expression in both the tumour
stroma vasculature (n = 241; HR = 0.68; p = 0.04) and within
the subset of tumour positive cases (n = 24; HR = 0.3;
p = 0.02) correlated with improved relapse free survival (RFS).
ELTD1 expression in human breast cancer cell lines did not affect
proliferation or spheroid growth, but reduction in tumour growth
was seen in xenograft models. Tumours grown in the constitutive
and inducible Eltd1 knockout mice showed no difference in
growth but marked changes in vasculature and necrosis. ELTD1 is
incorporated into EV’s. Vesicles isolated from ELTD1 overexpres-
sing breast cancer cell lines and HUVECs were pro-angiogenic
in vitro and reduced tumour growth when injected into
xenografts.
Conclusion: Eltd1 knockdown affects tumour vasculature, parti-
cularly in inducible models suggesting that monoclonal antibodies
targeted the calcium binding EGF domain should be considered
for further therapeutic development.
Disclosure: Funded by Cancer Research UK
Corresponding author: Koon Hwee Ang
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74. Neutrophil counts and cancer prognosis: an umbrella
review of systematic reviews and meta-analyses of
observational studies
Meghan Cupp1, Margarita Cariolou1, Ioanna Tzoulaki1, Evangelou
Evangelos1, Antonio Berlanga-Taylor1
1Imperial College London
Background: Neutrophil counts have been linked to the
progression of cancer due to their tumourigenic role in the
cancer microenvironment. Numerous meta-analyses and indivi-
dual studies explore the association between neutrophil counts
and cancer prognosis, contributing to a large body of evidence
with variable strength and validity. Uncertainty exists around the
association between neutrophils and cancer outcomes depending
on the site, outcome and treatments considered.
Method: For this umbrella review we searched Medline, EMBASE,
and the Cochrane Database of Systematic Reviews for meta-
analyses of observational studies evaluating the association
between neutrophil to lymphocyte ratio (NLR) or tumour
associated neutrophils (TAN) and speciﬁc cancer outcomes related
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to prognosis. The available evidence was graded as strong, highly
suggestive, suggestive, or weak through the application of pre-set
grading criteria. For each included meta-analysis, the grading
criteria considered the signiﬁcance of the random effects estimate,
the signiﬁcance of the largest included study, the number of
studies and individuals included, the heterogeneity between
included studies, the 95% prediction intervals, presence of small
study effects, excess signiﬁcance and credibility ceilings.
Results: Ultimately, 81 meta-analyses from 36 studies met the
criteria for inclusion. All meta-analyses suggested a hazard ratio in
the same direction of effect (HR>1). When assessed for
signiﬁcance and bias related to heterogeneity and small study
effects, only three (4%) associations between NLR and overall
survival and progression-free survival in gastrointestinal and
nasopharyngeal cancers were supported by strong evidence.
Conclusion: Despite many publications exploring the association
between NLR and cancer prognosis, the evidence is limited by
signiﬁcant heterogeneity and small study effects. There is a lack of
evidence on the association between TAN and cancer prognosis,
with all nine meta-analyses identiﬁed arising from the same study.
Further research is required to provide strong evidence for
associations between both TAN and NLR and poor cancer
prognosis.
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75. Salivary melatonin and squamous cell carcinoma antigen 1
levels in patients with oral squamous cell carcinoma
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Background: Oral squamous cell carcinoma (OC) is one of the ten
most frequent cancers in the world, with a 5-year survival rate
between 30-60%. Melatonin (MLT) has anti-oxidant, anti-
inﬂammatory and immunomodulating properties and is consid-
ered to contribute in protecting the oral cavity from tissue
damage caused by endogenic and exogenic factors. Squamous
cell carcinoma antigen (SCCA) has been recognized as a potential
serum marker for various squamous cell carcinomas and other
diseases. However, most of the studies on serum SCCA and OC
have not distinguished SCCA1 and SCCA2, due to their similar
chemical structure. It is important to mention that the two
molecules play different roles in the organism. Aim of the
proposed study is to determine salivary MLT and SCCA1
concentrations in patients with OC.
Method: Unstimulated whole saliva (UWS) and stimulated whole
saliva (SWS) was sampled from 29 patients with OC (21 male, 8
female) and 29 age and sex matched healthy subjects (22 male, 7
female). Only patients with histologically diagnosed oral squa-
mous cell carcinoma were included in the study. Sandwich human
SCCA1 ELISA kits (My BioSource, San Diego, USA) and Melatonin
direct saliva ELISA kits (IBL International GmbH, Hamburg,
Germany) were used. This research has been funded by the
Croatian Science Foundation (IP-09-2014-9376).
Results: Melatonin UWS levels were higher in the OC than in the
control group (p=0.045; median OC: 2.18 pg/mL(95% CI:1.37-2.88),
median control group: 0.84 pg/mL(95% CI: 0.50-1.71)). SCCA1
levels were higher in the OC group both in WUS (p=0.030; median
OC: 244,26 pg/mL(95% CI:133,00 to 513,27), median control group:
2pg/mL(95% CI: 2,00-321,47)) and WSS (p=0.014; median OC:
478,03 pg/mL(95% CI:125,16-618,74), median control group: 2,00
(95% CI:2,00-207,46)).
Conclusion: Salivary MLT and SCCA1 could serve as satisfactory
biomarkers for OC. To our knowledge, MLT and SCCA1 have not
yet been measured in the saliva of OC patients.
Disclosure: Funded by Croatian Science Foundation (IP-09-2014-
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76. Exploring experiences of referral for diagnostic
investigations and attitudes towards the new Faster
Diagnostic Standard
Marianne Coleman1, Georgia Black2, Dorothee Amelung1, Emily
Power3, Katriina Whitaker1
1University of Surrey, 2University College London, 3Cancer Research
UK
Background: The Faster Diagnosis Standard (introduced in
England from 2020) is a new patient-centred policy stipulating
that patients must have cancer ruled out or diagnosed within
28 days of referral for diagnostic testing. We explored public
attitudes towards this new standard, within the context of their
own recent referral experiences.
Method: Four 90-minute focus groups were conducted
(2 Guildford, 2 Bradford, n=29), recruiting men and women aged
50+ years without a current cancer diagnosis, who had completed
certain diagnostic tests (e.g. ultrasound) and received results
within the last 6 months. Age, education and gender were evenly
distributed across groups through purposive sampling. Topic
guide was developed with input from people with cancer, Cancer
Research UK, and the public.
Results: The biggest cause of concern to patients was the process
of waiting for and obtaining test results. Most had experienced
swift referral/testing, and it was difﬁcult for participants to
understand how the new standard could impact upon time spent
progressing through the system. Responsibility for meeting the
standard was also a concern: patients did not see their own
behaviours such as accepting a cancellation appointment as a
form of involvement in the standard being met. The GP’s role was
conceptualised as communicating with the patient about their
referral, establishing their preferences for information and
continued involvement at each stage of the referral process. The
standard legitimised chasing for test results, but 28 days was
considered too long.
Conclusion: Patients should be asked what they would like to
know about their referral. Where appropriate, GPs should be more
transparent about the referral process and the potential for lack of
clarity around next steps, timescales and outcomes. Patients
should know that it’s ok to make use of opportunities perceived as
‘manipulating the system’ but this needs to be balanced against
adding to existing patient burden.
Disclosure: Funded by Cancer Research UK
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77. Correlation between clinic-pathological features, MSI,
PD-L1 and survival in resected gastric cancer: looking for
prognostic biomarkers
Margherita Ratti1, Nicola Valeri2, Jens Claus Hahne2, Andrea Lampis2,
Michele Ghidini1, Gianluca Tomasello1, Giulia Tanzi1, Matteo Fassan3,
Rodolfo Passalacqua1
1Cremona Hospital Institutes, Italy, 2Institute of Cancer Research,
3University of Padua, Italy
Background: The identiﬁcation of prognostic biomarkers for
gastric cancer patient selection is compelling to improve survival
outcomes. Microsatellite instability (MSI) is related with a positive
prognostic effect in resected gastric cancer, whereas perioperative
chemotherapy is detrimental. In metastatic MSI gastric cancer,
immunotherapy with anti-PD1/PD-L1 drugs has shown promising
results. Nevertheless, in early stages, data on the relation between
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MSI, clinic-pathological features, PD-L1 expression and overall
survival (OS) remains sparse, especially in Western population. In
this study, the prognostic role of MSI status, clinic-pathological
features and PD-L1 expression in a large cohort of Italian gastric
cancer patients was examined.
Method: Clinic-pathological data of 148 consecutive stage I-III
gastric cancer patients resected in Cremona Institute between
2010 and 2014 (mostly chemo and/or radio-naive) were collected.
MSI analysis was performed on tissue samples for all cases, by
polymerase chain reaction. PD-L1 expression, evaluated by
immunoistochemistry, was assessed in MSI patients. Differences
between subgroups were evaluated with Chi-square test; Kaplan-
Meier method and Long Rank test were used to calculate OS.
Results: Female sex (p=0.012), earlier TNM stages (p=0.011) and
limited nodal involvement (p=0.029) signiﬁcantly correlated with
MSI status. MSI is signiﬁcantly associated with prolonged survival
(p<0.001), with an advantage of 28.6 months in OS compared with
the microsatellite stable (MSS) group. Most MSI patients (71%)
expressed PD-L1. Altough not statistically signiﬁcant, MSI patients
without PD-L1 expression showed a better trend in OS compared
with MSI gastric cancer patients expressing PD-L1 and with MSS
group.
Conclusion: MSI is an independent prognostic biomarker in
gastric cancer and identiﬁes a subset of patients with better OS
and speciﬁc clinic-pathological features, including high expression
of PD-L1. MSI could be a promising biomarker to select patients
for chemotherapy versus immunotherapy in resectable gastric
cancer.
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78. Focal Asymmetry and Laterality of Cancer
Faraz Janan1, Michael Brady2
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Background: The BIRADS score for mammographic density does
not currently indicate which breast has the higher density, and
may be at higher risk of developing (or having) cancer. A focal
density (‘developing’) is a region that is apparent on a recent
mammogram, is present in both CC and MLO views, but can only
be seen in one breast. Using focal density (FD) quantiﬁcation, we
assign a density score to each breast separately in order to assess
breast asymmetry.
Method: Our method, which substantially improves our previous
method (RICE) [1], suppresses normal breast parenchyma in order
to highlight ROIs (see Figure 1). It embodies the reasonable
assumption that the neighborhood typically has a similar tissue
density to that of the tissue encompassing the candidate masked
tumor. In this preliminary study, the method was applied to 11
patient cases of very dense mammograms, each of which
contained at least one cancer. Our method produces a density
score for each individual breast and determines asymmetry as a
percentage score.
Results: Table 1 summaries our results. Except for a single instance
(CL0081 – a marginal case), all asymmetric FD scores indicate the
laterality of the cancer. All mammograms were pre-processed with
Volpara breast density quantiﬁcation software [2]. We note that in
some cases (i.e. CL0037, CL0077, CL0090) where the volumetric
density grade percentage VGD% is very similar for both the left
and right breast, our method effectively produces distinct FD
scores conﬁrming to the laterality of cancer.
Conclusion: We assessed asymmetric FD in bilateral mammo-
grams using a method based on the actual composition of the
breast. In initial experiments, our method shows a promising
potential for quantifying breast asymmetry with respect to the
laterality of cancer. It works very well in all BIRADS classes,
including BIRADS-D.
Disclosure: Funded by Matakin UK/ASSURE Project (2014-15)
Corresponding author: Faraz Janan
79. Improving the intra-operative diagnosis of high-grade
glioma using a ﬂuorescence biomarker – result of the UK NCRI
GALA-BIDD study
Colin Watts1, Keyoumars Ashkan2, Michael Jenkinson3, Kathreena
Kurian4, Wendi Qian5, Stephen Price5, Tomasz Matys6, Gail
Doughton5, Andrea Machin5, Josephine Jung2, Ibrahim Jalloh3,
Chloe Harman5, Katrina Gatley5, Gemma Young5, Richard Hardy5,
Alimu Dayimu7
1University of Birmingham, 2Kings College Hospital, 3University of
Liverpool, 4Southmead Hospital, 5Cambridge University Hospitals
NHS Foundation Trust, 6University of Cambridge, 7Shandong
University
Background: Correctly distinguishing gliomas as low or high
grade (LGG or HGG) during surgery can inﬂuence the surgical
procedure, enhancing resection and improving survival. The
GALA-BIDD study was designed to prospectively
investigate whether the presence of visible ﬂuorescence is a
pragmatic intra-operative diagnostic surgical biomarker of
high grade disease within a tumour mass in real time during
surgery.
Method: Patients with suspected intrinsic glioma discussed at
neuro-oncology Multidisciplinary Team meetings and suitable for
ﬂuorescence guided cytoreductive surgery were eligible. 5-
aminolevulinic acid (5-ALA) was used to generate visible
ﬂuorescence. Tissue samples were sent for peri-operative histo-
pathological analysis to establish an intra-operative diagnosis of
LGG or HGG. Presence of visible ﬂuorescence was collected. These
data were compared with the ﬁnal central pathological diagnosis.
Results: From Feb 2015 to March 2017 in the UK, 106 patients
were recruited: median age 59 (range 23–77); 59% male; 25%
WHO radiological grade II transforming to a higher grade and 55%
grade IV. 5-ALA were given for 103 patients with a median dose of
1500mg (range 960–2200mg). 67% of patients classiﬁed as HGG at
local per-operative diagnosis were conﬁrmed by the central
review (weighted Kappa 0.37 (95%CI = 0.21–0.54)). 88 patients
were evaluable for the primary endpoint: 81 had visible
ﬂuorescence of the tumour with central histopathology diagnosis
as 1 LGG, 78 HGG (a 99% concordance in HGG classiﬁcation with
the 99%CI = 91%-99.9%) and 2 not assessed; 7 patients had no
visible ﬂuorescence and were diagnosed as 6 LGG and 1 HGG.
Conclusion: There is an urgent need to improve the local peri-
operative diagnosis. The presence of visible ﬂuorescence can be
used as an additional pragmatic intra-operative diagnostic
surgical biomarker of high-grade disease within a tumour mass.
Use for assessment of low-grade disease needs further
investigation.
Disclosure: Funded by Cancer Research UK
Corresponding author: Kathreena Kurian
80. Comparison of performance of mammogram readers with
breast MRI readers at an abbreviated breast MRI
interpretation task: Results from a single centre multireader
study using an enhanced data-set
Lyn Jones1, Sam Harding1, Rebecca Geach1, Chris Foy2, Victoria
Taylor1, Andrea Marshall3, Janet Dunn*3
1North Bristol NHS Trust, 2Research Design Service, South West,
3Warwick Clinical Trials Unit, University of Warwick
Background: FAST MRI has been proposed as a screening tool for
a wider group of women than those currently offered screening
with breast MRI. Its shorter acquisition and reading times promise
potential cost effectiveness. However, any proposed change in
screening modality from mammograms to FAST MRI has work-
force implications. We need to know whether NHSBSP mammo-
gram readers, already adept at mammogram interpretation but
without previous experience of interpreting breast MRI, could
quickly learn to read FAST MRI with brief additional training.
Method: 8 Readers (4 NHSBSP breast MRI and mammogram
readers (Group 1) and 4 NHSBSP mammogram readers who do
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not read breast MRI (Group 2)) were trained using a standardized
training package. All Readers completed a test set of 125
anonymised FAST MRI examinations (250 breasts: 194 normal
and 56 cancer) blinded to the other Readers’ opinions; providing a
total of 2000 interpretations.
Results: Overall concordance with the true result was 1745 (87%)
when identifying MRI classiﬁcation 4 or 5 as cancers (898/1000
(90%) for Group 1 Readers; 847/1000 (85%) Group 2 Readers). The
agreement between all readers and the true value, kappa, was
0.69 (95% ci 0.65–0.72).
When identifying MRI 3, 4 or 5 as cancers, overall concordance
was 1550 (78%) for all readers (777 (78%) Group 1; 773 (77%)
Group 2) and kappa = 0.51 (95% ci 0.47-0.54).
Conclusion: These results suggest that NHSBSP image
readers could adapt to reading FAST MRI with brief additional
training.
Ethics: Integrated Research Application System (IRAS), Health
Research Authority (HRA) and Research Ethics Committee (REC)
approval obtained (IRAS: 219332, REC: 17/SW/0142, EDGE: 4002). –
https://www.hra.nhs.uk/planning-and-improving-research/
application-summaries/research-summaries/
Disclosure: Funded by North Bristol Hospital Trust Research
Capability Funding
Corresponding author: Lyn Jones
81. Patterns in haemoglobin levels over 10 years to predict
diagnosis of colorectal cancer by Duke’s staging: preliminary
ﬁndings using UK primary care routine blood test data
Pradeep S. Virdee1, Tim Holt2, Julietta Patnick3, Jacqueline Birks1
1Centre for Statistics in Medicine, University of Oxford, 2Nufﬁeld
Department of Primary Care Health Sciences, University of Oxford,
3Nufﬁeld Department of Population Health, University of Oxford
Background: Stage at diagnosis of colorectal cancer inﬂuences 5-
year survival: 94% at the earliest stage, but 7% at the latest.
Tumour growth causes subtle changes in levels of blood
components, such as haemoglobin, which may go unnoticed.
Such changes have not been explored. We report patterns in
haemoglobin levels up to 10 years before a diagnosis of colorectal
cancer, by Duke’s tumour staging.
Method: This retropspective study used data from the Clinical
Practice Research Datalink linked to the UK Cancer Registry.
Patients with a colorectal cancer diagnosis or no diagnosis of any
cancer, and at least one blood test result were included. The yearly
rate of change in haemoglobin levels was calculated from
longitudinal patient blood test data.
Results: 798 of the 68,301 patients included had a diagnosis of
colorectal cancer: 76 at stage A, 180 at B, 193 at C, 57 at D, and 292
with missing staging. Median age at diagnosis was 73.1 years and
52.8% were males. On average, the rate of decline in haemaglobin
levels was higher from 3 years before diagnosis compared to
earlier, but remained constant among those not diagnosed. At
stage A, average haemoglobin levels declined at a rate of 1.10g/dL
from 1 year before diagnosis, but by 1.31g/dL at stage D, observed
from 2 to 1 year before diagnosis. A decline in average
haemoglobin levels commenced 1 year before diagnosis of stage
A tumours, but at 3 years of stage D tumours.
Results from age- and gender-stratiﬁed analyses will be
presented.
Conclusion: Compared to those without cancer, those with
colorectal cancer had an increased rate of decline, detected
earlier in those with Dukes D. Subtle decreases in haemoglobin
levels over time may identify colorectal cancer in the early stages.
Patterns in other blood components, such as platelets, will be
explored.
Disclosure: Funded by NIHR Oxford Biomedical Research Centre
Corresponding author: Pradeep S. Virdee
82. Radiology review of MRI screening used to detect rSCC
(radiological spinal cord/compression) in a randomised trial of
asymptomatic castrate resistant prostate cancer patients with
spinal metastasis
Aslam Sohaib1, Keeley Tomkinson2, Philip Rich3, Graeme Houston4,
Clare Cruickshank2, Clare Grifﬁn2, Shama Hassan2, Laura Wiley2,
Stephanie Gibbs5, Ann Henry6, Gail Horan7, Heather Payne8, Ian
Pedley9, Narayanan Nair Srihari10, Emma Hall2, David Dearnaley1
1Royal Marsden Hospital, 2Institute of Cancer Research, 3St Georges
Hospital London, 4University of Dundee, 5Queen's Hospital Romford,
6Leeds Teaching Hospital, 7Addenbrooke's Hospital, 8University
College Hospital, 9Newcastle Hospital, 10Royal Shrewsbury Hospital
Background: PROMPTS (CRUK/11/053) is a phase III randomised
controlled trial which investigates whether detection of radi-
ological spinal cord/canal compression (rSCC) by screening MRI of
the spine reduces the incidence of clinical spinal cord/canal
compromise or compression (cSCC) in asymptomatic castrate
resistant prostate cancer (CRPC) patients with spinal metastasis.
Method: 420 CRPC patients from 53 UK centres, recruited
between 21/01/2013 and 28/04/2017, were randomised to a
screening MRI (n = 210, experimental) or standard follow-up
(n = 210, control). All MRI scans were reported by a named
radiologist at the local centre and a sample were reviewed centrally
by a panel of radiology specialists to ensure consistency and
accuracy of rSCC detection. The modiﬁed Bilsky Spinal Cord
Compression Scale was used to assign the degree to which SCC
had occurred in each vertebra; a 7-point scale ranging from 0
‘metastatic bone disease without epidural impingement’ to 3 ‘spinal
cord compression, no CSF visible around the cord’, 9 was assigned if
no metastasis were present. Patients with screen-detected rSCC
(locally assessed Bilsky score 1a,1b,1c,2,3) were offered pre-emptive
treatment and 6-monthly follow-up MRI scans. Local and central
assessments of the screening scans were compared at the vertebra
level with a discrepancy of +/− 1 Bilsky score and +/− 1 vertebral
level deemed acceptable (pragmatic agreement).
Results: 2060 vertebrae were locally and centrally assessed; the
reviewed scans included both positive (rSCC identiﬁed) and
negative (no rSCC identiﬁed) scans. On central review, the median
number of vertebra with metastatses per spine was 1 (range 0-10)
and the most common classiﬁcation of rSCC was Bilsky grade 1a.
Pragmatic agreement was 98.8%. Complete agreement was 92.4%.
Conclusion: The high level of agreement seen suggests that the
Bilsky scoring system is robust and reproducible in assessing the
presence and degree of rSCC in patients with CRPC.
Disclosure: Funded by Cancer Research UK
Corresponding author: Aslam Sohaib
83. Metabolic Pathways and Cell Proliferation in the
Advancing Front of Oropharyngeal Squamous Cell Carcinoma
Khaled Ben Salah1, Asterios Triantafyllou2, Andrew Schache1, Richard
Shaw1, Janet Risk1
1Department of Molecular & Clinical Cancer Medicine, University of
Liverpool, UK, 2Department pf Pathology, Liverpool Clinical Labora-
tories and School of Dentistry, University of Liverpool, Liverpool, UK
Background: Events related to progression of tumours are
centred on their advancing front. Metabolism likely inﬂuences
cell proliferation and a three compartment metabolic model in
head and neck cancer has been proposed. Little attention,
however, has been paid to the relationship between metabolism
and proliferation in oropharyngeal squamous cell carcinoma
(OPSCC). We investigated these properties at the advancing front
of OPSCC in relation to HPV status.
Method: Tissue microarrays were constructed from 45 HPV(+) and
63 HPV(-) OPSCCs and examined by IHC for mitochondrial
(TOMM20), metabolic pathways (monocarboxylate transporter 1/
4; MCT1/4) and cell proliferation (Ki67) markers. Immunoreactivity
was recorded at the tumour advancing front and in adjacent
stroma.
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Results: Cytoplasmic, granular TOMM20 and nuclear Ki67 were
highly expressed at the advancing front of OPSCCs, independent
of HPV status. Co-expression of membranous MCT1 and MCT4 at
the advancing front was observed in 84% and 30% of the HPV(+)
and HPV(-) tumours, respectively (p=0.001). While all HPV(+)
tumours showed MCT4(+) stromal spindled cells, regarded as
myoﬁbroblasts or cancer-associated ﬁbroblasts, adjacent to the
advancing front, only 70% of the HPV(-) tumours did so (p=0.002).
Conclusion: Tumour cells at the advancing front of both HPV(+)
and HPV(-) OPSCC are rich in mitochondria, show similar
proliferative activity, and consume mitochondrial fuel (lactate),
imported via MCT1 expression. The different frequencies of co-
expression of MCT1 and MCT4 in HPV(+) and HPV(-) OPSCC
indicate that the three compartment model is more compatible
with data from HPV(-) OPSCC. The metabolism of the stromal
component differs between HPV(+) and HPV(-) tumours, but these
differences are not reﬂected in the proliferative activity of the
tumour cells in the advancing front. We conclude that tumour
metabolism in OPSCC may be related to HPV status, but is
complex and requires further examination.
Disclosure: Funded by University of Liverpool
Corresponding author: Khaled Ben Salah
84. Attitudes towards faecal immunochemical testing in
patients at increased risk of colorectal cancer in primary care:
a survey of English General Practitioners
Christian von Wagner1, Sandro Stoffel1, Helga Laszlo1, Brian
Nicholson2, Jessica Sheringham1, Dorothy Szinay1, Yasemin Hirst1
1University College London, 2Nufﬁeld Department of Primary Care
Background: There is increasing interest in using quantitative
Faecal Immunochemical Test (FIT) to rule-out colorectal cancer
(CRC) among patients with high-risk symptoms in primary care.
The study aimed to investigate general practitioners’ (GP)
attitudes and willingness to use FIT over urgent two-week wait
(2WW) referral.
Method: As part of the UCLH Cancer Collaborative ('Q-Fit pilot
research study'), we conducted a cross-sectional online survey
with 1024GPs based in England. Data were analyzed using Logistic
regression models were used to explore their likelihood of using
FIT instead of 2WW, and reported using odds ratios and
conﬁdence intervals.
Results: Just over a third of GPs (n=365) preferred to use FIT as a
rule-out test over 2WW. GPs were more willing if they were aged
36-45 (1.59 [1.04-2.43]) and 46-55 (1.99 [1.14-3.47]), thought FIT
was highly accurate (1.63 [1.16-2.29]), thought patients will
beneﬁt compared to a colonoscopy (2.02 [1.46-2.79]) and
were highly conﬁdent in discussing the beneﬁts of FIT
(2.14 [1.46-3.16]). GPs were less willing if they had had more
than 10 urgent referrals in the last year (0.62 [0.40 - 0.94])
and thought that longer consultations will be needed
(0.61 [0.44 - 0.83]).
Conclusion: Our ﬁndings suggest that the acceptability of FIT as a
rule-out test in primary care is currently low with less than half of
GPs who perceived FIT to be accurate preferring it over
colonoscopy. Any potential guideline changes recommending
FIT in high-risk patients instead of urgent referral to rule-out CRC
are likely to require intensive supporting educational outreach to
increase GP conﬁdence in the accuracy and application of FIT in
this context.
Disclosure: Funded by NHS Cancer Vanguard Programme and
delivered by UCLH Cancer Collaborative
Corresponding author: Christian von Wagner
85. Characterising the metabolic fate of (2S, 4R)-4[19F]-
ﬂuoroglutamine in cancer cells using 19F-MRS
Nhat Nguyen, Andreas Doepner, Graham Smith, Yuen-Li Chung
The Institute of Cancer Research
Background: The (2S, 4R)-4-[18F]-ﬂuoroglutamine (“[18F]-
ﬂuoroglutamine”) Positron Emission Tomography (PET) radio-
tracer is potentially useful for imaging glutamine metabolism in
cancer cells. A ﬁrst in man clinical trial of [18F]-Fluoroglutamine
has been completed in adult glioma patients and imaging was
shown to differentiate between stable and progressive disease.
Despite these promising results, further metabolic characterisa-
tion of this probe is required to fully understand the metabolic
fate of [18F]-ﬂuoroglutamine in cancer cells. The aim of this study
is to evaluate the metabolic pathways of the [18F]-Fluorogluta-
mine PET tracer by using [19F]-Magnetic Resonance Spectro-
scopy (MRS).
Method: The metabolic pathways of the [18F]-Fluoroglutamine
PET tracer were evaluated by using the stable isotope version of
this radiotracer in [19F]-MRS. [1H]-MRS study was also performed as
a comparison method to conﬁrm the consistency of the
metabolism of [19F]-ﬂuoroglutamine with normal L-glutamine.
Colorectal cancer models (HCT116 WT and HCT116 Bax-ko) were
treated with glutaminase inhibitor CB-839 and alanine amino-
transferase inhibitor L-cycloserine in order to determine the
possible involvement of these enzymes in the metabolism of [19F]-
ﬂuoroglutamine.
Results: Following treatment with glutaminase inhibitor CB-839, a
signiﬁcant increase in cellular [19F]-ﬂuoroglutamine was found in
the treated group when compared with control (p<0.01). A
corresponding decrease in cellular [19F]-ﬂuoroglutamate was
observed following the CB-839 treatment (p<0.01). Following
treatment with alanine aminotransferase inhibitor L-cycloserine,
the cellular [19F]-ﬂuoroglutamate increased signiﬁcantly (p<0.001).
A drop in free ﬂuoride secretion was seen following L-cycloserine
treatment (p<0.001). Similar changes in L-glutamine metabolism
were also observed by 1H-MRS following treatment with these
two inhibitors.
Conclusion: This study found that similar to L-glutamine, [19F]-
ﬂuoroglutamine can be hydrolysed by the glutaminase enzyme to
yield [19F]-ﬂuoroglutamate which can subsequently be metabo-
lised by the alanine aminotransferase enzyme to form α-
ketoglutarate, L-alanine and release free ﬂuoride. Therefore, this
study infers that the metabolism of the [18F]-Fluoroglutamine PET
tracer follows the same pathway as L-glutamine in cancer cells.
Disclosure: Funded by Cancer Research UK and The Institute of
Cancer Research
Corresponding author: Nhat Nguyen
86. A novel blood-based biomarker for OAC with the potential
for use as an early treatment response predictor
Rachel Lawrence1, Lucy Swithenbank2, Hasan Haboubi2, Lisa
Williams3, Sarah Gwynne3, Shareen Doak4, Gareth Jenkins2
1Swansea University Medical school, 2Swansea University medical
school, 3ABMU NHS Trust, 4Swnasea University medical school
Background: Oesophageal adenocarcinoma (OAC) is the 13th
most common cancer in the UK with 9 211 new cases diagnosed
annually. Due to the late stage in which OAC is commonly
diagnosed, treatment options are usually limited to chemo/
radiotherapy with limited success, meaning the 5-year survival
rate remains poor at 15%.
Here we describe a novel blood-based biomarker for OAC based
on the PIG-A mutation assay, which has the further potential of
predicting early treatment response. We hypothesise that cancer
patients will have a higher level of this circulating mutation
compared to controls. Furthermore, will patients undergoing
chemo/radio therapy who display an increase in mutation
frequency during their treatment respond better to such
therapies?
Method: Blood samples were obtained from consenting patients
attending endoscopy including patients with reﬂux disease,
Barrett’s metaplasia (BM) and newly diagnosed OAC. Multiple
blood samples were obtained from patients with OAC throughout
their treatment course. Ten microliters of whole blood was stained
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with antibodies against the erythrocyte marker CD235a and two
GPI-linked proteins (CD55 and CD59) and analysed using ﬂow
cytometry.
Results: With over 300 participants currently recruited to the
study including healthy volunteers, data shows that treatment
naïve OAC patients had a 3-fold increase in PIG-A mutant
frequency compared to reﬂux patients (p<0.001). Reﬂux (n=75),
Barrett’s (n=63) and treatment naïve cancer patients (n=38) had a
median PIG-A mutant frequency of 3.2 (95% CI: 1.51-5.43), 4.52
(95% CI: 2.53-6.09) and 9.75 (95% CI: 3.76-17.52) respectively.
OAC patients undergoing treatment (n=13) had intra-individual
variation of 1 to 8 fold increase in mutation frequency compared
to their pre-treatment levels, with mutant frequencies in the range
of 1.0-29.8 mutant RBC’s/million. Correlation with therapeutic
response is on-going.
Conclusion: The PIG-A mutation assay has potential as a less-
invasive biomarker for OAC as well as a treatment-response tool to
identify patients with limited response to current therapies.
Disclosure: Funded by Cancer Research Wales and Health and
Care Research Wales
Corresponding author: Rachel Lawrence
87. Image fusion targeted prostate biopsy in 771 men at risk:
a multi-centre evaluation showing low diagnostic yield of
signiﬁcant cancer in non-targeted biopsies
Saiful Miah1, Feargus Hoskings-Jervis2, David Eldred-Evans2, Taimur
Shah2, Mark Laniado3, Richard Hindley3, Alan Doherty3, Andrew
Sinclair3, Daniel Burke3, Jeetesh Bhardwa3, Omer Karim3, Bruce
Montgomery3, Simon Bott3, Neil Barber3, Raj Nigam3, Manit Arya4,
Mathias Winkler1, Clare Allen4, Hashim Ahmed2
1Imperial College NHS Healthcare, 2Imperial College London, 3Nuada
Urology London, 4University College London Hospital
Background: MRI image guided prostate biopsy is an increasingly
utilized method of procuring tissue from men with suspected
prostate cancer. We sought to report the largest prospective series
of image-fusion transperineal prostate biopsies and compare the
diagnostic yield of clinically-signiﬁcant prostate cancer (csPCa)
between targeted and non-targeted biopsies.
Method: 771 men had transperineal image-fusion targeted
biopsy (MIM-Symphony-DXTM) (April 2014-June 2017) by 13
urologists.
Results: Mean age, median PSA and median prostate volume
were 63.58 years, of 6.3ng/ml and 43.5cc respectively. Overall, 363
(47.08%) were diagnosed with csPCa (Gleason >/=4+3 or any
grade >/=6mm) from the 771 men undergoing biopsy. The csPCa
detection rate from the target biopsies alone occurred in 341 men
(44.23%). Of those 409 men who underwent random biopsies,
only 14 men (3.42%) were discovered to have csPCa exclusively in
the non-targeted cores alone where the targeted cores demon-
strated no evidence of disease. None of these men harboured
high-grade disease and 11 out of the 14 (78.57%) had primary
pattern 3 disease. The presence of clinically insigniﬁcant disease in
the random targets occurred in 66 of the 409 (16.12%) men
underdoing going this type of biopsy format. Insigniﬁcant cancer
exclusively occurred in non-targeted prostate cores in 16 out of
409 men who underwent these random biopsies (3.91%) where
there was no evidence of disease in the target cores.
Conclusion: In this large multi-centre series, the added beneﬁt of
non-targeted cores is low. An image-fusion targeted-biopsy only
has high detection for csPCa and reduced over-detection of
insigniﬁcant cancers.
Acknowledgement: A similar version of this abstract has been
published previously, see http://journals.sagepub.com/doi/
10.1177/2051415818773021 for original and CC-BY license.
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88. Investigation of transglutaminase 2 as a biomarker of
invasive breast cancer that is likely to metastasise
Fiona Blows1, Elena Provenzano2, Raza Ali3, Wei Cope4, Paul
Pharoah4, Claire Pike5, Peter Coussons5
1Anglia Ruskin University and University of Cambridge, 2Addenbroo-
ke's Hospital, 3University of Cambridge and University of Zurich,
4University of Cambridge, 5Anglia Ruskin University
Background: Breast cancer, a heterogeneous disease, may be
subtyped using immunohistochemistry (e.g. estrogen receptor
(ER) and human epidermal growth factor receptor 2 expression).
Differences in survival occur between apparently similar cases.
Thus, better resolution of the disease into clinically meaningful
subtypes is needed. Breast cancer lacks a biomarker for invasive
disease that will metastasise and the discovery of such a
biomarker would represent a signiﬁcant step forward. Transglu-
taminase 2 (TG2), a multifunctional protein implicated in cell-cell
adhesion, apoptosis and metastatsis, warrants investigation. Levels
have been reported to vary with tumour progression.
Method: We used tissue-micro-arrays (TMAs) to evaluate TG2
expression in the tumours of 1,942 patients for whom we have
associated data for survival time (72% alive; 28% dead), and
tumour grade and stage. 1,917 samples also have hormone status
data (79%, positive; 21%, negative). Hormone status was derived
from ER and progesterone receptor (PR) expression data
(designated ‘positive’ if either was positive, ‘negative’ if both
were negative and where only the status of ER or PR was available
this was assigned individually as the hormone status). TMAs were
scored manually, and tumours expressing TG2 in more than 10 per
cent of cells were categorised as ‘TG2 positive’.
Results: AlthoughTG2 was expressed in 37% of tumours it was not
associated with outcome in hormone receptor positive disease.
This was not the case in hormone receptor negative disease where
its expression was associated with decreased breast cancer
speciﬁc mortality (HR, 0.57; 95% CI, 0.37 − 0.89; p value, 0.012).
Conclusion: These results need conﬁrming in a larger study.
Nevertheless, the molecular basis of this ﬁnding if true would be
intriguing, given the established links between TG2 and tumour-
igenesis. TG2 might be a novel drug target. Furthermore, given the
prognostic effect-size, TG2 could prove a useful marker for
identifying patients most likely to beneﬁt from adjuvant
chemotherapy.
Disclosure: Funded by Cancer Research UK; Horizon 20/20
Corresponding author: Fiona Blows
89. Cholangiocarcinoma survival prediction using machine
learning algorithms
Mohamed Osman1
1Faculty of Medicine, Zagazig University, Egypt
Background: Cholangiocarcinoma is the most common malig-
nancy of biliary tract and the second most common primary
hepatic malignancy. The incidence and mortality of cholangio-
carcinoma are increasing worldwide. Predicting cholangiocarci-
noma survival is difﬁcult due to different primary sites, treatments
and undeﬁned risk factors. Reliable predictions can help in
personalizing care and good treatment and management. Here,
we test the ability of machine learning to predict survival of
cholangiocarcinoma.
Method: Patients with cholangiocarcinoma were identiﬁed
through the Surveillance, Epidemiology and End Results database
from 2010-2013. Patients’ data were extracted including: age, sex,
race, primary site, TNM stage, grade, size, extension, lymph nodes,
metastasis, cancer sequence number, surgery, radiotherapy,
chemotherapy, radiation sequence with surgery, state, county
and survival months. Data were randomly divided into; a training
set (80%) and a validation set (20%). Machine learning algorithms
were used to predict survival.
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Results: A total number of 1,095 patients were identiﬁed with a
median survival of 15 months. The most common primary tumor
sites were intrahepatic bile duct (52.6%), extrahepatic bile duct
(27.7%), and liver (16.3%). Random Forests algorithm achieved
better results compared to other tested models. For evaluating
model performance, the Area Under the Receiver Operating
Characteristic Curve (AUC) was calculated. Random Forests yielded
AUCs of 81.5% at 6 months, 87.1% at 12 months and 80.6% at 24
months. Sensitivity of the trained model were 83%, 80% and 76%
at 6, 12 and 24 months, respectively. The model achieved an
average accuracy of 82.6%, 80.4% and 75.8% at 6, 12 and
24 months, respectively. The most important characteristics which
inﬂuenced the model performance were: surgery, age, and tumor
size.
Conclusion: Supervised machine learning algorithms achieved a
good performance of predicting survival of patients with
cholangiocarcinoma. Improved performance in survival prediction
can help in making better treatment decisions and planning social
and care needs.
Disclosure: None declared
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90. Investigation of exosomal miRNA as biomarker for
prostate cancer castration resistance development
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ment of Urology, Barts Health NHS, London, UK, 3Department of
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Background: Prostate cancer (PCa) remains the most frequently
diagnosed cancer and the third-leading cause of oncological
mortality in western men. Androgen deprivation therapy (ADT)
has been the standard care for initial management of locally
advanced or metastatic PCa, however progression to castration-
resistant prostate cancer (CRPC) would inevitably occur. Studies
have shown that miRNAs play a role in CRPC and miRNAs in
plasma exosomes may serve as biomarkers in cancers.
Method: Whole miRNA sequencing was performed to identify
candidate exosomal miRNAs in a screening cohort of 24 treatment-
naive PCa patients and 24 CPRC patients. Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed to further
validate candidate miRNAs in a set of 108 treatment-naive PCa
patients and 42 CRPC patients. An additional group of 43 non-CRPC
patients under hormone therapy was also evaluated.
Results: In the screening cohort, miRNA sequencing generated an
average of approximately 5-million reads per sample and
identiﬁed differentially expressed miRNA. Six miRNAs were
selected for further validation by qRT-PCR, which conﬁrmed four
out of the six candidate miRNAs comparing treatment-naïve PCa
and CRPC plasma exosomes (p-value<0.05), while the expression
of one miRNA was too low to be detected by our qRT-PCR
methods. QRT-PCR results also showed that the expression of
these four miRNAs were differently expression in non-CRPC
treatment patients compared to CRPC patients (p-value<0.0001).
When a receiver operating characteristic curve (ROC) was applied
to distinguish CRPC from treated non-CRPC treatment patients,
the area under the ROC curve (AUC) of the four miRNAs were
0.895(95% CI: 0.824–0.966), 0.807(95% CI: 0.712–0.902), 0.818(95%
CI: 0.721–0.914) and 0.776(95% CI: 0.675–0.876), respectively.
When combining the four miRNAs using a binary logistic
regression model, the AUC achieved 0.945(95%CI: 0.893–0.998).
Conclusion: This study demonstrated that plasma exosomal
miRNAs may serve as biomarkers for prostate cancer castration
resistance development and clinically for CRPC occurrence
prediction.
Disclosure: Orchid, Chinese Scholarship Council
Corresponding author: Tianyu Guo
91. Role of staging bone scans in the patients with newly
diagnosed prostate cancer. Are the current guidelines
acceptable?
Mohanarangam Thangavelu1, Ahmed Kotb2, Chrysovalantis Gkekas2,
Mohamed Yehia3, Jason Walker1
1Ysbyty Gwynedd, 2Bangor Hospital, 3Wrexham Hospital,
Background: Most guidelines recommend bone scan to newly
diagnosed patients with prostate cancer presenting with high risk
criteria. The aim of our study is to investigate whether these
recommendations are practically acceptable without missing
signiﬁcant bone metastasis in various risk groups of prostate
cancer patients.
Method: Retrospective data collection, for all patients who had
PSA, physical examination of prostate(DRE), prostate biopsy
(Gleasons Group) and bone scan done, as a part of investigations
to patients with newly diagnosed prostate cancer. Data was
collected from a single Hospital for a period of 6 years.
Results: Total - 669 patients. 520 / 669 patients had all three
criteria PSA, DRE and Histology. 149 / 669 patients were excluded
because Histology was not available. 94 / 520 (18 %) had Positive
and 426 / 520 (82%) had Negative bone scan.. The mean age is 71
± 7.8 years. The range of PSA in the study is 4439 ng/ml. The NPV
of bone scan in patients with PSA ≤ 20,Gleason group ≤ 2 and DRE
(T1/T2) were 91.7%,90.8% and 88.2 % respectively. The PPV of
bone scan in patients with PSA > 20, GG ≥ 3 and DRE (T3/T4) were
29.2%,25.8% and 36.9 % respectively.
In PSA ≤ 20, 23 patients had positive BS. Out of 23 patients, 5
patients had Gleason Group ≤ 7 with DRE T1/T2. So 5/94 (5.3 %)
patients with bone metastasis could have been missed in the
absence of high risk criteria mentioned in the guidelines.
Conclusion: The current guidelines are fairly accurate. However
according to our study there is 5.3 % chance of having bone
metastasis in the newly diagnosed prostate cancer patients, who
lack signiﬁcant risk factors for bone metastasis.This should be
discussed with the patients.Large multi-centre studies are required
to review the risk criteria for bone metastasis in prostate cancer.
Disclosure: None declared
Corresponding author: Mohanarangam Thangavelu
92. Pre-diagnostic BMI and ovarian cancer survival in the
Million Women Study
Kezia Gaitskell1, Carol Hermon1, Sarah Floud1, Kirstin Pirie1, Isobel
Barnes1, Jane Green1, Gillian K Reeves1, Valerie Beral1
1University of Oxford
Background: It is known that higher body mass index (BMI) is
associated with increased risk of ovarian cancer, with some
heterogeneity by tumour histotype. Ovarian cancer survival may
also vary with pre-diagnostic BMI, but evidence is mixed, and
studies recording BMI retrospectively may not have accounted
fully for changes in weight preceding cancer diagnosis. We
explored the association between prospectively-recorded BMI and
ovarian cancer survival in a cohort of UK women.
Method: Study participants completed a questionnaire on
reproductive, anthropometric, and lifestyle factors, including
height and weight, at recruitment in 1996-2001, and were
followed for cancer and death via national registries. We used
Cox regression models to estimate adjusted relative risks (RRs) of
death attributed to ovarian cancer associated with BMI, overall
and by histotype.
Results: Among 9324 women diagnosed with ovarian cancer, 5352
had died with cause of death attributed to ovarian cancer after 4.4
years (SD 4.6) mean follow-up, with 43% 5-year survival. Average
time between recording of BMI and diagnosis of ovarian cancer was
8.77 years (SD 4.93). Deaths were rare for serous and mucinous
borderline tumours. Further analysis was restricted to the 4333
women with malignant ovarian cancer who had information on
stage at diagnosis. After adjustment for age at diagnosis, stage, and
tumour histotype, obese women (BMI 30+ kg/m2) had worse
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survival than women with normal BMI (<25 kg/m2) (HR = 1.11, 95%
CI: 1.00-1.24), but adjustment for reproductive, anthropometric and
lifestyle characteristics weakened the association (HR = 1.08, 0.97-
1.21, p = 0.18). There was no signiﬁcant variation by tumour
histological type: serous carcinoma RR = 1.04, 0.90-1.21; mucinous
carcinoma RR = 1.56, 0.86-2.84; endometrioid RR = 1.10, 0.66-1.81;
clear cell RR = 1.41, 0.81-2.45; other/ unspeciﬁed RR = 1.07, 0.88-
1.29 (heterogeneity: p = 0.2).
Conclusion: After adjustment for stage and other confounders,
there was no signiﬁcant association between pre-diagnostic BMI
and ovarian cancer survival, and this did not vary signiﬁcantly by
histotype.
Disclosure: Funded by Cancer Research UK, the Medical
Research Council, and the National Institute for Health Research.
Corresponding author: Kezia Gaitskell
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93. Communicating messages about alcohol-related BC risk:
the Alcohol and Breast Cancer (ABC) study
Emma Miller1, Paul Ward1, Ian Olver2, Samantha Meyer3, Darlene
McNaughton1, Lillian Mwanri1, Kristen Foley1, Sara Macdonald4
1Flinders University, 2University of South Australia, 3University of
Waterloo, 4University of Glasgow
Background: Breast cancer (BC) incidence in ‘middle-aged’
women (45-64 years) is increasing in industrialised countries,
despite ongoing warnings about modiﬁable risk factors such as
alcohol, the consumption levels of which have also increased in
middle-aged women. Alcohol use, entrenched in Australian
society, is directly linked to BC yet is seldom proposed as a causal
mechanism by women at risk.
We investigated the place of alcohol in the lives of South
Australian women at various levels of perceived risk for BC –
exploring the ways in which women think about BC in the context
of alcohol consumption as a socially-entrenched practice.
Method: In 2017, 122 women completed a brief online purposive
sampling survey. After cross-characterising responses according to
perceived cancer risk, level of alcohol consumption and education
level, 35 women were interviewed. The audio-recorded interviews
were transcribed, coded and thematically analysed.
Results: Socialising, relaxing and coping were the main purposes
of alcohol consumption in this group. Women with higher socio-
economic status (SES) tended to talk about alcohol as a
pleasurable social lubricant, while lower SES women tended to
talk about alcohol as a mechanism to cope and manage stress.
The principal marker of problematic alcohol use overall was
‘functionality’ in work, care-giving and social roles.
BC candidacy was determined by family history with BC
development generally seen as unpreventable and framed as
‘bad luck. Where a role for alcohol in BC was accepted, the risk was
weighed against the important social function of alcohol.
Conclusion: In this group, most aspects of alcohol use were
framed as social phenomena ﬁrmly outside of which context was
the concept of alcohol-related BC risk. Prevention activities will
need to respond to the social functions of alcohol, and
appropriately target their SES differences, if they are to enact
meaningful behaviour change to reduce BC risk.
Disclosure: Funded by Flinders Foundation
Corresponding author: Emma Miller
94. European Cancer Incidence is Signiﬁcantly Reduced in
Huntington’s Disease Patients – Unravelling it’s Protective
Mechanisms
Paul McNulty1, Raviram Ramesh1, Richard Pilcher1, Lesley Jones1, Alys
Hughes1, Daniel Farewell1, Timothy Stone1, Peter Holmes1, Renata
Neciunaite1
1Cardiff University
Background: Huntington's disease (HD) is a neurodegenerative
genetic disorder caused by the trinucleotide expansions of CAG
that results in the formation of elongated polyQtracts. It is
hypothesised that these polyQtracts accumulate intracellularly
causing cellular apoptosis prior to tumour-induced cell division.1
Thus, expanded polyQtracts may be a potential protective
mechanism against cancer. This theory is based on evidence
from studies in Denmark and Sweden who both report a reduction
of cancer incidence in HD patients. However, to date, no study has
explored the relationship between CAG length and cancer
incidence.2,3
Method: 6540 HD patients were identiﬁed using data from the
European Huntington’s Disease Registry. The age-standardised
incidence ratio (SIR) for speciﬁc types of cancer was calculated by
comparing risks to general population data from the WHO.4
Results: 173 of 6540 patients reported a previous history of
cancer. The overall SIR for all cancers was 0.26 (0.22-0.30). Each
individual type of cancer had a SIR below 1 with statistically
signiﬁcant conﬁdence limits. The average CAG repeat length in
cancer patients was 42.06 in comparison to non-cancer patients
(44.07). Non-cancer patients were also found to have an earlier
average age at HD diagnosis (45.71) in comparison to cancer
patients (57.97).
Conclusion: This cross-national study provides further evidence to
suggest a possible link between HD and a reduction of cancer
incidence.2,3
Individuals with early-onset HD have a lower cancer incidence
in comparison to late-onset HD patients as they experience its
protective effects much sooner. Non-cancer patients have longer
polyQtracts that protect against cancer by accumulating intracel-
lularly, restricting cellular proliferation and increasing apoptosis.
Furthermore, other polyQ diseases such as hereditary ataxia
showed a similar reduction in cancer incidence, albeit to a lesser
extent.5Further research is warranted to investigate these exact
mechanisms in the hope to establish the next break-through in
cancer research.
Disclosure: The European Huntington's Disease Network is
funded by the CHDI Foundation, Inc.: this project was EHDN
project 478, and this work was supported by the MRC (MR/
L010305/1).
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95. Mediterranean diet adherence and risk of pancreatic
cancer: a pooled analysis of two Dutch cohorts
Maya Schulpen1, Petra H. Peeters2, Piet A. van den Brandt1
1Maastricht University, 2University Medical Centre Utrecht
Background: Studies investigating the association of Mediterra-
nean diet (MD) adherence with pancreatic cancer risk are limited
and had inconsistent results. We examined the association
between MD adherence and pancreatic cancer incidence by
pooling individual subject data from two Dutch cohorts.
Method: The Netherlands Cohort Study (NLCS, 120852 subjects)
and the Dutch cohort of the European
Prospective Investigation into Cancer and Nutrition (EPIC-NL,
40011 subjects) were included in this pooled analysis. MD
adherence was assessed using alternate and modiﬁed Mediterra-
nean diet scores (aMED and mMED, respectively), including and
excluding alcohol. After median follow-ups of 20.3 (NLCS) and 19.2
(EPIC-NL) years, 449 cases of microscopically conﬁrmed pancreatic
cancer (MCPC) were included in study-speciﬁc multivariable Cox
proportional hazards models. Study-speciﬁc estimates were
pooled using a random-effects model.
Results: MD adherence was not signiﬁcantly associated with
MCPC risk in pooled and study-speciﬁc analyses, regardless of sex
and MD score. Pooled hazard ratios (95% conﬁdence interval) for
high (6-8) compared to low (0-3) values of mMED excluding
alcohol were 0.66 (0.40 – 1.10) in men and 0.94 (0.63 – 1.40) in
women. A two-point increment in mMED excluding alcohol was
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borderline signiﬁcantly associated with a reduced MCPC risk in
never smokers (p = 0.07), but not in ever smokers (pheterogene-
ity=0.03). Hazard ratios were consistent across strata of other
potential effect modiﬁers. Considering MD scores excluding
alcohol, mMED-containing models generally ﬁtted better than
aMED-containing models, particularly in men. Although associa-
tions somewhat differed when all pancreatic cancers were
considered instead of MCPC, the overall conclusion was similar.
Conclusion: MD adherence was not associated with pancreatic
cancer risk according to a pooled analysis of two Dutch cohorts.
Disclosure: Funded by Wereld Kanker Onderzoek Fonds Neder-
land (WCRF-NL); World Cancer Research Fund (WCRF); the Dutch
Ministry of Public Health, Welfare and Sports (VWS); the Dutch
Prevention Funds; the Dutch ZON (Zorg Onderzoek Nederland)
Corresponding author: Maya Schulpen
96. A cluster randomised feasibility study of an adolescent
incentive intervention to increase uptake of HPV vaccination
Alice Forster1, Victoria Cornelius2, Lauren Rockliffe1, Laura Marlow1,
Helen Bedford1, Jo Waller1
1University College London, 2Imperial College London
Background: In England, uptake of the human papillomavirus
(HPV) vaccine for the prevention of HPV-related cancers is
suboptimal among girls from ethnic minority backgrounds and
in some regions, particularly London. As part of the school-based
HPV immunisation programme, a consent form with parental
signature has to be returned regardless of whether consent for
vaccination is given or withheld. Lack of a signed consent form is
the main reason for adolescent girls not receiving the vaccine in
the UK. We aimed to determine the feasibility of undertaking a
cluster randomised controlled trial (RCT) of incentivising consent
form return to improve HPV vaccine uptake.
Method: An equal-allocation, two-arm cluster RCT design was
used. We invited 60 London schools to participate. Those agreeing
were randomised to either a standard invitation or incentive
intervention arm, in which Year 8 girls had the chance to win a
£50 shopping voucher if they returned a vaccination consent
form, regardless of whether consent was provided. We collected
data on school and parent participation rates, questionnaire
response rates, consent form return and vaccine uptake. Analyses
were descriptive.
Results: Six schools completed the trial and only 3% of parents
opted out. The response rate was 70% for the girls’ questionnaire
and 17% for the parents’ questionnaire. In the intervention arm,
87% of girls returned a consent form compared to 67% in the
standard invitation arm. The proportion of girls whose parents
gave consent for vaccination was higher in the intervention arm
(76%) than the standard invitation arm (61%).
Conclusion: A RCT of an incentive intervention is feasible. This
incentive intervention has the potential to substantially improve
HPV vaccination uptake, which should reduce HPV-related cancer
incidence, with minimal work from immunisation providers, but a
fully-powered RCT is needed.
A version of this abstract has been published previously, see
https://doi.org/10.1038/bjc.2017.284 for original and CC-BY
licence.
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97. Beliefs about medication and uptake of preventive
therapy in women at increased risk of breast cancer: Results
from a multi-centre prospective study
Rachael Thorneloe1, Rob Horne2, Lucy Side3, Michael Wolf4, Samuel
Smith1
1Leeds Institute of Health Sciences, University of Leeds, 2Centre for
Behavioural Medicine, School of Pharmacy, University College
London, 3Wessex Clinical Genetics Service, University Hospitals
Southampton, 4Division of General Internal Medicine and Geriatrics,
Northwestern University
Background: The effectiveness of preventive therapy for breast
cancer depends on adequate uptake, but initiation rates remain
low. Little is known about factors inﬂuencing the decision to use
chemoprevention. We examined whether women at increased risk
of breast cancer can be categorised into groups with similar
medication beliefs and evaluated whether belief group member-
ship was associated with uptake.
Method: Women (n = 732) attending an appointment at one of
20 centres in England to discuss breast cancer risk were
approached; 55.7% (408/732) completed a survey containing the
Beliefs about Medicines Questionnaire (BMQ) and the Perceived
Sensitivity to Medicines (PSM) scale. Self-reported uptake of
tamoxifen at 3-month follow-up was reported in 258 (63.2%). The
optimal number of medication belief groups was identiﬁed using
Latent Proﬁle Analysis (LPA).
Results: Among baseline respondents (mean age = 45.3 years,
SD = 7.8), 59.6% were at moderately high risk of breast cancer
(17-30% lifetime risk) and 39.0% were at high risk of breast
cancer (≥30% lifetime risk). Uptake of tamoxifen was 14.7% (38/
258). The LPA model supported a 2-group model. Both groups
held weak beliefs about their perceived need for tamoxifen.
Group 2 (38% of the sample) reported stronger concerns about
tamoxifen and medicines in general, and stronger perceived
sensitivity to the negative effects of medicines compared
with Group 1 (62%). Women with low necessity and lower
concerns (Group 1) were more likely to initiate tamoxifen
(18.3%; 33) than those with low necessity and higher concerns
(Group 2) (6.4%; 5). After adjusting for demographic and clinical
factors, the OR was 3.37 (95% conﬁdence interval: 1.08 – 10.51,
p = .036).
Conclusion: Uptake of breast cancer preventive therapy was low.
An important sub-group of women reported low need for
preventive therapy and strong medication concerns. These
women were less likely to initiate tamoxifen. Medication beliefs
are modiﬁable targets to support informed treatment decision-
making.
Disclosure: SGS was supported by a Cancer Research UK
postdoctoral fellowship (C42785/A17965) during the collection
of these data. He also acknowledges funding support from a
Yorkshire Cancer Research University Academic Fellowship.
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98. A novel application of two-step Mendelian randomization:
applying the results of small feasibility studies of
interventions to infer causal effects on clinical endpoints
Meda R. Sandu1, Rhona Beynon1, Rebecca Richmond1, Diana L.
Santos Ferreira1, J Athene Lane1, Richard M. Martin1
1University of Bristol
Background: Feasibility trials are preliminary trials that assess the
viability and acceptability of intervention studies and the effects of
the intervention on intermediate endpoints. Due to their short
duration, they are unable to establish the effects of the
intervention on long-term clinical outcomes. We propose a novel
method that could transform the interpretation of feasibility trials
using modiﬁed two-stage randomization analyses.
Method: In this two-stage process, we explored the effects of a 6-
month feasibility factorial randomised controlled trial (RCT) of
lycopene and green tea dietary interventions (ProDiet) on
159 serum metabolic traits in 133 men with raised PSA levels
but prostate cancer (PCA) free. In the ﬁrst stage, we conducted an
intention-to-treat analysis, using linear regression to examine the
effects of the interventions on metabolic traits, compared to the
placebo group. In the second stage, we used a two-sample
Mendelian Randomization (MR) approach to assess the causal
effect of metabolic traits altered by the interventions, on PCA risk,
using summary statistics data from an international PCA
consortium of 44,825 cancer cases and 27,904 controls.
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Results: The systemic effects of lycopene and green tea
supplementation on serum metabolic proﬁle were comparable
to the effects of the respective dietary advice interventions
(R2 = 0.65 and 0.76 for lycopene and green tea respectively).
Metabolites which were altered in response to lycopene
supplementation were acetate (standard deviation difference
versus placebo (β)): 0.69; 95% CI = 0.24, 1.15; p = 0.003), valine
(β: -0.62; -1.03, -0.02; p=0.004), pyruvate (β: -0.56; -0.95, -0.16;
p = 0.006), and docosahexaenoic acid (β: -0.50; -085, -0.14;
p = 0.006). Using MR, a genetically instrumented SD increase in
pyruvate increased the odds of PCA by 1.29 (1.03, 1.62; p = 0.027).
Conclusion: Using a two-stage randomization analysis in a
feasibility RCT, we found that lycopene lowered levels of pyruvate,
which our Mendelian randomization analysis suggests may be
causally related to reduced PCA risk.
Disclosure: Funded by NIHR, Wellcome Trust, Cancer Research
UK
Corresponding author: Meda R. Sandu
99. Investigating causal relationships between sleep
characteristics and risk of breast cancer: a Mendelian
randomization study
Rebecca Richmond1, Emma Anderson1, Hassan Dashti2, Samuel
Jones3, Jacqueline Lane2, Caroline Relton1, Marcus Munafò4, Debbie
Lawlor1, Martin Rutter5, Richa Saxena2, Mike Weedon3, Richard
Martin1, George Davey Smith1
1University of Bristol, 2Massachusetts General Hospital, Boston,
3University of Exeter, 4University of Bristol, UK, 5University of
Manchester
Background: Previous observational studies have identiﬁed
associations between sleep characteristics and breast cancer.
The carcinogenic effect of sleep patterns has also been
investigated among night shift workers, with inconsistent ﬁndings.
Here we conducted a Mendelian randomization (MR) analysis
using genetic variants robustly associated with chronotype
(morning/evening preference), insomnia and sleep duration to
investigate causal links with breast cancer.
Method: Observational associations between sleep characteristics
and breast cancer in UK Biobank (9,599 cases, 170,616 controls)
were ﬁrst assessed using logistic regression with adjustment for
age, assessment centre, ancestry and several socio-economic,
lifestyle and reproductive factors. For the MR analysis, breast
cancer status was regressed against predicted values of sleep
characteristics based on genotype in a logistic regression model,
with adjustment for age, assessment centre, ancestry and
genotyping chip. Two-sample MR was also conducted using
summary data from a large genome-wide association study of
breast cancer (122,977 cases, 105,974 controls) conducted by the
Breast Cancer Association Consortium (BCAC).
Results: In observational analysis, morning preference was
inversely associated with breast cancer risk (OR:0.89; 95%CI:0.85,
0.93), insomnia was positively associated (OR:1.21;1.14,1.29) and
there was little evidence for an association with sleep duration
(OR:1.01;0.99,1.03). Using 351 genetic variants associated with
chronotype, 57 with insomnia and 91 with sleep duration, in one-
sample MR analysis there was some evidence for a causal effect of
morning preference (OR 0.77;0.56,1.05) and weaker evidence for
insomnia (OR:1.11;0.70,1.76) and sleep duration (OR:1.14;0.91,1.43).
Findings for a protective effect of morning preference (OR
0.93;0.89,0.96) and adverse effect of sleep duration
(OR:1.20;1.01,1.41) were supported by two-sample MR using data
from BCAC, while there was limited evidence for insomnia
(OR:0.97;0.84,1.11).
Conclusion: Consistent ﬁndings for a protective effect of morning
preference on breast cancer risk in both observational and
Mendelian randomization analysis support hypotheses around
carcinogenic light-at-night, while evidence for a causal effect of
sleep disruption is more limited.
Disclosure: Funded by Cancer Research UK, Medical Research
Council
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100. Cancer, risk and decision making in vulnerable women:
An exploratory study
Sarah Hanson1, Duncan Gilbert2, Rebecca Landy3, Grace Okoli4,
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Background: Cancer is associated with socio-economic disadvan-
tage. Yet many interventions designed to reduce risk and improve
health fail to reach those with the greatest needs and the most
vulnerable. Disadvantaged women, including those who have
suffered domestic abuse or who are within the judicial system,
represent a group that is particularly poorly accessed in
prevention strategies and in research. Our study focused on such
disadvantaged women, at two women’s centres that provide
support and training.
Method: This qualitative study involved thirty participants (23
women and seven staff) in individual interviews and two focus
groups. It sought to understand perceptions of, and vulnerability
to, cancer; decision making (including screening); cancer symptom
awareness and views on health promotion within the context of
the women’s daily lives. Verbatim transcripts were analysed
thematically.
Results: Mental distress dominated our ﬁndings. Risk factors of
alcohol use, smoking, physical inactivity and unhealthy eating
were common but reported within the context of distressing
experiences of mental ill-heath, poverty, addition and abuse.
Walking, for example, was reported due to lost driving licences or
a symptom of anxiety; smoking was reported as part of other
additive behaviours such as alcohol abuse. Women’s views of
themselves such as self-worth were often negative, shaped by
experiences of neglect and abuse. Health-seeking behaviours such
as accessing screening services or being aware and presenting
with symptoms needed to be understood in the context of highly
complex and difﬁcult to navigate, and sometimes even obstruc-
tive, health services.
Conclusion: Women in this study were at high risk of chronic
diseases, including cancer. Their experiences of social disadvan-
tage and lack of control profoundly shaped their practices,
aspirations and attitudes towards risk, health and healthcare. Our
ﬁndings will inform the design of a feasibility study to test a
cancer prevention strategy co-designed by and tailored to
vulnerable women.
Disclosure: Funded by Cancer Research UK
Corresponding author: Sarah Hanson
101. Investigating the effects of dietary and physical activity
interventions on the metabolome of men with prostate
cancer: The PrEvENT randomised controlled trial
Meda R. Sandu1, Diana L. Santos Ferreira1, Rebecca Richmond1, Lucy
Hackshaw-McGeagh1, Rhona Beynon1, Richard M. Martin1, J Athene
Lane1
1University of Bristol
Background: Lycopene, plant-based diets (PBD) and physical
activity (PA) have been previously associated with reduced risk
and slower progression of prostate cancer (PCA), however, the
potential mechanisms are not completely understood.
Method: We explored the effects of the PrEvENT randomised
controlled trial (RCT) with a 6-month dietary (lycopene supple-
mentation and PBD advice) and brisk walking(BW) intervention on
155 serum metabolites in 74 men with PCA who had undergone
prostatectomy, using linear regression and instrumental variable
(IV) analysis. One-stage-individual-participant meta-analysis was
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performed using a subset of data from ProDiet, an RCT of men
with raised PSA levels but PCA free who were randomised to
lycopene supplements (n=85). The causal effect of the metabolic
traits on PCA was assessed by Mendelian Randomization (MR) on
44,825 cancer cases and 27,904 controls in the PRACTICAL
consortium.
Results: The effects of lycopene supplementation and PBD advice
on the serum metabolic proﬁle were comparable (R2=.64). There
were no strong differences in metabolite levels in either the BW or
the dietary intervention. After adjustment for baseline metabo-
lites, there was evidence for decreases of triglycerides in
intermediate-density lipoproteins, large, medium and small low-
density lipoproteins and saturated fatty acids (p<0.00385) in the
BW arm. When accounting for the effect of the dietary
intervention on serum lycopene (IV analysis), pyruvate decreased,
and acetate increased (p-value<0.05). After pooled meta-analysis
with ProDiet, there was strong evidence (p-value<0.004) of
decreased pyruvate and alanine, and increased acetate levels, in
the lycopene arm. Using genetic instruments, the MR analysis
showed evidence for a causal effect of pyruvate on PCA (OR 1.29,
95%CI 1.03-1.62).
Conclusion: The interventions to increase lycopene, PBD and PA
altered the serum metabolome of men with PCA. BW improved
the cardiometabolic proﬁle; lycopene and PBD advice lowered
pyruvate, which is known to be involved in cancer mechanisms
and may be causally linked to PCA risk.
Disclosure: Funded by NIHR, Wellcome Trust, Cancer Research
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102. Genetic determinants underlying the variation in
response to cancer chemoprevention agents
Salwa Almayouf1, David B.H. Barton1, Yue Hu1, Edward J. Louis1,
Steven S. Foster1
1University of Leicester
Background: Cancer chemoprevention is the use of natural or
chemical agents to prevent or delay the development of cancer.
However, there is variation in response to chemopreventive
agents amongst individuals because it is a complex trait controlled
by multiple genes and environmental factors.
Here, we aimed to decipher the genetic factors controlling the
variation in response to aspirin, metformin, curcumin and
eicosapentaenoic acid using a yeast-based genetic screen before
translating ﬁndings to humans. This approach was feasible due to
the conservation of genes between these two organisms.
Method: A multiparent quantitative trait loci (QTL) mapping
approach was applied. A panel of 111 F12 meiotic segregants
generated from a cross of four S. cerevisiae wildtype isolates were
genotyped by whole genome sequencing. Segregants were
phenotyped using an automated pipeline which measured yeast
growth in different chemopreventive agent treatments. Subse-
quently, linkage-based ﬁne QTL mapping strategies were
performed to locate regions of the genome correlating to the
observed phenotype and the identiﬁcation of causative genes.
Results: Linkage analysis has mapped hundreds of genetic loci in
the yeast genome responsible for the variation in response to the
agents tested. Conserved homologues to human genes with DNA
damage repair, histone modiﬁcation and kinase functions were
identiﬁed. Some hits have been previously supported in the
literature such as the effect of aspirin and metformin on MTOR
thus validating this screening approach. Novel genes identiﬁed
revealed different pathways by which these agents may exhibit
their anti-cancer properties.
Conclusion: Detection of genetic variants inﬂuencing the
differences in drug response could help identify individuals at
risk or beneﬁt of using chemoprevention agents. Current work
includes validating the alleles of causative genes in human cells to
assess their biological relevance. This study could aid the
development of biomarkers for drug response and validate the
repurposing of drugs for prevention of cancer and cancer
recurrence.
Disclosure: Funded by Cancer Research UK and Minsitry of
Health Kuwait
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103. Effective chemoprevention strategies in APC driven
mouse models of intestinal tumourigenesis
Michael Hodder1, Patrizia Cammareri1, Dennis Timmerman1, Owen
Sansom1
1Beatson Institute for Cancer Research
Background: Truncation of the negative regulator of the Wnt
signalling pathway, Adenomatous Polyposis Coli (APC), represents
one of the earliest commonly occurring events in Colorectal
Cancer (CRC) progression. In addition, a number of factors
substantially increase the risk of developing CRC, including
inherited mutations in APC, such as Familial Adenomatous
Polyposis (FAP). Here we exploit vulnerabilities in APC mutant
stem cells and use chemo-preventative strategies to inﬂuence
tumour initiation in the mouse intestinal epithelium.
Method: Using in vivo mouse models we mutate APC speciﬁcally
in the Lgr5+ve stem cell population of the intestine. We
subsequently challenge these models with short term therapeutic
strategies to inﬂuence early lesions, and assess the ability of
chemotherapy to inﬂuence mutant clone establishment, as well as
tumour formation and overall survival.
Results: We demonstrate that APC deﬁcient intestinal stem cells
are more sensitive to chemotherapy when compared with wild
type stem cells. In addition, we establish that short term
therapeutic interventions, including those which cause DNA
damage and those which speciﬁcally target apoptotic machinery,
are able to inﬂuence tumour initiation, extend survival and reduce
tumour numbers in mouse models. Furthermore, we identify that
timing is crucial for therapeutic efﬁcacy, as treatment of
established tumours has no signiﬁcant impact on tumour
progression.
Conclusion: Overall we provide evidence that chemoprevention is
a tenable approach to combat CRC, and could be of signiﬁcant
beneﬁt to high risk patients, such as those with FAP. Similar to our
mouse models, chemoprevention could offer more tangible
patient beneﬁt than treatment of established tumours. This work
highlights that early lesions are exquisitely sensitive to a variety of
therapies and that mutant clones can be eliminated and readily
replaced with healthy stem cells prior to tumour formation.
Disclosure: Funded by Cancer Research UK and Medical
Research Council
Corresponding author: Michael Hodder
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104. Real-world evidence of the effectiveness of adjuvant
chemotherapy for early stage breast cancer from Scottish
routine data
Ewan Gray1, Joachim Marti2, David Brewster1, Jeremy Wyatt3, Peter
Hall1
1University of Edinburgh, 2University of Lausanne, 3University of
Southampton
Background: Real world evidence (RWE) has been proposed as a
means to address the ‘efﬁcacy-effectiveness gap’ in evidence-
based oncology. A major barrier to use of RWE is the perceived
lack of internal validity arising from the increased potential for bias
compared to evidence generated from randomised trials. This
study tested the internal validity of RWE methods applied to
estimating to effectiveness of adjuvant chemotherapy for early
breast cancer.
Method: Data were obtained from the Scottish cancer registry. All
cases of primary breast cancer from 2001 to 2015 were extracted
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for analysis. Follow-up of vital status until April 2016 was provided
by linkage of death records to the cancer registry. Cases meeting
the eligibility criteria for adjuvant chemotherapy trials were
selected based on age, co-morbidity and prognostic factors.
Hazard ratios (HRs) estimating the effectiveness of chemotherapy
for preventing breast cancer speciﬁc and all-cause mortality, in
this trial-eligible group, were calculated using Cox regression on a
propensity score matched sample. The HRs were compared with
estimates from a published individual patient data meta-analysis
of all adjuvant therapy randomised trials.
Results: 13,560 trial eligible cases were selected from 56,565
individual records. The primary estimate of the HR for adjuvant
chemotherapy for breast cancer speciﬁc mortality was 0.679 (95%
CI: 0.678, 0.681). In comparison, the meta-analysis reported a HR of
0.64 (95%CI: 0.585, 0.700) for the chemotherapy regimens most
commonly used in Scotland during this period. The HR varied
between trial-ineligible subgroups.
Conclusion: The RWE and meta-analysis of randomised trials
provide results that are consistent within an acceptable degree of
precision. This suggests RWE estimates of effectiveness have
internal validity in the adjuvant therapy setting for early breast
cancer. Future studies should consider RWE methods in this
setting to address speciﬁc gaps in the evidence base provided by
clinical trials
Acknowledgement: A version of this abstract has been published
previously, see http://abstracts.asco.org/214/AbstView_214_226519.
html for original and CC-BY license.
Disclosure: Funded by Chief Scientist Ofﬁce
Corresponding author: Peter Hall
105. Radiotherapy (RT) to the primary tumour for men with
newly-diagnosed metastatic prostate cancer (PCa): Survival
results from STAMPEDE (NCT00268476)
Christopher C Parker1, Nicholas D James2, Chris Brawley3, Noel W
Clarke4, Gerhardt Attard5, Simon Chowdhury6, Bill Cross7, Clare
Gilson3, Robert J Jones8, Robin Millman9, David P Dearnaley10,
Malcolm D Mason11, Alastair Ritchie9, J Martin Russell12, Syed Adnan
Ali13, Chinnamani Eswar14, Joanna Gale15, Alex Hoyle13, Jason
Lester16, Denise Sheehan17, Anna Tran13, Silke Gillessen18, Claire
Amos3, Mahesh KB Parmar3, Matthew R Sydes3 on behalf of The
STAMPEDE investigators working group
1Institute of Cancer Research, Sutton; Royal Marsden Hospital,
Sutton, 2Institute of Cancer and Genomic Sciences, University of
Birmingham, Edgbaston, Birmingham, 3Medical Research Council
Clinical Trials Unit at University College London, 4Christie and Royal
Salford Hospital, Manchester, 5University College London Cancer
Institute, 6Guy's and St Thomas' NHS Foundation Trust, 7St James
University Hospital, 8Institute of Cancer Sciences, University of
Glasgow, Glasgow; Beatson West of Scotland Cancer Centre,
University of Glasgow, Glasgow, 9c/o Medical Research Council
Clinical Trials Unit at University College London, 10Institute of Cancer
Research, Sutton, 11University of Cardiff, 12Institute of Cancer
Sciences, Beatson West of Scotland Cancer Centre, University of
Glasgow, UK, 13Christie Hospital, 14Royal Liverpool University
Hospital, 15Queen Alexandra Hospital, 16Weston Park Hospital,
17Royal Devon and Exeter NHS Foundation Trust, 18Division of
Oncology and Hematology, Kantonsspital St. Gallen
Background: Primary tumours in men with metastatic PCa could
contribute to overall disease progression and shorter survival. To test
this hypothesis, we evaluated whether RT to the prostate improves
overall survival in men presenting with metastatic PCa.
Method: STAMPEDE is a multi-arm multi-stage platform protocol
which included a randomised phase III comparison to test the
above hypothesis. Standard-of-care (SOC) was lifelong ADT, with
6*3-weekly docetaxel permitted from 2016. Stratiﬁed randomisa-
tion allocated pts 1:1 to SOC or SOC+RT. Pts allocated to RT
received daily (55Gy/20f over 4 weeks) or weekly (36Gy/6f over
6 weeks) RT according to investigators’ pre-speciﬁed (before
randomisation) choice. Randomisation was ≤12 weeks on ADT; RT
started ≤8 weeks after randomisation or docetaxel. The primary
outcome measure (OM) was death from any cause; secondary
efﬁcacy OMs included failure-free survival (FFS) & symptomatic
local event-free survival (SLEFS). Comparison to control for survival
had 90% power at 2.5% 1-sided alpha for hazard ratio (HR) of 0.75,
requiring ~267 control arm deaths, accounting for 3 intermediate
lack-of-beneﬁt analyses on FFS. Analyses used Cox proportional
hazards & ﬂexible parametric models, adjusted for stratiﬁcation
factors. Subgroup analyses will show effects by disease volume at
entry and planned RT schedule.
Results: 2061 pts from UK & Switzerland with newly-diagnosed
M1 PCa were contemporaneously randomised to the 2 arms
(Jan2013 – Sep2016). Randomised groups were well balanced:
median age 68yrs; median PSA 97ng/ml; 18% early docetaxel; pre-
speciﬁed RT schedule: 52% daily, 48% weekly; volume 39% low,
54% high, 8% pending/NK.
Conclusion: The pending results from this large randomised
comparison will deﬁne the role of RT to the primary tumour in
men with newly-diagnosed M1 PCa.
(CTU follows a controlled access approach for data sharing. The
data are available after independent review to bona ﬁde
researchers following a formal application. They are not freely
available because we have sensitive personal information. A data
release request can be initiated by submitting an email to mrcctu.
stampede@ucl.ac.uk or the CTU Enquiries address.)
Disclosure: Funded by Cancer Research UK -- dedicated grant;
Medical Research Council -- core trials unit funding; Contribution
to the platform protocol from Astellas, Clovis, Janssen, Pﬁzer and
Sanoﬁ-Aventis.
Corresponding author: Christopher C Parker
106. A Phase I dose-ﬁnding and safety study of AZD8931 with
Oxaliplatin and Capecitabine chemotherapy in patients with
Oesophago-gastric adenocarcinoma: the randomised
expansion phase of the DEBIOC trial
Anne Thomas1, Pradeep S. Virdee2, Martin Eatock3, Simon Lord4,
Stephen Falk5, D. Alan Anthoney6, Richard Turkington7, Matthew
Goff8, Leena Elhussein2, Linda Collins8, Joanna Moschandreas2, Mark
Middleton4
1University of Leicester, 2Centre for Statistics in Medicine, University of
Oxford, 3Belfast City Hospital, 4University of Oxford, 5Bristol
Haematology & Oncology Centre, 6St. James University Hospital,
7Centre for Cancer Research and Cell Biology, Queens University
Belfast, 8Oncology Clinical Trials Ofﬁce, University of Oxford
Background: AZD8931 is a novel small-molecule inhibitor with
equipotent activity against EGFR, erbB2 (HER2), and
erbB3 signalling. The recommended Phase 2 dose (RP2D) of
AZD8931 with Oxaliplatin and Capecitabine (XELOX), determined
in the DEBIOC escalation phase, is 20mg twice-daily, 4 days on,
3 days off, in a 3-week cycle. The dose expansion phase aims to
give a preliminary efﬁcacy assessment and further investigate the
safety and tolerability of AZD8931+XELOX.
Method: Following written informed consent, thirty patients with
operable oesophago-gastric adenocarcinoma (OGC) were rando-
mised 2:1 to receive XELOX with AZD8931 (n = 20) at the RP2D or
XELOX only (n = 10) for two 3-week cycles, with radical
oesophago-gastric surgical resection 4-6 weeks later. Patients on
neo-adjuvant AZD8931 could have maintenance AZD8931 6-12
weeks after complete (R0) or margin positive (R1) resection.
Expansion phase outcomes analysed by intention-to-treat
included 6-month progression-free survival (PFS), R0 rate, and
overall survival.
Results: The median age was 64 (range 25-78) years and the
median follow-up 26.8 (range 4.5-32.5) months. Six-month PFS
was 85% (90% CI 66%-94%) in the AZD8931+XELOX and 100% in
the XELOX-only group. R0 rate was 45% in the AZD8931+XELOX
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and 90% in the XELOX-only group (p=0.024). Seven disease-
related deaths (35%) occurred in the AZD8931+XELOX group, one
(10%) in the XELOX-only group.
In the neo-adjuvant period, 10% of AZD8931+XELOX and 50%
of XELOX-only patients had ≥1 grade 3-4 adverse events (AE).
Thirteen serious AEs (SAEs; 7 AZD8931+XELOX, 6 XELOX-only)
were reported. Two SUSARs were reported: thoracotomy wound
dehiscence (AZD8931+XELOX) and hypophosphataemia (XELOX-
only). During maintenance, two patients (18%) had a grade 3 AE;
there was one non-treatment related SAE.
Conclusion: AZD8931+XELOX has an acceptable safety proﬁle but
no early signal of superior activity compared to standard
treatment in operable OGC patients was demonstrated.
Clinical Trials Registry: 12/SC/0090- http://www.isrctn.com/
search?q=12%2FSC%2F0090
Disclosure: University of Oxford served as sponsor and
AstraZeneca and CRUK (an ECMC/AstraZeneca alliance trial)
funded the work.
Corresponding author: Leena Elhussein
107. SCALOP-2: A randomised trial of induction GEMABX
followed by chemoradiation (high/standard dose radiation)
+/-nelﬁnavir for locally advanced pancreatic cancer: results of
the dose-ﬁnding component
Somnath Mukherjee1, Pradeep S. Virdee2, Rachel Shaw3, John
Bridgewater4, Ganesh Radhakrishna5, Stephen Falk6, Martin Scott-
Brown7, Victoria Y. Strauss2, Claire Brookes3, Roopinder Gillmore8,
Neel Patel9, Bethan Tranter10, Phil Parsons11, David Sebag-
Monteﬁore12, Maria Hawkins1, Pippa Corrie13, Tim Maughan1
1Department of Oncology, University of Oxford, Oxford, UK, 2Centre
for Statistics in Medicine, University of Oxford, Oxford, UK, 3Oncology
Clinical Trials Ofﬁce, University of Oxford, Oxford, UK, 4Department of
Oncology, University College London Hospitals, London, UK,
5Oncology Department, The Christie NHS Foundation Trust, Man-
chester, UK, 6Bristol Haematology and Cancer Centre, Bristol
University Hospitals NHS Foundation Trust, Bristol, UK, 7Arden Cancer
Centre, University Hospitals Coventry & Warwickshire, Coventry, UK,
8Academic Oncology, Royal Free Hospital NHS Foundation Trust,
London, UK, 9Department of Radiology, Churchill Hospital, Oxford,
UK, 10Pharmacy Department, Velindre Cancer Centre, Velindre NHS
Trust, Cardiff, UK, 11Cardiff NCRI RTTQA group, Department of
Medical Physics, Velindre Cancer Centre, Cardiff, UK, 12University of
Leeds, Leeds Cancer Centre, St James's University Hospital, Leeds UK,
13Oncology Centre, Addenbrooke's Hospital, Cambridge, UK
Background: The anti-retroviral agent, nelﬁnavir, demonstrates
radiosensitising effects in pre-clinical models of pancreatic cancer.
The primary objective of Stage 1 was to establish the maximum
tolerated dose (MTD) of nelﬁnavir combined with capecitabine-
chemoradiation (CRT) after gemcitabine+nab-paclitaxel (GEMABX)
induction chemotherapy. Other outcomes included overall
survival and progression-free survival.
Method: Patients with inoperable, histologically/cytologically
proven locally advanced pancreatic cancer (LAPC) and WHO
performance status 0-1 were eligible for this rolling-six dose-
escalation stage. After 3 cycles of induction GEMABX (28-day cycle
of nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days
1, 8, and 15), patients with non-progressive disease had 1 further
cycle followed by CRT (50.4Gy/28 fractions, capecitabine 830mg/
m2 bd on radiotherapy days) and 1000mg or 1250mg nelﬁnavir bd
continuously during CRT.
Results: 27 patients were recruited from 8 UK centres (March
2016-June 2017). Median age was 62 years, 30% were male, 78%
had head tumours, and 30% had biliary stents. Baseline median
tumour diameter was 36mm.
67% commenced CRT. 11 patients received 1000mg and there
was one dose-limiting toxicity (DLT) in this group: grade 3 acute
coronary syndrome. The nelﬁnavir dose was escalated as per the
rolling-six design. 7 patients received 1250mg nelﬁnavir and no
DLTs were observed.
During GEMABX, common grade ≥3 toxicities among partici-
pants were neutropenia (30%), fatigue (22%), and diarrhoea
(15%). During CRT, grade ≥3 toxicities included fatigue (6%)
and anorexia (6%). No grade 5 adverse events were reported in
Stage 1.
Survival analysis will be presented.
Conclusion: 1250mg nelﬁnavir was recommended for combining
with capecitabine-CRT in the ongoing randomised component of
the trial (Stage 2).
Disclosure: Funded by Cancer Research UK and Celgene Limited
Corresponding author: Pradeep S. Virdee
108. Molecular characterisation of lung adenocarcinoma using
a 22-gene panel: A United Kingdom tertiary cancer centre
experience
Kam Zaki1, Doraid Alrifai1, Danny Ulahannan1, Tanya Ahmad1,
Dionysis Papadatos-Pastos1, Siow Ming Lee1, Charles Swanton1, Phil
Bennett2, Mary Falzon1, Elaine Borg1, Neal Navani1, Sam Janes1,
Martin Forster1
1University College London Hospitals NHS Foundations Trust, 2Sarah
Cannon Molecular Diagnostics
Background: Several licenced therapies targeting somatic driver
aberrations in lung adenocarcinoma have demonstrated superior
outcomes compared to chemotherapy. Incorporating molecular
panels into diagnostic services is imperative to identify targetable
driver events and improve patient access to these agents. The
Thoracic Oncology Unit at University College London Hospitals
(UCLH) utilised a 22-gene next generation sequencing (NGS) panel in
addition to other standardised diagnostic tools such as immunohis-
tochemistry (IHC) and ﬂuorescence in situ hybridisation (FISH).
Method: Between September 2014 to April 2016, 228 lung cancer
patient tumour samples were subjected to 22-gene panel
sequencing at UCL Advanced Diagnostics. Samples also under-
went IHC staining for ALK translocations, with equivocal IHC ALK
results conﬁrmed by FISH. Clinical data were collected from UCLH
electronic records system e-CareLogic (CDR).
Results: NGS results for 190 patients with lung adenocarcinoma
were available, of which 164 patients harboured somatic variants.
136 unique variants of 20 genes were identiﬁed. The most
common variants detected were TP53, EGFR and KRAS in 128
(67.3%), 43 (22.6%) and 32 (16.8%) patients respectively. MET
ampliﬁcations were detected in 2 patients. 24 unique EGFR
variants were detected of which 15 were known sensitising
variants. 39 patients harboured an EGFR sensitising variant,
including 24 metastatic patients.
Patients with sensitising EGFR variants who received ﬁrst line
EGFR TKIs (tyrosine kinase inhibitors) have a median overall
survival (OS) of 21 months compared to 6.5 months for those who
did not . ALK translocation was detected in 3 (1.7%) patients. The
two patients who received ALK TKI are still alive (OS 28 and
32 months respectively). 5 (2.6%) patients went on to participate
in targeted therapy clinical trials.
Conclusion: Deﬁning the genomic landscape of lung adenocarci-
noma personalises treatment options and improves patient
outcomes. Newly developed diagnostic platforms such as
circulating free DNA are under continuous evaluation and
incorporated into standard clinical practice.
Disclosure: None declared
Corresponding author: Kam Zaki
109. Optimising the use of platinum chemotherapies in
combination with the ATR inhibitor, AZD6738, in breast
cancer
Charlie Huins1, Sally Hall2, Christopher Ottley3, Gareth Veal2, Yvette
Drew2
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sity
Background: Platinum chemotherapy has an evolving role in the
treatment of BRCA mutant and triple negative breast cancers
(TNBC). Platinums (Pt) exert their cytotoxic effect by forming DNA
crosslinks (Pt-DNA adducts), which impair DNA function if left
unrepaired. AZD6738 is an oral inhibitor of ataxia telangiectasia
and rad-3-related (ATR) protein kinase, a key component of the
DNA damage response (DDR). ATR signals to prevent the onward
transmission of DNA damage at cell division. Whilst the rationale
for combining AZD6738 with Pt is one of potential enhanced
efﬁcacy, a greater understanding of the mechanism of AZD6738-
Pt interaction, particularly with regards to the formation and repair
of Pt-DNA adducts, may help guide the optimum dose and
scheduling in the clinic.
Method: The cytotoxicity of AZD6738 alone, and in combination
with cisplatin was assessed by clonogenic survival assay in three
human breast cell lines: MCF7 (BRCA1 heterozygous), HCC1806
(TNBC, BRCA wildtype) and T47D (BRCA wildtype). Pt-DNA adduct
formation in MCF7 cells treated with cisplatin and AZD6738 was
measured by inductively-coupled plasma mass spectrometry (ICP-
MS).
Results: Sensitivity to AZD6738 monotherapy varied: LC50s
ranged from 0.25µM +/- 0.07 in MCF7 to 0.64µM +/- 0.04 in
HCC1806. AZD6738 in combination with cisplatin was synergistic
in MCF7 and HCC1806 cells. Neither pre-exposure, co-exposure
nor post-exposure of AZD6738 in relation to cisplatin affected
total numbers or longevity of Pt-DNA adducts formation in MCF7
cells.
Conclusion: The synergistic action of AZD6738 with cisplatin in
non-pathogenic BRCA mutant cells supports their combination in
the clinic. However, more work is required to understand the
mechanism of interaction. To this end, this synergistic effect is
under investigation in additional cell lines. Investigation of
baseline expression of key DDR proteins as a determinant of
AZD6738 sensitivity is ongoing and will be presented.
Disclosure: Funded by Newcastle University
Corresponding author: Charlie Huins
110. Developing new paradigms for overcoming drug
resistance in cancer using novel humanised mouse models
Colin Henderson1, Yury Kapelyukh1, Kenneth MacLeod2, De Lin1,
Aileen McLaren1, Roland Wolf1
1University of Dundee, 2Concept Life Sciences
Background: Use of molecularly-targeted agents in cancer
treatment has signiﬁcantly improved patient survival, but is
severely constrained by toxicity and rapid onset of drug
resistance. This can be attributed in part to the high potency of
such drugs, which are used at doses (close to MTD), which can be
several orders of magnitude > IC50. A key question is whether
treatment regimens can be changed to retain efﬁcacy and reduce
the onset of drug resistance, greatly facilitating the development
of effective combination treatments. Such studies require new
animal models which more closely reﬂect human responses to
drugs.
Method: To address the limitations of mouse models in predicting
drug efﬁcacy in man, we developed transgenic mice nulled or
humanised for the key P450 enzymes involved in drug disposition
in man. We have characterised these models and carried out
pharmacokinetic and drug/drug interaction studies with targeted
anti-cancer drugs.
Results: Whereas murine Cyp2d enzymes metabolise the EGFR
inhibitor osimertinib, we have shown that CYP3A4 is the major
human enzyme involved, also uncovering a novel pathway of
disposition involving human CYP1A1. Preliminary data using our
8HUM model - where 32 mouse P450s are replaced with six
human enzymes accounting for >90% of P450-catalysed drug
metabolism in man - found in vivo PK of the BRAF inhibitor
dabrafenib to closely match that in patients, and that induction or
inhibition of CYP3A4, the major human P450 involved in
dabrafenib disposition, signiﬁcantly alters dabrafenib PK. We also
demonstrated that dabrafenib is a potent CYP3A4 inducer which
will markedly affect its own disposition and that of co-
medications.
Conclusion: We have validated a powerful new in vivo model
system for determining PK/PD relationships for novel drug
combinations and for the study of drug resistance. These models
have signiﬁcant potential in the personalisation of cancer
treatment using patient-derived xenografts.
Disclosure: Funded by Cancer Research UK, Medical Research
Council
Corresponding author: Colin Henderson
111. Results of CALIBER: A phase II randomised feasibility trial
of chemoablation with MMC versus surgical management in
low risk non-muscle invasive bladder cancer (NMIBC)
Hugh Mostaﬁd1, Joanne Cresswell2, Leyshon Grifﬁths3, John Kelly4,
Allen Knight5, James Catto6, Kim Davenport7, Andrew Feber8,
Margaret Knowles9, John McGrath10, Peter Cooke11, Shikohe
Masood12, Aicha Goubar13, Steven Penegar13, Nuria Porta13, Laura
Wiley13, Rebecca Lewis13, Emma Hall13
1Royal Surrey County Hospital NHS Foundation Trust, 2South Tees
Hospitals NHS Foundation Trust, 3University Hospitals of Leicester
NHS Trust, 4University College London Hospital, 5Patient Representa-
tive, 6University of Shefﬁeld, 7Gloucestershire Hospitals NHS Founda-
tion Trust,, 8University College London, 9Leeds Institute of Cancer and
Pathology, 10Royal Devon and Exeter NHS Foundation Trust, 11The
Royal Wolverhampton Hospitals NHS Trust, 12Medway NHS Trust,
13Institute of Cancer Research
Background: Mitomycin C (MMC) chemotherapy has a well-
deﬁned safety proﬁle and is used in the treatment of intermediate
and high risk NMIBC. CALIBER aimed to demonstrate that
intravesical MMC (chemoablation) had sufﬁcient activity to
warrant further investigation as an alternative to surgery for low
risk NMIBC.
Method: CALIBER has a Simon two-stage design, incorporating a
surgical control group to test feasibility of randomisation. Patients
with recurrent low risk NMIBC were randomised 2:1 to chemoa-
blation (4x 40mg weekly MMC) vs. surgery (standard of care). The
primary endpoint was complete response (CR) to chemoablation
by visual assessment and histological biopsy at 3 months post-
treatment, aiming at excluding CR rate <45% (Stage 1). Quality of
life (QoL) at 3, 6 and 12 months post-treatment was measured
using EORTC QLQ-C30 and QLQ-NMIBC24.
Results: 82 participants (54 chemoablation, 28 surgery) were
recruited from 37 UK centres (28/01/2015 to 04/09/2017).
Feasibility of randomisation was demonstrated with acceptance
rates of 55%. Stage 1 CR criterion was not met and the trial
closed to recruitment in September 2017. Estimated 3 month CR
rate is 37.0% (95% CI: 24.3, 51.3) in the chemoablation group
and 80.8% (95% CI: 60.6, 93.4) in the surgery group. No grade 3-4
toxicities were reported in either group. 70/78 (89.7%) patients
participated in the optional QoL sub-study and completed
baseline questionnaires (49 chemoablation, 21 surgery). 6-
months mean change from baseline in QLQ-C30 global health
status was +1.5 surgery vs -4.8 chemoablation (no statistically
signiﬁcant difference).
Conclusion: Chemoablation with MMC is safe, however it did not
meet pre-speciﬁed activity levels to pursue further investigation.
Whilst surgery appears more effective in this setting, the
proportion of patients with residual disease at 3 months suggests
surgery alone may be suboptimal. Further research is required to
determine the role of chemoablation with other agents in patients
with low risk NMIBC.
Disclosure: Funded by National Institute for Health Research
Corresponding author: Laura Wiley
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112. 12 week PET-CT scans post-radiotherapy for Human
Papillomavirus (HPV) positive Oropharygeal Squamous Cell
Cancers (OPSCC) have low positive predictive value (PPV) for
lymph node (LN) residual disease
Robert Rulach1, Suyun Zhou1, Fraser Hendry2, David Stobo2, Mary
Frances Dempsey2, Derek Grose1, Carolynn Lamb1, Allan James1,
Stefano Schipani1, Christina Wilson1, Mohammed Rizwanullah1,
Claire Paterson1
1The Beatson West of Scotland Cancer Centre, 2NHS Greater Glasgow
and Clyde
Background: The PET-NECK study showed that a complete
metabolic response on PET-CT 12 weeks after radiotherapy (RT)
spared neck dissections (ND) with no resultant reduction in
survival. As HPV-positive OPSCC respond later on anatomical
imaging, it remains unclear whether an immediate ND is necessary
for patients with equivocal responses on the 12 week PET-CT
(12wk PET-CT).
Method: 12wk PET-CT scans of patients treated with RT/ChemoRT
for OPSCC were evaluated retrospectively by a radiologist to
categorise incomplete, equivocal or complete responses (IR/EQR/
CR) in LNs. Patient details were obtained from electronic records.
Results: 154 patients treated with chemo/radiotherapy were
identiﬁed (116 males, 38 females, median age 58 (range 39-78)).
HPV status was as follows: HPV-positive (126), HPV-negative (21),
HPV-unknown (7). Median follow up was 24.4 months (range
3–52 months). 38 patients (24.7%) had an EQR. 17 EQR patients
(44.7%), all HPV-positive, had a second PET-CT scan at a median of
90 days after the 12wk PET-CT. These scans showed 12 late CRs
(70.6%), 2 continued EQRs (both are recurrence-free) and 3 late IRs
(two patients were recurrence-free, one had distant metastases).
For HPV-positive patients, the PPV and the negative predictive
value (NPV) of the 12wk PET-CT is 27.9% and 97.4% respectively,
derived from relapse data in Table 1. For HPV-negative patients,
the PPV and NPV are 77.8% and 87.5% respectively.
Conclusion: 12wk PET-CT scans have a high NPV for residual/
recurrent disease OPSCC regardless of HPV status. The PPV of an
IR/EQR for HPV-positive OPSCC is low so the optimal surveillance/
salvage strategy for these patients requires further clariﬁcation.
Disclosure: None declared
Corresponding author: Robert Rulach
Table 1 [Abstract 112]. 12wk PET-CT responses and relapse by HPV
status. *Includes distant metastases and residual disease on ND
HPV-positive
No Relapse Relapse* Total
CR 75 2 77
EQR/IR 31 12 43
106 14 120
HPV-negative
No Relapse Relapse*
CR 7 1 8
EQR/IR 2 7 9
9 8 17
113. PET-CT surveillance post radiotherapy in advanced head
and neck squamous cell cancer (HNSCC) - real life application
of the PET-Neck protocol
Suyun Zhou1, Robert Rulach1, Fraser Hendry1, David Stobo1, Mary
Frances Dempsey1, Derek Grose1, Carolynn Lamb1, Allan James1,
Stefano Schipani1, Mohammed Rizwannullah1, Christina Wilson1,
Claire Paterson1
1Greater Glasgow and Clyde NHS Scotland
Background: The PET-NECK study demonstrated surveillance CT-
PET scan 12 weeks post-radiotherapy for HNSCC was non-inferior
to planned neck dissection (ND). We evaluated this practice in our
centre.
Method: Patients with node positive HNSCC treated with radio-
therapy between January 2013 and September 2016 were
identiﬁed from the PET-CT database. CT-PET responses were
classiﬁed retrospectively as complete (CR), incomplete (ICR) or
equivocal (EQR) by a radiologist. Patient demographics and clinical
outcomes were obtained from electronic patient records.
Results: 187 patients with HNSCC were identiﬁed, 74.8% male,
mean age 59 years. 8%(15/187) with N2a, 57%(107/187) with N2b,
16%(29/187)with N2c, and 5%(9/187)with N3 disease. 80.2%
received chemoradiotherapy. 81%(154/187) of patients had
oropharyngeal cancer, 80.5%(124/154) were HPV-positive. Median
follow-up was 30 months (IQR 21.6-39.7). Median time from end of
radiotherapy to PET scan was 90days.
59.4%(111/187) had CR, 17.6%(33/187) ICR, and 23%(43/187)
EQR nodal response. 21(11%) NDs were performed, 57.1% were
pathologically positive. 1-year recurrence was 9.3%, 29.4% and
7.7% for CR, ICR and EQR groups respectively (p=0.04). 2 year
survival was 91.9%, 50.0% and 87.5% respectively (p<0.001). No
statistical differences in recurrence and survival rates between CRs
and EQR at 1-year and 2-years. Only 10 NDs were carried out for
the EQR subset with 50% pathological involvement. 20 patients
with EQR underwent a repeat PET resulting in a further 12 CRs,
suggesting the comparable outcomes between EQRs and CRs are
not due to salvage ND and more likely to be related to slowly
responding disease.
Overall locoregional control at 2 years was 94.8%(95% CI, 89.6-
97.9) and 2 years survival was 83.5%(95% CI, 76.6-88.3).
Conclusion: Real life application of the PET-NECK protocol has
resulted in similar outcomes to that seen in the study. Most
patients are spared ND and disease control is maintained with
PET-CT surveillance post-radiotherapy.
Disclosure: Funded by Beatson West of Scotland
Corresponding author: Suyun Zhou
114. Aspirin use after radical cancer therapy – feasibility and
toxicity data from the Add-Aspirin trial
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Background: Pre-clinical, observational and randomised evidence
suggests aspirin may prevent or delay the development of cancer
and metastases, and is strongest for colorectal and gastro-
oesophageal cancer. However, concerns around feasibility, adher-
ence and tolerability (particularly serious bleeding) have limited
aspirin use for cancer chemoprevention.
Method: Add-Aspirin is a double-blind, randomised-controlled
trial encompassing 4 individually powered phase III trials in early-
stage breast, prostate, colorectal and gastro-oesophageal cancer,
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evaluating the effect of aspirin after radical therapy. All
participants initially take open-label aspirin (100mg daily) for
8 weeks (run-in), to assess adherence and toxicity prior to
randomisation (1:1:1, aspirin 300mg, aspirin 100mg or matched
placebo for ≥5 years). A pre-planned feasibility analysis was
performed to assess tolerability and adherence when >2000
participants had completed the run-in period.
Results: Between October 2015 and October 2017, 3494 of a
targeted 11000 participants were registered from 165 sites in the
UK; recruitment rates differed across tumour sites compared to
predictions. Run-in data (n=2253) showed good adherence: 95%
took 6-7 tablets/week and 85% proceeded to randomisation, with
rates consistent across tumour cohorts. Main reasons for not
proceeding to randomisation were toxicity (mostly minor, grade 1/
2) and/or patient choice, with only 0.7% (16/2253) of participants
experiencing toxicity requiring discontinuation during the run-in.
Fewer than 1% (13/2253) experienced a grade > 3 toxicity
(including one lower gastrointestinal bleed in a prostate cancer
participant; no upper gastrointestinal bleeds).
Conclusion: The data demonstrate that aspirin is well-tolerated
over an 8-week run-in, and acceptable to patients after radical
cancer therapy, with low toxicity rates in all tumour cohorts,
including gastro-oesophageal participants. A run-in approach may
be useful in adjuvant (or prevention) studies for reducing the risk
of non-adherence and participant attrition at a later date. Trial
recruitment continues with >5000 participants now registered
from the UK and India.
Disclosure: Funded by Cancer Research UK (C471 /A15015); the
National Institute for Health Research Health Technology Assess-
ment Programme (12/01/38); MRC Clinical Trials Unit at University
College London; Sir Dorabji Tata Trust
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115. FAST-Forward phase 3 RCT of 1-week hypofractionated
breast radiotherapy: 3-year normal tissue effects
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Judith Bliss2, John Yarnold2
1University Hospitals of North Midlands NHS Trust and Keele
University, 2The Institute of Cancer Research, 3The Beatson West of
Scotland Cancer Centre, 4Brighton and Sussex University Hospitals
NHS Trust, 5Nufﬁeld Health Cheltenham Hospital, 6Worcestershire
Acute Hospitals NHS Trust, 7Imperial College Healthcare NHS Trust,
8Cambridge University Hospitals NHS Foundation Trust, 9Royal
Devon and Exeter NHS Foundation Trust, 10Norfolk and Norwich
University Hospitals NHS Foundation Trust, 11The Royal Marsden
Hospital NHS Foundation Trust, 12Manchester University NHS
Foundation Trust, 13Independent Cancer Patients' Voice, 14Guy's
and St Thomas' NHS Foundation Trust, 15Wirral University Teaching
Hospital NHS Foundation Trust, 16RTTQA Mount Vernon Hospital,
17Royal Cornwall Hospitals NHS Trust
Background: FAST-Forward aims to identify a 1-week 5-fraction
schedule of adjuvant radiotherapy as effective and safe as the UK
standard 15-fraction regimen for early breast cancer. We report
normal tissue effects (NTEs) up to 3 years (shown in previous
breast radiotherapy trials to predict comparisons at 5+ years).
Method: The FAST-Forward trial (ISRCTN19906132; NIHR-HTA 09/
01/47) randomised patients (pT1-3 pN0-1 M0) following breast
conservation surgery or mastectomy (immediate reconstruction
permitted) to 40Gy/15 fractions/3 weeks (control), 27Gy or 26Gy/5
fractions/1 week to whole breast or chest wall. A tumour bed
boost of 16Gy/8 fractions or 10Gy/5 fractions was given where
indicated. NTEs were assessed annually by clinicians, by patients at
baseline, 3, 6, 12 and 24 months and from photographs at 2 years
compared with a pre-radiotherapy baseline. Schedules were
compared using cross-sectional and survival analyses. A lymphatic
sub-study is ongoing.
Results: From 09/2011-06/2014, 4096 patients were recruited
(40Gy: 1361, 27Gy: 1367, 26Gy: 1368). Median follow-up is
48 months (IQR 37-50). Marked NTEs at 2 or 3 years were
uncommon (<5% for clinician and photographic assessments,
<15% for patient assessments). Clinician assessments of individual
NTEs at 3 years and patient assessments at 2 years were similar
between schedules. 2-year prevalence of mild/marked change in
photographic breast appearance was statistically signiﬁcantly
higher for 27Gy (16.1%, 95%CI 12.9-19.9%) compared with 40Gy
(8.3%, 6.0-11.5%), but similar for 26Gy (10.6%, 8.0-13.9%) and
40Gy. 3-year cumulative incidence rates of any clinician-assessed
moderate/marked NTE in the breast/chest wall were highest for
27Gy (28.8%, 26.4-31.4%) but similar for 26Gy (21.8%, 19.6-24.2%)
and 40Gy (20.8%, 18.6-23.2%).
Conclusion: Levels of marked NTEs were low for all schedules.
Late effects after 26Gy in 5 fractions over 1 week were similar to
40Gy in 15 fractions over 3 weeks.
Disclosure: Funded by National Institute for Health Research
Health Technology Assessment Programme (09/01/47)
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116. Adjuvant therapy with nivolumab versus ipilimumab
after complete resection of stage III/IV melanoma: Updated
results from a phase 3 trial (CheckMate 238)
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Veneto IRCCS, 10Hospital Gregorio Marañón,, 11Hôpital de la Timone,
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Research Foundation and University of Queensland, 16University
Hospital of Zurich, 17Bristol-Myers Squibb, 18The Royal Marsden NHS
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Background: Previously, at 18 months' minimum follow-up,
nivolumab demonstrated signiﬁcantly longer recurrence-free
survival (RFS) vs ipilimumab in patients with resected stage III/IV
melanoma in the phase 3 CheckMate 238 trial. Here, we report
updated 24-month efﬁcacy results.
Method: Eligible patients included those ≥15 years of age who
underwent complete resection of stage IIIB/C or IV melanoma. 906
patients were randomized 1:1 (stratiﬁed by disease stage and 5%
PD-L1 expression status) to receive nivolumab 3 mg/kg Q2W
(N = 453) or ipilimumab 10 mg/kg Q3W for 4 doses, then Q12W
(N = 453) for up to 1 year, or until disease recurrence or
unacceptable toxicity. The primary endpoint was RFS with an
exploratory endpoint of distant metastasis-free survival (DMFS).
Results: At 24 months' follow-up, RFS remained signiﬁcantly
longer for nivolumab vs ipilimumab (hazard ratio 0.66, P<0.0001),
with 171/453 vs 221/453 events, respectively. The patient
subgroup 24-month RFS rates were higher for nivolumab vs
ipilimumab (Table). DMFS remained signiﬁcantly longer for
nivolumab vs ipilimumab; 24-month rates were 70.5% and
63.7%, respectively (hazard ratio 0.76, P = 0.034).
Conclusion: With extended follow-up, nivolumab demonstrated
sustained efﬁcacy beneﬁt vs ipilimumab in patients with resected
stage III/IV melanoma at high risk of recurrence, regardless of
disease stage, PD-L1 expression, or BRAF mutation status.
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Table 1 [Abstract 116].
Nivolumab Ipilimumab
RFS, 24-month rates; % (N)
ITT 62.6% (453) 50.2% (453)
Stage IIIB 70.8% (165) 60.7% (148)
Stage IIIC 58.0% (203) 45.4% (218)
Stage IV 58.0% (82) 44.3% (87)
PD-L1 ≥5% 75.5% (152) 58.4% (154)
PD-L1 <5% 55.2% (275) 45.5% (286)
BRAF mutant 61.9% (187) 51.7% (194)
BRAF wild-type 63.5% (197) 46.2% (212)
117. Hepatic resection following selective internal
radiotherapy in the FOXFIRE clinical trial: survival, safety, and
histopathology
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Background: Colorectal cancer (CRC) commonly metastasises to
the liver and is a leading cause of cancer-related death. The
FOXFIRE trial compared the safety and efﬁcacy of radiosensitising
chemotherapy (OxMdG: oxaliplatin, 5-ﬂuorouracil and folic acid)
with selective internal radiotherapy (SIRT) using yttrium-90 resin
microspheres (SIR-Spheres®; Sirtex Medical Limited) to OxMdG
alone as ﬁrst-line management for liver-dominant metastatic CRC.
In patients downsized to potentially-curative hepatic resection, we
explored survival, safety, and histopathological ﬁndings.
Method: FOXFIRE (ISRCTN83867919) was an open-label, multi-
centre, randomised (1:1) trial of 12 cycles of OxMdG with or
without SIRT (Wasan HS et al. Lancet Oncol 2017). Eligible patients
provided written informed consent and were considered untrea-
table by surgical resection or local ablation. Suitability for surgery
was reassessed after 3 months of treatment. Surgical complica-
tions were graded using Dindo D et al. Annals of Surgery 2004.
Cox models and a 5% signiﬁcance level were used.
Results: FOXFIRE randomised 364 patients: 182 per treatment
group. Seventy-one (20%) underwent hepatic resections following
ﬁrst-line treatment: 38 (21%) in the OxMdG+SIRT and 33 (18%) in
the OxMdG group. Among those resected, 22 in the OxMdG+SIRT
and 19 in the OxMdG group had primary tumour in situ. Common
surgeries performed were right hepatectomy (n = 22) and
segmentectomy (n = 12). Among those resected, overall survival
from the time of resection did not differ signiﬁcantly between
groups (OxMdG median = 25.2 months; OxMdG+SIRT median =
21.9 months; HR = 1.55, 95% CI = 0.83-2.89). Twenty patients had
grade I/II complications: 11 in the OxMdG and 9 in the OxMdG
+SIRT group. Less viable tumour was histologically observed in
patients receiving SIRT. Zonal analysis demonstrated that median
microsphere density was highest at the tumour periphery and
lowest in non-neoplastic tissue.
Conclusion: This study reports that hepatic resection following
SIRT with OxMdG chemotherapy has an acceptable safety proﬁle
and demonstrates the histopathological distribution of micro-
spheres in liver metastases.
Disclosure: Funded by Bobby Moore Fund of Cancer Research
UK; Sirtex Medical Limited, Australia
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Background: Membrane type I matrix metalloproteinase
(MT1-MMP) is a member of the matrix metalloproteinase
(MMP) family involved in tissue remodelling through proteolysis
of extracellular matrix components. Overexpression of MT1-
MMP is seen in multiple tumour types including non-small
cell lung cancer (NSCLC), triple negative breast cancer
(TNBC) and sarcoma. BT1718 is a novel ﬁrst in class bicyclic
targeting peptide that binds MT1-MMP and is linked to the
maytansinoid tubulin inhibitor DM1 by a cleavable disulﬁde
linker. Bicyclic peptides have a low molecular weight in
comparison to other conjugated toxin approaches, enabling
rapid penetration and a short systemic half-life, potentially
reducing toxicity.
Method: This is an open label ﬁrst in human phase I/IIa study. The
primary objective is to propose a recommended phase 2 dose
(RP2D) and schedule of BT1718. Secondary objectives include
pharmacokinetic (PK) parameters and preliminary clinical
responses in biomarker pre-deﬁned cohorts of patients. Tertiary
objectives include correlative studies related to predictive
biomarkers of response.
Dose escalation (phase I)
Stage 1: Exploring an initial twice-a-week schedule. There will
be single patient cohorts until either Grade 2 drug related toxicity
or dose exceeding 6 mg/m2 twice a week. A 3+3 design will then
be followed until the RP2D.
Stage 2: Exploring a once-weekly schedule, using a 3+3 design
until the RP2D for this schedule has also been established.
Dose expansion (phase IIa)
Part A: 14 patients with MT1-MMP expressing NSCLC or TNBC,
treated with BT1718 at the twice-a-week RP2D. At least 6 will have
pre- and post-treatment biopsies.
Part B: 14 patients with MT1-MMP expressing NSCLC or TNBC,
treated with BT1718 at the once-weekly RP2D. At least 6 will have
pre- and post-treatment biopsies.
Part C/D: following parts A & B, a decision will be made
to explore the selected schedule in tumour-speciﬁc cohort(s)
of around 15 patients, with reﬁned MT1-MMP biomarker
selection.
Acknowledgement: “© 2018 American Society of Clinical
Oncology, Inc. Reused with permission. This abstract was
accepted and previously presented at the 2018 ASCO Annual
Meeting. All rights reserved see http://abstracts.asco.org/214/
AbstView_214_223089.html for original and CC-BY license.
Disclosure: Funded by Cancer Research UK
Corresponding author: Udai Banerji
Selected Abstracts from the 2018 NCRI Cancer Conference of National. . .
42
119. Vertebral fractures in patients treated with FOLFIRI-
Cetuximab at the Edinburgh Cancer Centre
Amanda Swan, Sally Clive, Lesley Dawson, Donna McGowan,
Catriona McLean, Hamish Phillips, Maria Sakala, Mark Zahra, Ewan
Brown
Edinburgh Cancer Centre
Background: Osteoporosis in patients with cancer is common and
considered multi-factorial in aetiology. A high frequency of
symptomatic fractures was observed in patients treated with
chemotherapy and cetuximab at our institution. We therefore
performed a retrospective analysis of patients with metastatic
colorectal cancer treated with cetuximab in combination with
chemotherapy to determine the incidence and potential risk
factors for the development of fractures.
Method: Consecutive patients treated with ﬂuorouracil, folinic
acid and irinotecan in combination with cetuximab (FOLFIRI-
cetuximab) at the Edinburgh Cancer Centre were retrospectively
analysed. Baseline characteristics, number treatment cycles and
cumulative steroid dose were collected. FRAX scores were used to
calculate 10-year probability of major fracture. Fractures were
assessed by reviewing serial CT scan reports during treatment.
Patients treated with capecitabine and oxaliplatin (CAPOX) were
chosen as a comparison group.
Results: 31 patients treated with FOLFIRI-cetuximab and 30
patients treated with CAPOX were reviewed. Patients received a
median of 9 two weekly cycles of FOLFIRI-cetuximab (range 1-32)
and 6 three weekly cycles of CAPOX (range 1-18). One patient in
the FOLFIRI-cetuximab group and no patients in the CAPOX group
had a fracture documented prior to treatment. Median FRAX score
in the FOLFIRI-cetuximab group was 8%. Ten patients developed
new non-metastatic fractures in the FOLFIRI-cetuximab group
(28%), 90% were symptomatic. One patient in the CAPOX group
(3%) developed a new vertebral fracture. Median cumulative
steroid dose for the patients in the FOLFIRI-cetuximab group was
dexamethasone 306mg and for the CAPOX group 204mg.
Conclusion: Patients with metastatic colorectal cancer treated
with FOLFIRI-cetuximab demonstrate a high incidence of sympto-
matic fractures with signiﬁcant morbidity. The high incidence may
be related to higher steroid exposure although an effect of the
chemotherapy regime cannot be excluded. The introduction of
bone protection and changes to anti-emetic protocols to reduce
cumulative steroid dose should be considered.
Disclosure: None declared
Corresponding author: Amanda Swan
120. PERSEPHONE: A randomised phase 3 non-inferiority trial
of 6 versus 12 months (m) of adjuvant trastuzumab in patients
with HER2 positive (+) early breast cancer (EBC)
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Background: Adjuvant trastuzumab has signiﬁcantly improved
outcomes for HER2+ EBC patients, using the 12m duration
empirically adopted from the pivotal registration trials. A shorter
duration could reduce toxicities and cost whilst providing similar
efﬁcacy. No reduced-duration trial to date has demonstrated non-
inferiority.
Method: PERSEPHONE is a randomised phase 3 non-inferiority
trial comparing 6 to 12m trastuzumab, the largest reduced-
duration non-inferiority trial internationally. Mapping onto stan-
dard UK practice, all HER2+ EBC patients were eligible.
Stratiﬁcation is by ER status, chemotherapy type, and chemother-
apy and trastuzumab timing. The primary endpoint is DFS from
diagnosis (ﬁrst relapse or death). Randomising 4000 patients (1:1)
enabled the trial to assess non-inferiority of 6m (5% 1-sided
signiﬁcance, 85% power), deﬁned as ‘no worse than 3%’ below the
12m arm’s assumed 80% 4-year DFS. The pre-planned deﬁnitive
DFS analysis required 500 events.
Results: 4089 patients were randomised from 152 UK sites
(Oct’07–Jul’15). ER+ 69%; chemotherapy - 42% anthracycline (A)-
based / 48% A and taxane (T)-based / 10% T-based; adjuvant
chemotherapy 85%; sequential trastuzumab 53%. At 5.4 years
median follow-up, there were 512 (13%) DFS events. 12m and 6m
4-year DFS rates were 89.8% (95%CI 88.3–91.1) and 89.4% (95%CI
87.9–90.7) respectively. The HR of 1.07 (90%CI 0.93–1.24)
demonstrated non-inferiority (HR<1.32) of 6m trastuzumab (1-
sided p = 0.01). Congruent results were found for overall survival
(OS) and within the pre-planned DFS and OS landmark analyses
(after 6m of trastuzumab). Heterogeneity was observed in some
stratiﬁcation variables. Cardiac events were reduced in 6m
patients (4% v 8% of 12m patients stopping treatment due to
cardiotoxicity (p<0.0001)).
Conclusion: PERSEPHONE demonstrates 6m of trastuzumab as
non-inferior to 12m with an observed difference in DFS of only
0.4% at 4 years. Given cardiac and other toxicities during months
7-12 of treatment, our results support a reduction of trastuzumab
duration to 6m.
Acknowledgement: A version of this abstract has been published
previously, see http://abstracts.asco.org/214/AbstView_214_217191.
html for original and CC-BY license.
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121. Use of Theoretical Domains Framework to identify
psychosocial determinants associated with adjuvant
hormonal treatment adherence among breast cancer
population: mixed method systematic review
Haley Ong, Christine Campbell, David Weller
University of Edinburgh
Background: Adjuvant hormonal therapy (AHT) is a standard
treatment for all HR-positive breast cancer patients upon
completion of primary systemic therapy. Despite the proven
efﬁcacy of AHT in reducing cancer recurrence by 65 %, adherence
rates fall to below 50% by the end of the 5year course of therapy.
Suboptimal adherence rate not only jeopardies the treatment
outcome but also incurs additional healthcare costs. This
systematic review aims to summarise the evidence regarding
the psychosocial determinants associated with medication-
compliance behaviours for adherence and persistence measures
among both female and male breast cancer populations using
Theoretical Domains Framework.
Method: The protocol of this systematic review followed PRISMA-
P guideline. We searched MEDLINE (OVID interface), EMBASE
(OVID interface), Web of Science, Cochrane Library, Cochrane
Central Register of Controlled Trials (CENTRAL, Wiley interface),
PsycINFO (OVID interface), PsycARTICLE (OVID interface) and
Cumulative Index for Nursing and Allied Health Literature
(CINAHL) for studies that examined association between at least
one psychosocial domains (cognitive or health beliefs, behavioral
or coping, emotional, and social or interpersonal) and at least one
medication-taking behavior (adherence, persistence or disconti-
nuation). Papers published from January 1998- April 2018 were
included.
Results: 1229 titles and abstracts were screened; after title and
abstract screening and full-text review, 60 eligible papers were
included for narrative synthesis. Negative health beliefs, low
perceived efﬁcacy, limited social support are the main psychoso-
cial barriers among female breast cancer patients whereas distress
and stigma are commonly cited among male breast cancer
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patients. Efﬁcient patient-oncologist communication and involve-
ment of patients in decision making greatly decrease patient
psychological distress and reduce the misunderstanding on the
treatment.
Conclusion: AHT medication adherence is an important lever in
reducing cancer mortality rates due to recurrence. Identifying the
potentially modiﬁable psychosocial factors will inform compre-
hensive interventions to improve patient adherence in this ever-
growing breast cancer population.
Disclosure: Funded by University of Edinburgh
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Background: TEAMM was a randomised, double-blind, placebo-
controlled multi-centre phase III trial assessing beneﬁts of antibiotic
prophylaxis and effects on healthcare associated infections (HCAI).
Infection is the biggest cause of early deaths in myeloma.
Levoﬂoxacin is effective against the common bacterial infections
in myeloma but there is concern about the development of HCAI.
Method: Patients were randomised to receive 500 mg levoﬂoxacin
or placebo tablets once daily for 12 weeks, dose adjusted for renal
function. Patients were eligible if >21 years old with newly
diagnosed symptomatic myeloma, intention to treat myeloma
actively, and were +/- 14 days into a programme of anti-myeloma
treatment. Primary endpoint was the number of febrile episodes
(temperature ≥38°C treated with anti-infectives) and/or death by
any cause in the ﬁrst 12 weeks obtained using Kaplan-Meier
curves censored at 12 weeks. Febrile episodes, faecal and throat
samples were collected at clinic visits every 4 weeks. Patients
included in an intention to treat analyses.
Results: TEAMM recruited 977 patients from August 2012-April
2016 from 92 centres within the UK. Median age 67 years, 63%
male, 76% eGFR>50 ml/min, 54% planned high dose chemother-
apy with autologous-stem cell transplantation, 93% ECOG
performance status ≤2, 71% with bone disease. Primary endpoint
showed a signiﬁcant beneﬁt for the use of levoﬂoxacin with 95 of
489 patients (19%) on levoﬂoxacin reporting events (87 febrile
episodes; 4 deaths; 4 febrile episodes and death) versus 134 of 488
patients (27%) on placebo (112 febrile episodes; 15 deaths; 7
febrile episodes and death); hazard ratio 0.66 (95%CI 0.51-0.86)
p=0.002. There was no increased carriage or infection with HCAI
on Levoﬂoxacin versus placebo.
Conclusion: Prophylactic use of 12 weeks levoﬂoxacin for patients
undergoing treatment for active myeloma signiﬁcantly reduces
febrile episodes and deaths without increasing HCAI.
Acknowledgement: A version of this abstract has been
published previously, see http://web.oncoletter.ch/id-59th-ash-
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html for original and CC-BY license.
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123. Improving treatment and care for older people with
cancer
Rose Gray1, Kerry Allen2
1Cancer Research UK, 2University of Birmingham
Background: 36% of cancer diagnoses in 2015 were in people 75
and over. By 2035, this will rise to 46%. Cancer services in the UK
must meet the needs of the patients they serve and adapt to a
changing population.
However, cancer survival is generally lower for older patients,
older patients are also more likely to be diagnosed in an
emergency and are less likely to receive many different
treatments.
The Cancer Strategy highlighted that current methods of
assessing older patients are not ﬁt for purpose, meaning older
people’s needs are not considered.
CRUK commissioned the University of Birmingham to identify
solutions for improving the quality of decision-making.
Method: A literature review to understand the current evidence
base : (1) 15 qualitative interviews with national policymakers, 80
interviews with health professionals. (2) Three UK surveys of
primary and secondary care health professionals and older
patients. (3)Clinical observations of MDT meetings and multi-
disciplinary clinics.
Results: Older patients have more complex medical and social
needs, however the most appropriate support is not always
available; including social care, or Clinical Nurse Specialists. Health
professionals are likely to include a wide range of clinical factors in
treatment decision-making for older patients, but Comprehensive
Geriatric Assessments (CGA) are not used consistently in primary
or secondary care. Systemic issues also prevent the right
information being included in decisions, including with links
between primary and secondary care, or links into cancer MDTs.
This group will also be hardest hit by wider pressures - a lack of
time for consultations, and workforce shortages. Older patients are
also typically under-represented in clinical trials, meaning there is
limited evidence to support treatment choices.
Conclusion: Cancer services are not meeting the needs of older
patients and without mitigation, this will worsen. Addressing this
is vital if we are to achieve our ambition of world-class cancer
outcomes in the UK.
Disclosure: Funded by Cancer Research UK
Corresponding author: Rose Gray
124. Results of POUT - A phase III randomised trial of peri-
operative chemotherapy versus surveillance in upper tract
urothelial cancer (UTUC)
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James Catto5, Rik Bryan6, Rob Jones7, John Chester8, David Dolling9,
Jenny Donovan10, Ann French11, Chris Harris12, Thomas Powles13,
Rachel Todd9, Lucy Tregellas9, Caroline Wilson10, Andrew Winterbot-
tom14, Rebecca Lewis9, Emma Hall9
1Lancashire Teaching Hospitals NHS Foundation Trust, 2Newcastle
upon Tyne Hospitals NHS Trust, 3University Hospitals Leicester, 4North
Bristol NHS Trust, 5The University of Shefﬁeld, 6University of
Birmingham, 7Beatson West of Scotland Cancer Centre, 8Cardiff
University/Velindre Cancer Centre, 9The Institute of Cancer Research's
Clinical Trials and Statistics Unit, 10University of Bristol, 11Southend
University Hospital NHS, 12Consumer Representative, 13St Barts & the
London NHS Trust, 14Consumer representative/ Fight Bladder
Cancer
Background: The role of chemotherapy post nephro-
ureterectomy for UTUC is unclear. POUT addresses whether
adjuvant chemotherapy improves disease free survival (DFS) for
patients with histologically conﬁrmed pT2-T4 N0-3 M0 UTUC.
Method: Patients (up to 345), ≤90 days post NU, were randomised
(1:1) to 4 cycles gemcitabine-cisplatin (gemcitabine-carboplatin if
GFR 30-49ml/min) or surveillance. Primary endpoint was DFS. The
trial was powered to detect a hazard ratio (HR) of 0.65
(improvement in 3yr DFS from 40% to 55%; 2-sided alpha 5%,
80% power) with Peto-Haybittle early stopping rules. Secondary
endpoints included toxicity (CTCAE v4) and quality of life (QL;
measured using QLQ-C30 and EQ-5D).
Results: 261 participants (127 surveillance; 134 chemotherapy)
were randomised between 31/05/2012-10/11/2017, at 57 centres.
252 participants joined the QL study. In Oct 2017, independent
trial oversight committees recommended POUT recruitment
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closed as data collected met the early stopping rule for efﬁcacy in
favour of chemotherapy. At time of interim analysis (5/09/2017),
median follow-up was 17.6mths (IQR 7.5-33.6). Median age 69yrs,
30% pT2, 65% pT3; 91% pN0. Most common grade ≥3 toxicities for
chemotherapy pts during treatment were neutropenia 29% (0%
surveillance) & thrombocytopenia 7% (0%). 47/123 (surveillance) &
29/125 (chemotherapy) DFS events were reported; unadjusted
HR = 0.47 (95%CI: 0.29, 0.74) in favour of chemotherapy (log-rank
p = 0.0009). The difference in the mean change from baseline in
QLQ-C30 global health status at 3 months was 7.7 (99% CI: 0.9,
14.6; p<0.001) in favour of surveillance and there was no
difference between arms at 12 months (6.1 in favour of
chemotherapy; 99% CI: -5.3, 17.4; p = 0.08).
Conclusion: Adjuvant chemotherapy improved DFS in UTUC
without adversely impacting QL. Recruitment to POUT was
stopped early due to efﬁcacy favouring chemotherapy; follow-up
for OS continues. Results of POUT, the largest UTUC randomised
trial, support adjuvant chemotherapy as a new standard of care.
Acknowledgement: A version of this abstract has been
published previously, see http://ascopubs.org/doi/abs/10.1200/
JCO.2018.36.6_suppl.407 for original and CC-BY license.
Clinical Trial Registry: CRUK/11/027; NCT01993979 – https://
clinicaltrials.gov/ct2/show/NCT01993979
Disclosure: Funded by Cancer Research UK (CRUK/11/027)
Corresponding author: Alison Birtle
125. PARTNER: Randomised, phase 2/3 trial evaluating safety
& efﬁcacy of adding olaparib to platinum-based neoadjuvant
chemotherapy in triple negative and/or germline BRCA
mutated breast cancer patients
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Louise Grybowicz2, Stanly Thomas2, Melanie Weiss2, Caron Harvey2,
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Roylance3, Ellen Copson4, Karen Pinilla1, Anne Armstrong5, Elena
Provenzano2, Marc Tischkowitz1, Emma McMurtry6, Helena Earl7
1University of Cambridge, Cambridge, Cambridgeshire, 2Cambridge
University Hospitals NHS Foundation Trust, Cambridge, Cambridge-
shire, 3University College London, London, 4University of South-
ampton, 5The Christie NHS Foundation Trust, Manchester,
6AstraZeneca, 7University of Cambridge and NIHR Cambridge
Biomedical Research Centre
Background: No speciﬁc targeted therapies are available for
Triple Negative Breast Cancers (TNBC), an aggressive and diverse
subgroup. The basal TNBC sub-group share some phenotypic and
molecular similarities with germline BRCA (gBRCA) tumours. In
gBRCA patients, and potentially other homologous recombination
deﬁciencies, these already compromised pathways may allow
drugs called PARP inhibitors (Olaparib) to work more effectively.
Aims: To establish if the addition of olaparib to neoadjuvant
platinum based chemotherapy for basal TNBC and/or gBRCA
breast cancer is safe and improves efﬁcacy (pathological complete
response (pCR)).
Methods: Trial design: 3-stage open label randomised phase II/III
trial of neoadjuvant paclitaxel and carboplatin +/− olaparib,
followed by clinicians' choice of anthracycline regimen. Stage 1
and 2: Randomisation (1:1:1) to either control (3 weekly carbopla-
tin AUC5/weekly paclitaxel 80mg/m2 for 4 cycles) or one of two
research arms with the same chemotherapy regimen but with two
different schedules of olaparib 150mg BD for 12 days. Stage 3:
Patients are randomised (1:1) to either control arm or to the
research arm selected in stage 2.
Results: Stage 1: Safety; Stage 2: Schedule selection using pCR rate
and completion rate of olaparib using a “pick-the-winner” design.
Stage 3: pCR rate. Enrichment design is applied with an overall
signiﬁcance level 0.05(α) and 80% power. A total of 527 patients
will be included to detect an absolute improvement of 15% (all
patients) and 20% (gBRCA patients) by adding olaparib to
platinum based chemotherapy.
Conclusion: PARTNER has been recruiting in UK since 27th May
2016. IDSMC recommended to continue the trial without change
after reviewing the Stage 1 safety data. The recruitment of stage 2
was completed in April 2018 and results to be reviewed by the
IDSMC in early 2019. The trial is open and enrolling patients to
national and international sites.
Acknowledgement: A version of this abstract has been
published previously, see http://ascopubs.org/doi/abs/10.1200/
JCO.2017.35.15_suppl.TPS591 for original and CC-BY license.
Disclosure: Funded by Cancer Research UK, AstraZeneca
Corresponding author: Jean Abraham
126. Propensity Score-Matched Comparison of Focal High
Intensity Focused Ultrasound (HIFU) to Laparoscopic Radical
Prostatectomy (LRP) for Clinically Signiﬁcant Localised
Prostate Cancer
Daniel Ball1, Na Hyun Kim1, Ashley McFarlane1, Taimur Shah2, Max
Peters3, Enrique Gomez4, Saiful Miah2, Stephanie Guillaumier5,
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Persad14, Karishma Shah5, Jaspal Virdi15, Mark Emberton5, Hashim
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1Imperial College Healthcare, 2Imperial Health and Imperial College
London (ICL), 3University Medical Center Utrecht, 4University of
Cordoba, 5University College London, 6Dorset County Hospital NHS
trust, 7University Hospital Southampton NHS Trust, 8Imperial College
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Hospital, 11Princess Alexandra Hospital, Harlow and University
College London Hospitals NHS Trust, 12Royal Surrey County Hospital,
13Royal Marsden Hospital, 14Southmead Hospital, 15Princess Alexan-
dra Hospital NHS Strust, 16Imperial health and Imperial College
London (ICL)
Background: Focal HIFU is an emerging minimally invasive
treatment option for localised prostate cancer. Phase II clinical
trials and prospective databases have shown promising oncolo-
gical outcomes. However, there is a paucity of data comparing
HIFU to standard of care therapies such as radical prostatectomy.
Method: All consecutive men undergoing either focal HIFU
(n = 625) or laparoscopic radical prostatectomy (LRP) (n = 571)
between 2007 – 2017 had their pre- and post- operative data
collected in prospective databases.
A propensity score was constructed with groups matched 1:1
using nearest neighbour matching based on the propensity score.
Inclusion criteria: PSA <20 ng/ml; Gleason score ≤ 7; T-stage
≤T2c
Exclusion criteria: 3-month nadir of > 0.02 in the LRP cohort;
Patients with any missing matching variables [Table 1].
Primary outcome was Failure Free Survival (FFS) deﬁned as
transition to salvage or systemic therapy. Up to two focal-HIFUs
was part of this intervention as deﬁned in NCRN PART.
Results: After inclusion/exclusion criteria, 425 HIFU and 194 LRP
patients remained with matching leading to 86 in each cohort. At
all-time points, there was no signiﬁcant difference in FFS
(p = 0.29). The actuarial FFS for those undergoing HIFU was
91% at 4-years and 86% for those undergoing LRP Figure 1 and
Table 2].
Conclusion: Our data show medium-term disease control follow-
ing focal-HIFU that appears comparable to laparoscopic radical
prostatectomy.
Disclosure: Funded by Imperial College Healthcare
Corresponding author: Daniel Ball
127. Safety of outpatient management of cancer patients at
risk of neutropenic sepsis using MASCC score at the Norfolk
and Norwich University Hospital
Ahmed Eltinay1, Gill Gray1, Saif Ahmad1
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Background: Neutropenic sepsis (NS) is a potentially fatal
complication of chemotherapy. Patients with febrile neutropenia
or neutropenia with other infective symptoms are at risk of NS.
The MASCC score (Multinational Association for Supportive Care in
Cancer) stratiﬁes potential NS patients as low (≥21) or high-risk
(<21) and has NICE approval. Patients at low-risk may not require
admission.
Method: This study evaluated the use of MASCC score in the
management of NS at Norfolk and Norwich University Hospital.
Patients with favourable clinical and social circumstances and a
low-risk MASCC score were discharged with oral antibiotics. An
electronic register was used to study all emergency presentations
of possible NS between April 2016 and April 2018 to Acute
Oncology (AOS), Medical Admissions (MAU) and A&E.
Results: In total, 242 patients presented with potential NS. 170
attended AOS and 72 attended MAU/A&E. The most common
primary tumours were breast (64%), lung (13%) and prostate
(9.6%). The most common regimens were carboplatin and
docetaxel (72%) and FEC (17%). Among AOS attendees 83
patients (49%) were discharged, all of whom had a low-risk
MASCC score. Within these 83 patients, median age was 60, and
64 patients (77%) were female. 11 patients (13%) post-discharge
were re-admitted within a week; none of these patients died or
were admitted for more than one week. Signiﬁcantly, those
patients who were re-admitted had a lower MASCC score at the
time of assessment (22 vs 24; p = 0.0028). Among non-AOS
attendees, only 2 patients (2.7%) were not admitted suggesting
that early discharge using MASCC score had not yet been adopted
outside of AOS.
Conclusion: MASCC score accurately identiﬁes patients at risk of
NS who can be safely managed at home. Re-admission of these
patients is more likely if the absolute MASCC score nears 21 and
this should inform counseling and follow-up in this patient group.
Disclosure: None declared
Corresponding author: Ahmed Eltinay
128. Structure-based virtual screening identiﬁes pranlukast as
a CD49f antagonist that reduces stemness in MDA-MB-231
breast cancer cells
Marco Velasco-Velazquez1, Inés Velázquez-Quesada1, Angel Ruiz-
Moreno1, Diana Casique-Aguirre1, Charmina Aguirre-Alvarado1,
Fabiola Cortés-Mendoza1, Marisol de la Fuente-Granada1, Mayra
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1National Autonomous University of Mexico, 2National Polytechnic
Institute, 3The European Bioinformatics Institute (EMBL-EBI)
Background: Breast cancer is the neoplastic disease with higher
mobility and mortality in women worldwide. The Cancer Stem Cell
(CSC) model proposes that a subpopulation at the top of the
tumor cell hierarchy drives the initiation, maintenance, and
therapy response in breast cancer. CD49f is an integrin subunit
that is expressed in breast CSCs and promotes maintenance of
stemness. Thus, blockade of CD49f is a potential therapeutic
approach for targeting breast CSCs.
Method: To repurpose drugs as CD49f antagonists, we performed
consensus molecular docking using a subdomain critical for
heterodimerization and a collection of 13,000+ drugs. Five drugs
were selected for in vitro biological validation using MDA-MB-231
cells. We performed limiting-dilution xenotransplantation using
the drug with better CSC-selectivity.
Results: Pranlukast, a cysteinyl leukotriene receptor 1 (CysLTR)
antagonist that is used to treat asthma, inhibited cell adhesion to
laminin and decreased the mammosphere-forming efﬁciency but
had no impact on the viability of bulk tumor cells. Short exposure
of breast cancer cells to pranlukast reduced CD49f-downstream
signaling, including Focal Adhesion Kinase (FAK) and phosphati-
dylinositol 3-kinase (PI3K) activation. Pranlukast-treated cells
showed reduced transactivation of Sox2 promoter and decreased
tumorigenicity in vivo, indicating that this drug decreases the
number of CSCs.
Conclusion: Pranlukast antagonizes CD49f, impairing CSC-
associated functions. Since the pharmacokinetics and toxicology
of pranlukast are known, it is a potential adjuvant therapy for
breast cancer patients.
Disclosure: This work was supported by CONACYT 221103 and
PAPIIT IN228616
Corresponding author: Marco Velasco-Velazquez
129. A systematic review of eligibility criteria for phase II
clinical trials for patients with lung cancer
Gary Doherty1, Innocent Ogunmwonyi2, Rohan Shotton1
1Cambridge University Hospitals NHS Foundation Trust, 2University of
Cambridge
Background: Signiﬁcant barriers exist for the successful enrol-
ment of Oncology patients in early phase clinical trials. These
include restrictive eligibility criteria that often exclude patients
with intracranial disease, abnormal organ function or laboratory
tests, and particular co-morbidities. To investigate these further,
we performed a systematic review of the eligibility criteria in
recent phase II clinical trials for patients with lung cancer.
Method: We searched the clinicaltrials.gov database for trials
registered in 2016 using the criteria “lung cancer” and “phase 2.”
223 trials were identiﬁed. Duplicate/incomplete entries, and those
not investigating systemic anti-cancer agents, were excluded.
Eligibility criteria were then determined for the remaining 173
trials. Results were matched against known pharmacokinetic/
toxicity data for the relevant agents, trial outcomes, sponsorship
type, and country. Further analyses were performed to determine
temporal trends.
Results: Common eligibility criteria were highly variable. Highly
signiﬁcant variability existed for the exclusion of patients with liver
function derangement (used in 79.2%; 12.7% even without known
hepatic drug metabolism/hepatotoxicity), renal function derange-
ment (used in 79.2%; 14.5% even without known renal drug
clearance/nephrotoxicity), low blood cell/haemoglobin counts
(used in 78.6%), or coagulation abnormalities (used in 16.8%).
Wide ranges of cut-offs and methodologies were used to
determine eligibility. While 89.6% of trials permitted patients with
brain metastases, 41.2% of these excluded patients taking
concomitant corticosteroids. Successfully suppressed HIV/HepB/
HepC was permitted in 41.6, 82.7% and 81.5%, respectively.
Comprehensive eligibility criteria analyses, pairwise correlations
with drug metabolism/toxicities, temporal trends, and correlation
between eligibility restrictiveness and trial outcomes, will be
presented.
Conclusion: The safety of patients participating in clinical trials is
paramount. However, our results suggest that the signiﬁcant
variability in eligibility criteria cannot be wholly explained by a
priori knowledge of the investigational agents’ metabolism and
known toxicities, which may lead to irrational and unjustiﬁable
exclusion of patients in a high-need population from access to
experimental therapies.
Disclosure: None declared
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130. The CamGFR model for renal function in patients with
cancer: Validation and extension for use with data from
isotope mass dilution spectrometry creatinine assays
Edward Williams1, Cameron Whitley1, Jamie Weaver2, Claire
Connell1, Reed Stratton Geisler1, Daniel Giglio3, Simon Tavaré1,
Duncan Jodrell1, Tobias Janowitz1
1Cancer Research UK Cambridge Institute, Cambridge, 2Christie NHS
Foundation Trust, Mancherster, 3University of Gothenburg
Background: Estimation of renal function using glomerular
ﬁltration rate (GFR) is important for the management of patients
with cancer and is often performed using serum creatinine
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measurements. These are increasingly determined using isotope
dilution mass spectrometry (IDMS) assays. We present validation
of the CamGFR model that we developed originally with non-IDMS
data (JCO, 2017) and a validated extension using IDMS creatinine
data.
Method: The study was approved by the relevant ethics
committees. Data on age, sex, height, weight, serum creatinine,
and results for GFR from 51Cr-EDTA excretion measurements were
obtained from adult patients with cancer from one Swedish and
two UK centres. Data were split 4:1 into development and
validation datasets. For IDMS data, we reﬁtted the CamGFR model
using interaction terms between all creatinine terms and the
creatinine measurement type. We assessed bias, accuracy, and
precision for GFR using median residuals, root-mean-squared-error
(RMSE), and residual interquartile range (IQR). A comparison of
carboplatin dosing accuracy based on an absolute percentage
error more than 20% (APE > 20%) was undertaken.
Results: Data from 6200 patients were obtained, 1913 of these
contained IDMS creatinine data. The CamGFR model was the most
accurate (RMSE 15.1, 95% CI 14.4 to 15.8) and least biased (median
residual 0.85, 95% CI 0.01 to 1.64) model for estimating GFR
compared with all other published models for IDMS creatinine
data. Body surface area (BSA) adjusted CKD-EPI was the second
most accurate model (RMSE 17.0, 95% CI 16.2 to 17.8). Importantly,
the CamGFR model reduced the fraction of patients with a
carboplatin dose APE >20% to 0.150 (95% CI 0.131 to 0.170) from
0.190 (95% CI, 0.168 to 0.213) for the BSA CKD-EPI.
Conclusion: The CamGFR model represents a better standard for
estimation of GFR in patients with cancer, in particular when using
IDMS creatinine data.
Disclosure: Funded by Cancer Research UK Cambridge Institute
Corresponding author: Cameron Whitley
131. Glyoxalase 1 overexpression associated multidrug
resistance in cancer chemotherapy
Hafsa Abbas, Dr Mingzhan Xue, Dr Naila Rabbani, Professor Paul
Thornalley
University of Warwick
Background: Overexpression of Glo1 induces anti-cancer multi-
drug resistance (MDR) in human tumour cells lines and human
tumour cells in primary culture. We hypothesize that the
cytotoxicity of anticancer drugs is mediated, in part, by inducing
increase of MG to cytotoxic levels. This may be achieved by drug-
induced increased MG formation and/or decreased MG metabo-
lism; the latter achieved by drug-induced direct or indirect Glo1
inhibition.
Method: Using a model human tumour cell line, HEK293 cells
were stably vector-transfected to overexpress Glo1 and with
empty vector as control. The effect of anticancer drugs on growth
and toxicity of HEK293 cells in three conditions (wild-type, Glo1-
ioverexpression and empty vector) was studied in vitro and
median growth inhibitory concentration (GC50) values deter-
mined. The effect of cell permeable Glo1 inhibitor, S-p-
bromobenzylglutathione cyclopentyl diester (BBGCp2) on the
potency of anticancer drugs was also studied. The glyoxalase
system and dicarbonyl metabolism were characterised by
measuring cellular activities of Glo1, Glo2, MG reductase and MG
dehydrogenase. The ﬂux of formation of D-lactate – a surrogate
indicator of ﬂux of MG formation, glucose consumption and net L-
Lactate formation were measured in HEK293 cells cultures by end-
point enzymatic assays.
Results: Doxorubicin, mitomycin C, paclitaxel, mechlorethamine
and methotrexate had the highest resistance conferred by Glo1
overexpression: MDR was 16-fold, 15-fold, 8-fold, 7-fold and 7-fold,
respectively. BBGCp2 potentiated the cytotoxicity of anti-cancer
drugs. There was an increase in ﬂux of formation of D-lactate and
L-lactate and consumption of D-glucose in HEK293 cells treated
with mechlorethamine, doxorubicin, paclitaxel and methotrexate,
compared to untreated cells. However, cells treated with
mitomycin C had a decrease and increase in D-lactate and L-
lactate formation respectively.
Conclusion: Stable increased Glo1 expression in HEK293 cells
conferred MDR to clinical anticancer drugs. In most cases, MG was
increased by drug-induced increased glycolysis and increased ﬂux
of MG formation. Anticancer drugs were not direct Glo1 inhibitors.
Disclosure: None declared
Corresponding author: Hafsa Abbas
132. Prehabilitation is feasible during neoadjuvant
chemoradiotherapy and may minimize physical deterioration:
Results from The REx randomised controlled trial
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Robert Steele4, Charles Boachie3, Annie Anderson4
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Background: Rectal cancer patients undergoing NACRT (neo-
adjuvant chemoradiotherapy) experience physical deterioration
and reductions in their quality of life. This feasibility study
assessed pre-habilitation (a walking intervention) before, during
and after NACRT to inform a deﬁnitive multi-centred RCT.
Method: Patients planned for NACRT then potentially curative
surgery were approached (August 2014 - March 2016) (www.
isrctn.com; 62859294). Baseline physical and psycho-social mea-
sures were performed before NACRT. Participants were rando-
mised to either the intervention (exercise counselling session
followed by 13-17 weeks telephone-guided walking programme)
or control group (standard care). Follow-up testing was under-
taken 1-2 weeks before surgery.
Results: Of 296 screened patients, 78 were eligible (26%) and 48
were recruited (62%): 65% male; mean age 65.9 years (range 33.7-
82.6). Mean intervention duration was 14 weeks with 75%
adherence. 83% of participants completed follow-up testing and
both groups recorded reductions in daily walking, however, the
reduction was less in the Intervention group. Participants reported
high satisfaction and ﬁdelity to trial procedures.
Conclusion: This study demonstrates that prehabilitation is
feasible in rectal cancer patients undergoing NACRT. Good
recruitment, adherence, retention and patient satisfaction rates
support the development of a fully powered trial. The effects of
the intervention on physical outcomes were promising.
Disclosure: Funded by Chief Scientist Ofﬁce, Scotland.
Corresponding author: Susan Moug
133. Progression free survival as a surrogate endpoint for
overall survival in ﬁrst-line therapy of advanced ovarian
cancer: A Gynecologic Cancer InterGroup (GCIG) individual
patient-level meta-analysis
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Selected Abstracts from the 2018 NCRI Cancer Conference of National. . .
47
Trousseau, Paris, 14National Cancer Institute of Naples, Naples,
15Foundation for Biomedical Research and Innovation, Translational
Research Informatics Center, Kobe, 16London Regional Cancer
Program, London, ON, 17Ligue Nationale Contre le Cancer Meta-
Analysis Platform, Department of Biostatistics and Epidemiology,
Gustave-Roussy Cancer Campus, Villejuif, 18The Institute of Cancer
Research and The Royal Marsden Hospital, Sutton, 19Leeds Teaching
Hospitals NHS Trust, Leeds, 20The Royal Marsden NHS Foundation
Trust, London, 21Gustave Roussy Institute, Villejuif
Background: Overall survival (OS) is considered the gold standard
endpoint for controlled clinical trials but it requires extended
follow-up (median OS> 40 months for ﬁrst line therapy) and large
sample sizes. The UK contributed 3 trials to this Gynaecological
Cancer Intergroup (GCIG) meta-analysis. The objective was to
evaluate whether progression free survival (PFS) based on CA125
measurements conﬁrmed by radiological exam or combined GCIG
criteria is a surrogate endpoint for OS in advanced ovarian cancer
(AOC).
Method: Using the meta-analytic approach on trials published
after 2000, correlations between PFS and OS at the individual
level, and between treatment effects on PFS and on OS at the trial
level, were estimated using Kendall’ tau and copula bivariate
(R2Copula) models respectively. Criteria for PFS surrogacy required
R2Copula ≥ 0.80.
Results: We analyzed individual patient data (IPD) from 10,502
patients in 16 randomized ﬁrst line trials of standard (n = 7),
intensiﬁcation (n = 5) and maintenance (n = 4) . No heterogeneity
in the treatment effects across trials was detected. High
correlations were found at the individual level (tau = 0.77) but
low correlation at the trial level (R2Copula = 0.2). Sub-group
analyses led to similar results (see table 1).
Conclusion: This large IPD meta-analysis did not establish PFS as a
surrogate endpoint for OS in ﬁrst line treatment of AOC. The
analysis was limited by the narrow range of treatment effects
observed and/or post study treatment.
Disclosure: Funded by Programme Hospitalier pour la
Recherche Clinique, French Ministry of Health
Corresponding author: Rosalind Glasspool
Table 1 [Abstract 133].
Endpoint / Trial type TrialsN
(pts)
taua R2Copula
a R2
Overall 16 (10502) 0.77 0 0.2
CA125 conﬁrmed by radiological
exam
10 (5319) 0.75 0.01 0.24
GCIG criteria 5 (4076) 0.78 0.14 0.04
Carbo-Tax as control 10(7336) 0.72 0 0.2
Standard or intensiﬁcation 12 (7704) 0.77 0.20 0.24
Maintenance 4 (2798) 0.64 0.14 0.01
a tau and R2 values range from 0 (no association) to 1 (perfect
correlation)
134. Precision oncology in surgery: Patient selection
biomarkers for operable pancreatic cancer
Stephan Dreyer1, Nigel Jamieson1, Mark Pinese2, Rosie Upstill-
Goddard1, Colin McKay1, Fraser Duthie1, Andrew Biankin1, David
Chang1
1University of Glasgow, 2Garvan Institute of Medical Research
Background: About 80% of patients with pancreatic cancer (PC)
succumb to the disease despite curative resection, many of whom
recur within 6 months of surgery. This suggests current staging is
inadequate and there is a need to better deﬁne the biology and
clinical behaviour of PC prior to surgery. This study aimed to
develop and validate gene signature sets and biomarkers that
accurately predicts disease recurrence patterns in patients under-
going resection for PC.
Method: Disease patterns were deﬁned as early recurrence after
surgery (< 12 months), liver metastases, lung metastases (no
evidence of liver recurrence) and local recurrence only.
The molecular features of clinical disease patterns were investi-
gated using transcriptomic analysis and immunohistochemistry
(IHC). These were correlated with recurrence patterns, disease
presentation (localised, locally advanced and metastatic) and
molecular subtypes of PC.
Results: Early recurrence, liver metastases and metastatic pre-
sentation were strongly associated with gene expression sets that
deﬁne the squamous subtype of PC (P < 0.001). Lung recurrence,
localised disease and long-term survival were associated with the
classical pancreatic subtype and an anti-tumour immune response
(P < 0.001). High S100A2 and S100A4 IHC expression was
associated with the squamous subtype of PC and were
independent poor prognostic factors in 3 independent patient
cohorts of PC (totalling n = 1184 patients). Using these
biomarkers, a molecular prognostic nomogram was generated
to identify poor prognostic PC and validated using 3 independent
cohorts of PC.
Conclusion: Gene signature and biomarker expression sets
generated from biological relevant processes and known poor
prognostic features of PC can allow accurate prognostication of
patients with operable PC. Deﬁning poor prognosis can allow
stratiﬁcation towards systemic neoadjuvant therapy in operable
disease. Conversely, if a patient is predicted to have a favourable
prognosis, more aggressive and extensive surgery in the setting of
borderline resectable or locally advanced disease could be justiﬁed.
Disclosure: Funded by Cancer Research UK
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135. Improving patient experience of immunotherapy
treatment for melanoma: the Leeds nurse-led immunotherapy
telephone clinic
Maria Marples, Helen Jackson, Helen Nicholson, Beverley Ryder,
Karen Ingham, Jane Hook
Leeds Cancer Centre
Background: Immunotherapy has transformed the outcomes of
metastatic melanoma, but the burden on patients of frequent
hospital visits for assessments is high. We devised, implemented,
developed and evaluated a nurse-led telephone clinic to assess
patients being treated with immunotherapy.
Method: We piloted a questionnaire, enquiring about a range of
potential immunotherapy toxicities, as well as symptoms of
progressive disease and medication changes. This formed the
basis of a telephone clinic starting in November 2016, where
patients who were established on pembrolizumab immunother-
apy were telephoned by a clinical nurse specialist up to 1 week
prior to treatment. Outcomes were emailed to a consultant for a
prescription, blood tests were done locally, and annotations saved
in the electronic patient record. In 2017, patients being treated
with nivolumab were added to the clinics. A separate code was
created for patients being monitored for immunotherapy toxicity
(mainly hepatitis). We evaluated the clinic with a patient
satisfaction questionnaire and a detailed review of 6 months'
clinical activity.
Results: In the ﬁrst 6 months of the clinic, monthly assessments
increased from 14 to 49. Patient satisfaction was high, with 98%
patients reporting that the clinic was convenient and saved them
time, and 100% that concerns were addressed and they and their
GP had the necessary information. Review of the work done in the
subsequent 6 months showed that 50% of calls resulted in no
additional action, around 40% required telephone advice, and
only 4% required medical review that week.
Conclusion: Patients on immunotherapy can be safely and
effectively assessed on the telephone, which is well-received by
patients, and saves transport and clinic costs. This approach is
applicable to other tumour types which are treated with
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immunotherapy, with nurses cross-covering each other to increase
service resilience.
Disclosure: None declared
Corresponding author: Maria Marples
136. Cost effectiveness analyses of 6 versus 12 months of
adjuvant trastuzumab in patients with HER2 positive early
breast cancer: Results from the PERSEPHONE trial
Claire Hulme1, Peter Hall2, Beth Shinkins3, Fadi Chehadah3, Chris
McCabe4, Janet Dunn5, Louise Hiller5, Helena Earl6
1University of Leeds, 2University of Edinburgh, 3University of Leeds,
4Institute of Health Economics, Alberta, 5University of Warwick,
6Addenbrooke's Hospital, Cambridge
Background: Adjuvant trastuzumab has signiﬁcantly improved
outcomes for HER2 positive early breast cancer patients, using the
12 month duration empirically adopted from the pivotal registra-
tion trials. Given an annual per patient cost of trastuzumab
treatment of over £30,000 (Euro35,000), a shorter duration has the
potential to improve cost-effectiveness if efﬁcacy is maintained.
Method: The within trial cost effectiveness analyses uses data
collected as part of the PERSEPHONE trial, a randomised phase 3
non-inferiority trial comparing 6 to 12 month trastuzumab, the
largest reduced-duration non-inferiority trial internationally. Com-
prehensive health service activity and costs were collected. Quality
of life was measured using the EQ-5D. The analyses adopted the
perspective of the health and social care sector over 2 years
follow-up. Incremental cost effectiveness ratios (ICER) present the
cost per quality adjusted life year (QALY). Additional analysis
presents the ICER using the primary outcome of the trial, disease
free survival at 4-years. Uncertainty around the ICER is estimated
using the non-parametric bootstrap method.
Results: 4088 patients were randomised between 4th October
2007 and 31st July 2015. The results of the cost effectiveness
analyses will be presented.
Conclusions: The cost effectiveness analyses will provide evi-
dence to demonstrate the value for money of 6 versus 12m
trastuzumab. The results will inform decisions around reduction of
standard trastuzumab duration to 6 month.
Disclosure: Funded by NIHR HTA
Corresponding author: Peter Hall
137. Cancer Medicines Outcomes Programme (CMOP): Better
use of existing data to understand outcomes in a local
population
Jennifer Laskey1, Julie Clarke1, Kelly Baillie1, Yvonne Semple1, Olivia
Wu2, Christine Crearie1, Rob Jones1, Ashita Waterston1, Tanja
Mueller3, Jiafeng Pan3, Marion Bennie3
1NHS Greater Glasgow and Clyde, 2University of Glasgow, 3University
of Strathclyde
Background: Cancer medicines comprise the highest proportion
of new medicines introduced within NHS Scotland. There is
increasing interest in ‘real world’ data to understand local
population outcomes. The Cancer Medicines Outcomes Pro-
gramme (CMOP) aims to maximise use of routinely collected
healthcare data to determine outcomes in the local population.
Method: Melanoma and prostate cancer were year 1 exemplar
projects. Quality and quantity of data available from electronic
record linkage in a safe haven were compared to individual case
note review. Outcomes were compared with trial data.
Results: Record linkage data appeared broadly comparable to
individual case note review (table 1).Outcomes were generally
inferior to clinical trial results. Differences in baseline demo-
graphics, associated with poorer outcomes, may contribute to this.
Conclusion: This demonstrates a more efﬁcient process of
describing local population outcomes. Future work includes
further validation of datasets in other cancer types.
Disclosure: Funded by Scottish Government
Corresponding author: Julie Clarke
Table 1 [Abstract 137]
Dataset Source
(electronic
record linkage)
Comparable with
individual case note
review?
Diagnosis
Diagnosis SMR06 – initial
diagnosis only
✕*
Line of treatment CEPAS ✓ **
Demography
Age / Gender NRS ✓
Scottish Index Multiple
Deprivation 2012
CHI
Performance Status(ECOG PS) CEPAS
Baseline blood results SCI store
Previous treatments CEPAS/ARIA®/
PIS/ SMR00/
SMR01
Co-morbidities PIS/SMR00/
SMR01
✕
Treatment
Dose information; duration CEPAS ✓
Toxicity/Reason for
discontinuation
CEPAS ✕
Outcome
Overall survival NRS ✓***
Biochemical response SCI store
Other e.g. time to
radiotherapy/opioid
prescribing/other treatment
CEPAS/ARIA®/
PIS/ SMR00/
SMR01
*except metastatic status, **number of previous treatments
prescribed, ***except time to radiotherapy
SMR06 = Scottish Cancer Registry; CEPAS= Chemotherapy
Prescribing System; NRS = National Records Scotland;
CHI = community health index; SCI = Scottish Care Information;
PIS = Prescribing Information System; SMR00 & 01 = Scottish
Morbidity Records for outpatients & inpatients / day case;
ARIA=radiotherapy records
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